Conditions: Oral Hygiene
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 280
Healthy volunteers: yes

Brief summary:
The aim of this study is to investigate the stain removal efficacy of 2 experimental anti-dentin hypersensitivity (DH) dentifrices with four and eight weeks twice daily use. A daily use, regular fluoride dentifrice will be included as a reference dentifrice.

Detailed description:
This will be a single-center, 8-week, randomized, controlled, single-blind, three treatment-arm, parallel design, stratified clinical study in healthy volunteers with a propensity to form dental stain. It has been designed to investigate changes in tooth stain and color, following twice-daily use of two experimental dentifrices, after four and eight weeks twice daily use; a regular fluoride dentifrice will be included as reference dentifrice. Sufficient participants will be screened to randomize approximately 300 participants to study treatment to ensure approximately 270 participants complete the study.

Arms:
arm 1: Randomized participants will brush their teeth with the experimental dentifrice (covering the entire length of the toothbrush), twice daily (morning and evening) for 2 minutes for 8 weeks. arm 2: Randomized participants will brush their teeth with the experimental dentifrice (covering the entire length of the toothbrush), twice daily (morning and evening) for 2 minutes for 8 weeks. arm 3: Randomized participants will brush their teeth with the Reference dentifrice (covering the entire length of the toothbrush), twice daily (morning and evening) for 2 minutes for 8 weeks.

Interventions: intervention 1: Experimental Dentifrice 1 intervention 2: Experimental Dentifrice 2 intervention 3: Reference Dentifrice
Intervention descriptions: intervention 1: 5 percent (%) potassium nitrate (KNO3) dentifrice with 1% alumina and 5% sodium tripolyphosphate (STP). intervention 2: 5% KNO3 dentifrice with 1% alumina, 5% STP and 2% high cleaning silica. intervention 3: Regular Fluoride Dentifrice.

Protocol document:
Prot_000.pdf: 
GSK Consumer Healthcare 
Clinical Protocol 
Protocol Number: 300024 
Property of GSK Consumer Healthcare - Confidential  
May not be used, divulged, published or otherwise disclosed without the consent of GSKCH 
 Clinical Protocol Template v9.0 
Page 1 of 63 
CLINICAL PROTOCOL 
A Randomized, Controlled, Single-Blind Clinical Study to 
Investigate the Tooth Stain Removal Efficacy of Two Experimental 
Potassium Nitrate Dentifrices in Subjects with Extrinsic Dental Stain 
Compared to a Standard Dentifrice Control When Used Twice Daily 
for 8 Weeks 
Protocol Number: 
300024 
Compound/Product Name: 
Potassium Nitrate Dentifrices 
United States (US) Investigational 
New Drug (IND) Number: 
N/A 
European Clinical Trials Database 
(EudraCT) Number: 
N/A 
Other Regulatory Agency Identified 
Number: 
N/A 
Phase: 
N/A 
300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
This document contains confidentiality statements that are not relevant for this publicly
available version
CCI


GSK Consumer Healthcare 
 
Clinical Protocol 
 
 
Protocol Number: 300024 
 
Property of GSK Consumer Healthcare - Confidential  
May not be used, divulged, published or otherwise disclosed without the consent of GSKCH 
 Clinical Protocol Template v9.0 
Page 2 of 63 
 
Sponsor Information 
 
Sponsor Name & Legal 
Registered Address 
 
GlaxoSmithKline Consumer Healthcare 
(UK) Trading Limited 
980 Great West Road, 
Brentford, 
Middlesex, 
TW8 9GS, 
United Kingdom (UK) 
Sponsor Contact Details 
 
GlaxoSmithKline Consumer Healthcare 
(GSK CH) 
184 Liberty Corner Road, Warren, NJ, USA 
300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI


GSK Consumer Healthcare 
 
Clinical Protocol 
 
 
Protocol Number: 300024 
 
Property of GSK Consumer Healthcare - Confidential  
May not be used, divulged, published or otherwise disclosed without the consent of GSKCH 
 Clinical Protocol Template v9.0 
Page 3 of 63 
Document History 
 
Document 
Version Summary of Changes  
Original protocol 
1.0 
Not applicable (N/A) 
Amendment 1 
2.0 
Section 9.2.3: Change from performing 3 assessments 
per tooth to a single assessment per tooth. 
Amendment 2 
3.0 
Amalgamation of screening and baseline visits and 
correction of references associated with Table 12-1. 
 
 
 
Amendments incorporate all revisions to date, including amendments made at the request of 
country health authorities, institutional review boards/ethics committees (IRBs/ECs), etc.   
 
300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI


GSK Consumer Healthcare 
 
Clinical Protocol 
 
 
Protocol Number: 300024 
 
Property of GSK Consumer Healthcare - Confidential  
May not be used, divulged, published or otherwise disclosed without the consent of GSKCH 
 Clinical Protocol Template v9.0 
Page 4 of 63 
Principal Investigator Protocol Agreement Page 
• I confirm agreement to conduct the study in compliance with the protocol and any 
amendments according to the current International Conference on Harmonisation Good 
Clinical Practice (ICH GCP) guidelines. 
• I acknowledge that I am responsible for overall study conduct. I agree to personally 
conduct or supervise the described study. 
• I agree to ensure that all associates, colleagues and employees assisting in the conduct of 
the study are informed about their obligations. Mechanisms are in place to ensure site staff 
receives all appropriate information throughout the study. 
• I agree to conduct this study in full conformance with the laws and regulations of the 
country in which the research is conducted and the Declaration of Helsinki. 
 
Investigator Name: 
 
Investigator Qualifications: 
 
Investigator Signature: 
 
Date of Signature/Agreement: 
DD-Mmm-YYYY 
 
300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
PPD
PPD
PPD
CCI


GSK Consumer Healthcare 
 
Clinical Protocol 
 
 
Protocol Number: 300024 
 
Property of GSK Consumer Healthcare - Confidential  
May not be used, divulged, published or otherwise disclosed without the consent of GSKCH 
 Clinical Protocol Template v9.0 
Page 5 of 63 
Table of Contents 
Sponsor Information ............................................................................................................ 2 
Document History ............................................................................................................... 3 
Principal Investigator Protocol Agreement Page ................................................................ 4 
Table of Contents ................................................................................................................ 5 
1 
PROTOCOL SUMMARY ................................................................................................ 10 
1.1 
Synopsis ................................................................................................................. 10 
1.2 
Schedule of Activities ............................................................................................ 13 
2 
INTRODUCTION ............................................................................................................. 14 
2.1 
Study Rationale ...................................................................................................... 14 
2.2 
Background ............................................................................................................ 14 
2.3 
Benefit/Risk Assessment ....................................................................................... 15 
2.4 
Mechanism of Action/Indication ........................................................................... 16 
3 
STUDY OBJECTIVES AND ENDPOINTS .................................................................... 16 
4 
STUDY DESIGN .............................................................................................................. 17 
4.1 
Overall Design ....................................................................................................... 17 
4.2 
Scientific Rationale for Study Design ................................................................... 18 
4.3 
Justification for Dose ............................................................................................. 19 
4.4 
End of Study Definition ......................................................................................... 20 
5 
STUDY POPULATION .................................................................................................... 20 
5.1 
Type and Planned Number of Subjects ................................................................. 20 
5.2 
Inclusion Criteria ................................................................................................... 20 
5.3 
Exclusion Criteria .................................................................................................. 21 
5.4 
Randomization Criteria .......................................................................................... 22 
5.5 
Lifestyle Considerations ........................................................................................ 22 
5.5.1 
Oral Hygiene Restrictions ..................................................................... 23 
5.5.2 
Dietary Restrictions ............................................................................... 23 
5.5.3 
Use of Cosmetics .................................................................................. 23 
5.5.4 
Tobacco Product Restrictions ............................................................... 23 
5.5.5 
Medication and Treatment Restrictions ................................................ 23 
5.5.6 
Contraception ........................................................................................ 23 
5.6 
Screen Failures....................................................................................................... 23 
5.7 
Sponsor’s Qualified Medical Personnel ................................................................ 24 
5.8 
Clinical Examiner Qualifications .......................................................................... 24 
6 
INVESTIGATIONAL/STUDY PRODUCTS................................................................... 24 
6.1 
Investigational/Study Product Supplies ................................................................. 24 
6.1.1 
Medical Devices .................................................................................... 26 
6.1.2 
Dosage Form and Packaging ................................................................. 26 
6.1.3 
Preparation and Dispensing................................................................... 26 
300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI


GSK Consumer Healthcare 
 
Clinical Protocol 
 
 
Protocol Number: 300024 
 
Property of GSK Consumer Healthcare - Confidential  
May not be used, divulged, published or otherwise disclosed without the consent of GSKCH 
 Clinical Protocol Template v9.0 
Page 6 of 63 
6.2 
Administration ....................................................................................................... 26 
6.2.1 
Product Usage Errors ............................................................................ 27 
6.2.2 
Overdose ............................................................................................... 27 
6.3 
Investigational/Study Product Storage .................................................................. 28 
6.4 
Study Product Accountability ................................................................................ 28 
6.4.1 
Destruction of Investigational/Study Product Supplies ........................ 29 
6.5 
Blinding and Allocation/Randomization ............................................................... 29 
6.6 
Breaking the Blind ................................................................................................. 29 
6.7 
Compliance ............................................................................................................ 30 
6.8 
Concomitant Medication/Treatment(s) .................................................................. 30 
7 
DISCONTINUATION OF STUDY INTERVENTION AND SUBJECT 
DISCONTINUATION/WITHDRAWAL ......................................................................... 31 
7.1 
Subject Discontinuation/Withdrawal ..................................................................... 31 
7.2 
Lost to Follow up ................................................................................................... 31 
8 
STUDY PROCEDURES ................................................................................................... 32 
8.1 
Visit 1/Screening ................................................................................................... 32 
8.1.1 
Screening Procedures ............................................................................ 32 
8.2 
Study Period .......................................................................................................... 34 
8.2.1 
Visit 2/Day 0 - Baseline ........................................................................ 34 
8.2.2 
Visit 3/Week 4 (Day 28 ± 3) ................................................................. 34 
8.2.3 
Visit 4 /Week 8 (Day 56 ± 3) ................................................................ 35 
8.2.4 
Study Procedures ................................................................................... 36 
9 
STUDY ASSESSMENTS ................................................................................................. 36 
9.1 
Screening Assessments .......................................................................................... 36 
9.1.1 
OST Examination .................................................................................. 37 
9.1.2 
OHT Examination ................................................................................. 37 
9.2 
Efficacy Assessments ............................................................................................ 37 
9.2.1 
Macpherson Modification of the Lobene Stain Index (MLSI) ............. 37 
9.2.2 
Tooth Shade (Color) Assessment .......................................................... 38 
9.2.3 
VITA EasyShade Assessment ............................................................... 39 
9.3 
Safety and Other Assessments ............................................................................... 39 
9.3.1 
Oral Soft Tissue (OST) Examination .................................................... 39 
9.3.2 
Oral Hard Tissue (OHT) Examination .................................................. 40 
9.3.3 
Pregnancy Testing ................................................................................. 40 
10 ADVERSE EVENT AND SERIOUS ADVERSE EVENTS ........................................... 40 
10.1 
Definition of an Adverse Event (AE) .................................................................... 40 
10.2 
Definition of a Serious Adverse Event (SAE) ....................................................... 41 
10.3 
Time Period and Frequency for Collecting AE and SAE Information .................. 42 
10.4 
Reporting Procedures............................................................................................. 43 
300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI


GSK Consumer Healthcare 
 
Clinical Protocol 
 
 
Protocol Number: 300024 
 
Property of GSK Consumer Healthcare - Confidential  
May not be used, divulged, published or otherwise disclosed without the consent of GSKCH 
 Clinical Protocol Template v9.0 
Page 7 of 63 
10.4.1 
Reporting of an Adverse Event ............................................................. 43 
10.4.2 
Reporting of a Serious Adverse Event .................................................. 44 
10.5 
Evaluating Adverse Events .................................................................................... 44 
10.5.1 
Assessment of Intensity ........................................................................ 44 
10.5.2 
Assessment of Causality ....................................................................... 45 
10.6 
Follow-up of AEs and SAEs.................................................................................. 45 
10.7 
Withdrawal Due to an Adverse Event ................................................................... 46 
10.8 
Regulatory Reporting Requirements for SAEs...................................................... 46 
10.9 
Pregnancy .............................................................................................................. 46 
10.9.1 
Time Period for Collecting Pregnancy Information.............................. 46 
10.9.2 
Action to be Taken if Pregnancy Occurs .............................................. 47 
10.10 Medical Device Incidents ...................................................................................... 47 
10.10.1 
Definition of an Incident ....................................................................... 47 
10.11 Reporting of Incidents and Malfunctions .............................................................. 48 
10.12 Follow-up of Medical Device Incidents ................................................................ 48 
10.13 Regulatory Reporting Requirements for Medical Device Incidents...................... 49 
11 DATA MANAGEMENT .................................................................................................. 49 
11.1 
Case Report Form .................................................................................................. 49 
11.2 
Data Handling ........................................................................................................ 50 
11.2.1 
Data Queries .......................................................................................... 50 
12 STATISTICAL CONSIDERATIONS AND DATA ANALYSES .................................. 50 
12.1 
Sample Size Determination ................................................................................... 50 
12.2 
Populations for Analysis ........................................................................................ 52 
12.2.1 
Definitions of Analysis Populations ..................................................... 52 
12.2.2 
Exclusions of Data from Analysis......................................................... 52 
12.3 
Statistical Analyses ................................................................................................ 52 
12.3.1 
Primary Analyses .................................................................................. 52 
12.3.2 
Secondary and Exploratory Analyses ................................................... 54 
12.3.3 
Safety Analyses ..................................................................................... 54 
12.3.4 
Other Analyses ...................................................................................... 54 
12.3.5 
Demographic and Baseline Characteristics ........................................... 55 
12.3.6 
Study Product Compliance and Use of Other Therapies ...................... 55 
12.3.7 
Interim Analysis .................................................................................... 55 
13 STUDY GOVERNANCE CONSIDERATIONS.............................................................. 55 
13.1 
Quality Control ...................................................................................................... 55 
13.2 
Quality Assurance .................................................................................................. 56 
13.3 
Regulatory and Ethical Considerations ................................................................. 56 
13.3.1 
Institutional Review Board/ Ethics Committee..................................... 56 
13.3.2 
Ethical Conduct of the Study ................................................................ 57 
300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI


GSK Consumer Healthcare 
 
Clinical Protocol 
 
 
Protocol Number: 300024 
 
Property of GSK Consumer Healthcare - Confidential  
May not be used, divulged, published or otherwise disclosed without the consent of GSKCH 
 Clinical Protocol Template v9.0 
Page 8 of 63 
13.3.3 
Subject Information and Consent .......................................................... 57 
13.3.4 
Subject Recruitment .............................................................................. 57 
13.3.5 
Reporting of Safety Issues and Serious Breaches of the Protocol or 
ICH GCP ............................................................................................... 57 
13.4 
Posting of Information on Publicly Available Clinical Trial Registers ................. 58 
13.5 
Provision of Study Results to Investigators ........................................................... 58 
13.6 
Records Retention .................................................................................................. 58 
13.7 
Conditions for Terminating the Study ................................................................... 59 
14 REFERENCES .................................................................................................................. 59 
15 APPENDICIES.................................................................................................................. 61 
15.1 
Product Usage Instructions Sheet .......................................................................... 61 
15.2 
ABBREVIATIONS ............................................................................................... 62 
300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI


GSK Consumer Healthcare 
 
Clinical Protocol 
 
 
Protocol Number: 300024 
 
Property of GSK Consumer Healthcare - Confidential  
May not be used, divulged, published or otherwise disclosed without the consent of GSKCH 
 Clinical Protocol Template v9.0 
Page 9 of 63 
List of in text tables and figures 
Table 1-1 
Schedule of Activities ........................................................................... 13 
Table 3-1 
Study Objectives and Endpoints ........................................................... 16 
Table 6-1 
Investigational/Study Product Supplies ................................................ 25 
Table 6-2 
Sundry Items ......................................................................................... 25 
Table 12-1 
Sample Size Power by Endpoint at 5% and 2.5% Significance 
Levels with 90 Subjects per Arm .......................................................... 51 
Figure 12-1 
Graphical Approach Showing Allocation and Propagation of Alpha 
Between Hypotheses Within Each Experimental Dentifrice ................ 53 
Table 15-1 
Abbreviations ........................................................................................ 62 
 
 
 
300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI


GSK Consumer Healthcare 
 
Clinical Protocol 
 
 
Protocol Number: 300024 
 
Property of GSK Consumer Healthcare - Confidential  
May not be used, divulged, published or otherwise disclosed without the consent of GSKCH 
 Clinical Protocol Template v9.0 
Page 10 of 63 
1 
PROTOCOL SUMMARY  
1.1 
Synopsis 
Background and Rationale: 
This study will investigate the efficacy of two experimental 5% potassium nitrate (KNO3) 
dentifrices, one containing alumina and sodium tripolyphosphate (STP), the other alumina, STP 
and high cleaning silica, to reduce extrinsic dental stain and thereby whiten the teeth, compared 
to a marketed regular fluoride dentifrice with 8 weeks twice daily brushing. 
Objectives and Endpoints: 
Objectives 
Endpoints 
Primary 
To evaluate the change in extrinsic dental stain after 8 weeks 
twice daily use of a ‘5% KNO3/1% alumina/5% STP’ dentifrice, a 
‘5% KNO3/1% alumina/ 5% STP/2% silica’ dentifrice and a 
regular fluoride dentifrice, as measured by Total Modified 
Lobene Stain Index (Total MLSI (Area x Intensity)). 
Change from baseline in mean 
Total MLSI (Area x Intensity) 
score at week 8. 
Secondary 
To evaluate the change in extrinsic dental stain after 4 weeks 
twice daily use of a ‘5% KNO3/1% alumina/5% STP’ dentifrice, a 
‘5% KNO3/1% alumina/ 5% STP/2% silica’ dentifrice and a 
regular fluoride dentifrice, as measured by Total Modified 
Lobene Stain Index (Total MLSI (Area x Intensity)). 
Change from baseline in mean 
Total MLSI (Area x Intensity) 
score at week 4. 
To compare the change in extrinsic dental stain after 4 & 8 
weeks twice daily use of either a ‘5% KNO3/1% alumina/5% 
STP’ dentifrice or a ‘5% KNO3/1% alumina/ 5% STP/2% silica’ 
dentifrice, compared to a regular fluoride dentifrice, as 
measured by Total MLSI (Area x Intensity). 
Change from baseline in mean 
Total MLSI (Area x Intensity) 
score at weeks 4 & 8. 
To evaluate and compare the change in tooth shade (color) 
after 4 and 8 weeks twice daily use of either a ‘5% KNO3/1% 
alumina/5% STP’ dentifrice or a ‘5% KNO3/1% alumina/ 5% 
STP/2% silica’ dentifrice, compared to a regular fluoride 
dentifrice, as measured by the VITA Bleachedguide 3D-
MASTER. 
Change from baseline in mean 
VITA shade score (examiner 
assessed) at weeks 4 & 8. 
To evaluate and compare the changes in dental stain at specific 
tooth sites (along gingival margin, inter-proximally and on the 
body of the tooth) after 4 and 8 weeks twice daily use of either a 
‘5% KNO3/1% alumina/5% STP’ dentifrice or a ‘5% KNO3/1% 
alumina/ 5% STP/2% silica’ dentifrice, compared to a regular 
fluoride dentifrice, as measured by Total MLSI (Area x 
Intensity). 
Change from baseline in mean 
MLSI (Area x Intensity) in: 
• Gingival sites 
• Interproximal sites 
• Body sites 
To evaluate and compare change in extrinsic dental stain after 4 
and 8 weeks twice daily use of either a ‘5% KNO3/1% 
alumina/5% STP’ dentifrice or a ‘5% KNO3/1% alumina/ 5% 
STP/2% silica’ dentifrice, compared to a regular fluoride 
dentifrice, as measured by MLSI (Area) and MLSI (Intensity). 
Change from baseline in mean 
MLSI (Area) and MLSI (Intensity) 
Exploratory 
To evaluate and compare the change in tooth color co-ordinates 
after 4 and 8 weeks twice daily use of either a ‘5% KNO3/1% 
alumina/5% STP’ dentifrice or a ‘5% KNO3/1% alumina/ 5% 
Change from baseline in mean 
tooth shade, L*, a*, b*, WID and 
ΔE* determined using the VITA 
300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI


GSK Consumer Healthcare 
 
Clinical Protocol 
 
 
Protocol Number: 300024 
 
Property of GSK Consumer Healthcare - Confidential  
May not be used, divulged, published or otherwise disclosed without the consent of GSKCH 
 Clinical Protocol Template v9.0 
Page 11 of 63 
STP/2% silica’ dentifrice, compared to a regular fluoride 
dentifrice, as measured using the VITA EasyShade. 
EasyShade instrument at weeks 
4 & 8 
Safety 
To assess the safety and tolerability of the two experimental 
KNO3 dentifrices. 
Treatment emergent adverse 
events 
Mean MLSI values calculated for the facial surfaces of the six maxillary anterior teeth and 
six mandibular anterior teeth, and the lingual surfaces of the six mandibular anterior teeth. 
Mean tooth shade/color values are calculated for the facial surfaces of the 4 central and 
lateral maxillary incisors. 
Study Design: 
This will be a single-center, 8-week, randomized, controlled, single-blind (clinical examiner(s) 
and VITA EasyShade operator), three treatment-arm, parallel design, stratified clinical study in 
healthy volunteers with clinically confirmed dental stain (originating from the diet and/or 
smoking) on the surfaces of their anterior teeth. 
Potential subjects will attend a screening visit (Visit 1, Day 0) to determine their suitability to 
participate.  Having obtained their written informed consent, relevant details of their medical 
history and current medications will be recorded, followed by oral soft tissue (OST) and oral 
hard tissue (OHT) examinations.  Subjects meeting the relevant study criteria, will be 
considered as eligible to proceed for baseline assessments on the same day. 
At the baseline visit (Visit 2, Day 0), eligible subjects will undergo clinical and instrumental 
assessments of extrinsic dental stain (MLSI: facial surfaces of the six maxillary anterior teeth 
and six mandibular anterior teeth, and the lingual surfaces of the six mandibular anterior teeth) 
and tooth color (VITA Bleachedguide 3D-MASTER and VITA EasyShade instrument: facial 
surfaces of the central and lateral maxillary incisors). 
Qualifying subjects will be stratified by baseline Total MLSI (A x I) (calculated for the facial 
surfaces of the six maxillary anterior teeth and six mandibular anterior teeth only) and smoking 
status and randomized to one of the three study treatments.  Randomized subjects will be 
instructed to brush twice daily (for 2 minutes, morning and evening) with their assigned study 
dentifrice for the next 8 weeks. Extrinsic dental stain and tooth color assessments will be 
repeated after 4- and 8-weeks treatment. 
Study Products: 
Experimental Dentifrices 
Reference Dentifrice 
5% KNO3 dentifrice with 
1% alumina and 5% STP 
5% KNO3 dentifrice with  
1% alumina, 5% STP and  
2% high cleaning silica 
Regular Fluoride Dentifrice  
(Aquafresh Cavity Protection, 
US market) 
Each study dentifrice will contain 0.2542% sodium fluoride 
(1100 parts per million (ppm) fluoride) 
All dentifrices will be applied in the same manner and will be brushed on to the teeth, twice 
daily (morning and evening) for 2 timed minutes. 
300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI


GSK Consumer Healthcare 
 
Clinical Protocol 
 
 
Protocol Number: 300024 
 
Property of GSK Consumer Healthcare - Confidential  
May not be used, divulged, published or otherwise disclosed without the consent of GSKCH 
 Clinical Protocol Template v9.0 
Page 12 of 63 
Type and Planned Number of Subjects: 
Study subjects of either sex and any gender, aged of 18-65 years, will be in good general and 
oral health, with the level of extrinsic tooth stain and color required at baseline to participate in 
the study. 
Sufficient subjects will be screened to randomize approximately 300 subjects to study treatment 
(approximately 100 per treatment group) to ensure approximately 270 evaluable subjects 
complete the study.   
Statistical Analysis Summary: 
For the analysis of the change from baseline in the mean Total MLSI (Area x Intensity) and the 
change from baseline in the mean VITA shade score, separate Mixed Models with Repeated 
Measures will be used. Fixed effects will be included for smoking status, study product, visit 
and study product x visit interaction. The respective baseline score will be included as a 
covariate. Subject will be included as a repeated measure with unstructured covariance matrix. 
Kenward Rogers degrees of freedom approach will be applied. The least square means for each 
Experimental Dentifrice at week 8 will be presented based on observed margins and used to test 
for a negative change from baseline. The differences between least square means for each 
Experimental Dentifrice compared to the Reference Dentifrice at week 8 will be presented and 
used to test for a difference between products.  
The hypothesis testing of the of change from baseline in the mean Total MLSI (Area x Intensity) 
and the change from baseline in the mean VITA shade score will employ a graphical approach 
methodology, as per Bretz et al (Bretz et al., 2009) in order to maintain an overall two-sided 
familywise error rate of 5% within each Experimental Dentifrice (10% overall). The adjusted 
two-sided p-values and simultaneous 95% confidence intervals (following graphical testing 
approach) will be provided for all comparisons. 
 
 
300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI


GSK Consumer Healthcare 
 
Clinical Protocol 
 
 
Protocol Number: 300024 
 
Property of GSK Consumer Healthcare - Confidential  
May not be used, divulged, published or otherwise disclosed without the consent of GSKCH 
 Clinical Protocol Template v9.0 
Page 13 of 63 
1.2 
Schedule of Activities 
The schedule of activities table provides an overview of the subject visits and study procedures.   
The investigator may schedule visits (unplanned visits) in addition to those listed on the 
schedule of activities, to conduct evaluations or assessments required to protect the well-being 
of the subject. 
Table 1-1 
Schedule of Activities 
 
Procedure/Assessment 
Screening 
Treatment Period 
Visit 1 
Screening 
(Day 0)4 
Visit 2 
Baseline 
(Day 0)4 
 
Visit 3 
Week 4 
(Day 28 ±3 
days) 
 
Visit 4 
Week 8 
Day 56 ±3 
days) 
Informed consent 
X 
 
4 Weeks 
 
4 Weeks 
 
Demographics  
X 
 
 
 
Medical History / current oral care 
products / current and prior medication 
review 
X 
 
 
 
Review changes in health and 
concomitant medications/treatments 
 
 
X 
X 
OST Examination 
X 
 
X 
X 
OHT Examination 
X 
 
 
X 
Clinical assessment of extrinsic dental 
stain (MLSI)2 
 
X 
X 
X 
Clinical assessment of tooth color (VITA 
Bleachedguide) 
 
X 
X 
X 
Instrumental assessment of tooth color 
(VITA EasyShade) 
 
X 
X 
X 
Repeatability assessments3 
 
X 
X 
X 
Inclusion/exclusion criteria review 
X 
X 
 
 
Subject eligibility 
X 
X 
 
 
Subject continuance 
 
 
X 
X 
Randomization and stratification 
 
X 
 
 
Dispense study products, diary and 
sundry items 
 
X 
X 
 
Supervised tooth brushing 
 
X 
X 
 
Return of study dentifrice, toothbrush 
and completed diary 
 
 
X 
X 
Adverse events review1 
 
X 
X 
X 
Medical device incidents review1 
 
X 
X 
X 
Study conclusion 
 
 
 
X 
Abbreviations: OST: Oral Soft Tissue, OHT: Oral Hard Tissue, MLSI: Modified Lobene Stain Index 
Footnotes: 
1. 
Adverse Events (AEs), Serious Adverse Events (SAEs) and medical device incidents collected immediately after subject provides 
consent to participate in the study by the completion of the Informed Consent Form (ICF) until 5 days after last use of the study 
dentifrice (or last procedure).  Medical device in this study is the supplied toothbrush. 
2. 
Brushing and/or flossing of the subject’s assessment teeth will be performed prior to this assessment by the examiner if required (at the 
examiner’s discretion). 
3. 
Repeatability assessments for VITA Bleachedguide and MLSI assessments will be performed on a subset of subjects as described in 
Section 9. 
4. 
Note Visits 1 & 2 will occur on the same day. 
 
300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI


GSK Consumer Healthcare 
 
Clinical Protocol 
 
 
Protocol Number: 300024 
 
Property of GSK Consumer Healthcare - Confidential  
May not be used, divulged, published or otherwise disclosed without the consent of GSKCH 
 Clinical Protocol Template v9.0 
Page 14 of 63 
2 
INTRODUCTION 
Dental stain is common within the adult population.  Extrinsic dental stain is primarily caused 
by chromogens (originating from the diet, smoking and medications) binding to proteinaceous 
compounds found in the salivary pellicle (Watts and Addy, 2001, Shellis et al., 2005).  The 
etiology of stain is multiple, and while it is widely agreed to result from discoloration of plaque 
and pellicle on the surface of the tooth, the main site for extrinsic stain build up is generally 
accepted as the acquired salivary tooth pellicle (Shellis et al., 2005).  One of the main functions 
of a dentifrice is to help control the build-up of dental stain (Pader, 2012).  This is usually 
achieved by the inclusion of a common dental abrasive, such as silica, chalk or dicalcium 
phosphate dihydrate in the dentifrice formulation (Lippert, 2013).  More recently alumina has 
been investigated for its enhanced stain removal and stain protection properties compared to 
silica (Milleman et al., 2017, Young et al., 2017) with lower dentine abrasivity (Seong et al., 
2017). 
Chemical cleaning compounds, such as polyphosphates are also commonly employed in 
dentifrices to supplement the physical cleaning provided by dental abrasives.  Polyphosphates, 
such as sodium tripolyphosphate (STP), sodium pyrophosphate and hexametaphosphate, have 
been shown to bind strongly to the tooth surface and reduce the force of adhesion of adsorbed 
proteins (Shellis et al., 2005), thereby facilitating the removal of stain during toothbrushing.  
Polyphosphates have also been shown to desorb salivary proteins from enamel and inhibit 
protein adsorption (Ash et al., 2014) and thereby inhibit stain build up.  
The aim of this study is to investigate the stain removal efficacy of 2 experimental anti-dentin 
hypersensitivity (DH) dentifrices: 
• 5% potassium nitrate (KNO3) dentifrice containing 1% alumina and 5% STP 
• 5% KNO3 dentifrice containing 1% alumina, 5% STP and 2% high cleaning silica 
with four and eight weeks twice daily use.  A daily use, regular fluoride dentifrice (US market) 
will be included as a reference dentifrice.  
2.1 
Study Rationale 
This 8-week, randomized, controlled, parallel-design, stratified clinical study has been designed 
to evaluate the ability of two experimental dentifrices to reduce extrinsic dental stain 
(originating from the diet and/or smoking) and improve tooth color (whiten the teeth), compared 
to a regular fluoride dentifrice.   
The dental stain removal and tooth whitening properties of 1% alumina with 5% STP has been 
demonstrated for similar dentifrice formulations (see Section 2.2); additional data are required 
to confirm the stain removal/whitening efficacy of a modified 1% alumina and 5% STP 
formulation and demonstrate efficacy for a novel 1% alumina, 5% STP and 2% high cleaning 
silica formulation.  
2.2 
Background 
Both experimental dentifrices contain 5% KNO3 and 0.2542% sodium fluoride (NaF).  The 
efficacy of KNO3-containing dentifrices for the relief of DH (Schiff et al., 1994, Gillam, 1996) 
and the anti-caries benefit associated with use of topical NaF (Featherstone, 1999, Marinho et 
al., 2003) are well-established.   
The sponsor has completed four clinical studies evaluating the dental cleaning properties of 
dentifrices containing 1% alumina and 5% STP.   
300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI


GSK Consumer Healthcare 
 
Clinical Protocol 
 
 
Protocol Number: 300024 
 
Property of GSK Consumer Healthcare - Confidential  
May not be used, divulged, published or otherwise disclosed without the consent of GSKCH 
 Clinical Protocol Template v9.0 
Page 15 of 63 
• Clinical study 
 evaluated the ability of 4 experimental dentifrices 
(including a 1% alumina and 5% STP dentifrice) to lighten tooth color (whiten teeth) 
compared to a regular fluoride dentifrice (Aquafresh Advanced), after 4 weeks twice 
daily brushing.  A statistically significant improvement in tooth shade (1.48 units, VITA 
Classic shade guide), versus baseline, was observed for the 1% alumina and 5% STP 
dentifrice; there was no statistically significant difference between any of the test 
products and the regular fluoride dentifrice. 
• Clinical study 
 evaluated the stain removal efficacy of 4 experimental 
dentifrices (including a 1% alumina and 5% STP dentifrice), compared to a regular 
fluoride dentifrice (Aquafresh Advanced), after 8 weeks twice daily brushing. The 1% 
alumina and 5% STP formulation demonstrated statistically significantly better stain 
removal (as measured by MLSI) versus the regular fluoride dentifrice after 8 weeks use.   
• Clinical study 
 found that 8 weeks’ twice daily brushing with 2 
experimental dentifrice formulations, both containing 1% alumina and 5% STP, 
provided a statistically significant reduction of dental stain (as measured by MLSI) from 
baseline; no statistically significant differences were observed between the test products 
and a regular fluoride dentifrice. 
• Clinical study 
 evaluated the stain prevention properties of an 
experimental dentifrice containing 1% alumina and 5% STP formulation.  The study 
demonstrated statistically significantly less stain build-up (as measured by MLSI) after 
8 weeks twice-daily use, compared to a regular fluoride dentifrice. 
In all the above clinical studies, study treatments were found to be generally well tolerated. 
In vitro evaluation of the experimental dentifrices to be investigated in this study has been 
performed using established models for dental stain removal (sponsor data on file).  These 
studies show both experimental formulations to be effective at removing dental stain; the 1% 
alumina, 5% STP and 2% silica formulation (with the higher relative dentine abrasivity) 
outperforms the 1% alumina and 5% STP formulation. 
In summary, existing clinical and laboratory data provide evidence of tooth cleaning efficacy 
for 1% alumina and 5% STP dentifrice formulations.  However additional clinical ‘cleaning’ 
data is required to demonstrate dental stain removal/tooth whitening efficacy of the specific 
experimental formulations to be tested in this study to support the intended consumer claims 
for these products. 
2.3 
Benefit/Risk Assessment  
Complete information for the experimental dentifrices may be found in the single reference 
safety document (SRSD), which for this study is the Safety Statement. 
Whilst the exact formulations of the experimental dentifrices under investigation have not been 
previously clinically tested, very similar products containing 5% KNO3, 1% alumina and 5% 
STP have been evaluated in clinical studies of similar design (see Background Section 2.2).  
These studies demonstrated the efficacy and safety of similar formulations.  The active 
ingredients and formulation excipients contained in the study dentifrices have a history of safe 
use in oral care products and are currently used in marketed daily use dentifrices. 
The two experimental dentifrices are considered generally safe for topical oral use, with twice 
daily brushing, under the controlled conditions of a clinical trial. 
300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI
CCI
CCI
CCI
CCI


GSK Consumer Healthcare 
 
Clinical Protocol 
 
 
Protocol Number: 300024 
 
Property of GSK Consumer Healthcare - Confidential  
May not be used, divulged, published or otherwise disclosed without the consent of GSKCH 
 Clinical Protocol Template v9.0 
Page 16 of 63 
2.4 
Mechanism of Action/Indication 
One of the main functions of a dentifrice is to help control the build-up of dental stain (Pader, 
2012). This can be achieved by inclusion of dental grade abrasives for the physical removal 
(‘polishing’) of stain from tooth surface during toothbrushing and/or by the addition of a 
chemically active cleaning compound to the formulation.  
Polyphosphates (such as STP) are chemical cleaning compounds commonly employed in oral 
care products to supplement the physical stain removal properties of dental abrasives. 
Polyphosphates have been shown to bind strongly to the tooth surface and reduce the force of 
adhesion of adsorbed proteins (Shellis et al., 2005), facilitating the removal of stain during 
toothbrushing.  Polyphosphates have also been shown to desorb salivary proteins from enamel, 
and inhibit protein adsorption (Ash et al., 2014).  Combining such ‘chelating’ agents with 
effective abrasives, such as alumina and/or silica, can be more effective for the removal of 
dental stain compared to formulations with containing dental abrasive alone. 
 
 
3 
STUDY OBJECTIVES AND ENDPOINTS 
Table 3-1 
Study Objectives and Endpoints 
Objectives 
Endpoints 
Primary 
To evaluate the change in extrinsic dental stain after 8 weeks 
twice daily use of a ‘5% KNO3/1% alumina/5% STP’ dentifrice, a 
‘5% KNO3/1% alumina/ 5% STP/2% silica’ dentifrice or a regular 
fluoride dentifrice, as measured by Total Modified Lobene Stain 
Index (Total MLSI (Area x Intensity)). 
Change from baseline in mean 
Total MLSI (Area x Intensity) 
score at week 8. 
Secondary 
To evaluate the change in extrinsic dental stain after 4 weeks 
twice daily use of a ‘5% KNO3/1% alumina/5% STP’ dentifrice, a 
‘5% KNO3/1% alumina/ 5% STP/2% silica’ dentifrice or a regular 
fluoride dentifrice, as measured by Total Modified Lobene Stain 
Index (Total MLSI (Area x Intensity)). 
Change from baseline in mean 
Total MLSI (Area x Intensity) 
score at week 4. 
To compare the change in extrinsic dental stain after 4 & 8 
weeks twice daily use of either a ‘5% KNO3/1% alumina/5% 
STP’ dentifrice or a ‘5% KNO3/1% alumina/ 5% STP/2% silica’ 
dentifrice, compared to a regular fluoride dentifrice, as 
measured by Total MLSI (Area x Intensity). 
Change from baseline in mean 
Total MLSI (Area x Intensity) 
score at weeks 4 & 8. 
To evaluate and compare the change in tooth shade (color) 
after 4 and 8 weeks twice daily use of either a ‘5% KNO3/1% 
alumina/5% STP’ dentifrice or a ‘5% KNO3/1% alumina/ 5% 
STP/2% silica’ dentifrice, compared to a regular fluoride 
dentifrice, as measured by the VITA Bleachedguide 3D-
MASTER. 
Change from baseline in mean 
VITA shade score (examiner 
assessed) at weeks 4 & 8. 
To evaluate and compare the changes in dental stain at specific 
tooth sites (along gingival margin, inter-proximally and on the 
body of the tooth) after 4 and 8 weeks twice daily use of either a 
‘5% KNO3/1% alumina/5% STP’ dentifrice or a ‘5% KNO3/1% 
alumina/ 5% STP/2% silica’ dentifrice, compared to a regular 
fluoride dentifrice, as measured by Total MLSI (Area x 
Intensity). 
Change from baseline in mean 
MLSI (Area x Intensity) in: 
• Gingival sites 
• Interproximal sites 
• Body sites 
300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI
CCI


GSK Consumer Healthcare 
 
Clinical Protocol 
 
 
Protocol Number: 300024 
 
Property of GSK Consumer Healthcare - Confidential  
May not be used, divulged, published or otherwise disclosed without the consent of GSKCH 
 Clinical Protocol Template v9.0 
Page 17 of 63 
To evaluate and compare change in extrinsic dental stain after 4 
and 8 weeks twice daily use of either a ‘5% KNO3/1% 
alumina/5% STP’ dentifrice or a ‘5% KNO3/1% alumina/ 5% 
STP/2% silica’ dentifrice, compared to a regular fluoride 
dentifrice, as measured by MLSI (Area) and MLSI (Intensity). 
Change from baseline in mean 
MLSI (Area) and MLSI (Intensity) 
Exploratory 
To evaluate and compare the change in tooth color co-ordinates 
after 4 and 8 weeks twice daily use of either a ‘5% KNO3/1% 
alumina/5% STP’ dentifrice or a ‘5% KNO3/1% alumina/ 5% 
STP/2% silica’ dentifrice, compared to a regular fluoride 
dentifrice, as measured using the VITA EasyShade. 
Change from baseline in mean 
tooth shade, L*, a*, b*, WID and 
ΔE* determined using the VITA 
EasyShade instrument at weeks 
4 & 8 
Safety 
To assess the safety and tolerability of the two experimental 
KNO3 dentifrices. 
Treatment emergent adverse 
events 
Mean MLSI values calculated for the facial surfaces of the six maxillary anterior teeth and 
six mandibular anterior teeth, and the lingual surfaces of the six mandibular anterior teeth. 
Mean tooth shade/color values are calculated for the facial surfaces of the 4 central and 
lateral maxillary incisors. 
 
This study will be considered successful if either of the experimental dentifrices demonstrates 
statistically significant stain removal (as measured by mean Total MLSI (Area x Intensity) from 
baseline after 8 weeks twice daily use. 
4 
STUDY DESIGN  
4.1 
Overall Design 
This will be a single-center, 8-week, randomized, controlled, single-blind (clinical examiner(s) 
and VITA EasyShade operator), three treatment-arm, parallel design, stratified clinical study in 
healthy volunteers with a propensity to form dental stain. It has been designed to investigate 
changes in tooth stain and color, following twice-daily use of two experimental dentifrices, after 
four- and eight-weeks twice daily use; a regular fluoride dentifrice will be included as reference 
dentifrice.  Sufficient subjects will be screened to randomize approximately 300 subjects to 
study treatment to ensure approximately 270 subjects complete the study. 
At screening (Visit 1, Day 0), subjects will give their written informed consent to participate in 
the study.  Demography, relevant medical history and current medications/treatments will be 
recorded, followed by OST and OHT examinations.  Subjects meeting the relevant study criteria, 
will be considered eligible to proceed for baseline assessments on the same day.. 
At baseline (Visit 2, Day 0) subjects, having refrained from oral hygiene procedures for at least 
6 hours, will undergo clinical assessment of the stain on the facial surfaces of their six maxillary 
anterior teeth and six mandibular anterior teeth (tooth numbers 6-11 and 22-27) and the lingual 
surfaces of their six mandibular anterior teeth (tooth numbers 22-27) using the MacPherson 
modification (Macpherson et al., 2000) of the Lobene Stain Index (Lobene, 1968) (MLSI). The 
shade (color) of the facial surfaces of the central and lateral maxillary incisors (tooth numbers 
7-10) will then be assessed clinically using the VITA Bleachedguide 3D-MASTER (Gómez‐
Polo et al., 2015) and the color of the same surfaces will be evaluated using the VITA 
300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI


GSK Consumer Healthcare 
 
Clinical Protocol 
 
 
Protocol Number: 300024 
 
Property of GSK Consumer Healthcare - Confidential  
May not be used, divulged, published or otherwise disclosed without the consent of GSKCH 
 Clinical Protocol Template v9.0 
Page 18 of 63 
EasyShade instrument (Tung et al., 2002). Subjects who fulfil all inclusion/exclusion criteria 
will be enrolled into the study. 
Qualifying subjects with a Total MLSI (A x I)  15 for the facial surfaces of the 12 anterior teeth 
and a mean tooth shade  11 on the facial surfaces of the 4 maxillary incisors, who meet all 
other entry criteria, will be stratified according to their baseline Total MLSI (A x I) (low < 45; 
high ≥ 45) and smoking status (smoker; non-smoker) and randomized to study treatment.  
Randomized subjects will brush twice daily (morning and evening) with their assigned study 
dentifrice for the next 8 weeks and record each brushing in the diary provided; significant 
changes in diet or smoking status should also be noted in the diary. Subjects, having refrained 
from oral hygiene procedures for at least 6 hours, will return to the clinic after 4- and 8-weeks 
treatment (Visits 3 and 4, respectively) for clinical and instrumental assessments of dental stain 
and tooth shade/color.  
The clinical examiner will perform replicate MLSI and tooth shade assessments (as described 
in Sections 9.2.1.1 and 9.2.2.1, respectively) at Visits 2-4.  The clinical examiner may brush the 
subject’s anterior teeth with water and/or floss between the anterior teeth prior to MLSI 
assessments, if required, to remove any debris on the teeth.  
Safety and oral tolerability of the study products will be monitored over the 8-week usage period 
by review of reported AEs. 
4.2 
Scientific Rationale for Study Design 
Subjects will be stratified according to their smoking status and their baseline tooth stain score 
to ensure a balance in all treatment groups. 
A parallel group experimental design was selected as carryover effects from the treatment 
groups would be anticipated. 
According to the International Conference on Harmonisation (ICH) guidelines (ICH, Nov 2016), 
for a study to be classified as truly double-blind, not only does the examiner (and any 
appropriate member of staff who may be involved in the dispensing of products, analysis of 
data etc.) need to be blind to the treatment a subject receives, but the products under test must 
be identical in every way (color, flavor, rheology, appearance, packaging).  Given it is almost 
impossible to ensure identical appearance, taste and packaging for the dentifrices evaluated in 
oral care studies, the level of product blinding for this study is described as ‘examiner blind’. 
Study dentifrices will be supplied in overwrapped tubes. The blind will be maintained by staff 
involved in dispensing, brushing instruction and supervised brushings not being involved in the 
clinical examinations and study products being provided to subjects in blinded packs. 
Dental examiner(s) and VITA EasyShade operator(s) will be blind to treatment allocation to 
ensure there is no bias in the assessments. 
This is a single-center study.  The same examiner will perform the clinical assessments and 
instrumental measures throughout the study to eliminate the possibility of inter-examiner 
variability. 
A regular fluoride dentifrice has been selected as reference dentifrice.  For the purposes of this 
study, it was deemed more relevant to compare the efficacy of the experimental dentifrices 
against the stain removal/tooth whitening performance of a typical daily use dentifrice (which 
contains dental abrasive) rather than a placebo with no abrasive cleaning component. 
300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI


GSK Consumer Healthcare 
 
Clinical Protocol 
 
 
Protocol Number: 300024 
 
Property of GSK Consumer Healthcare - Confidential  
May not be used, divulged, published or otherwise disclosed without the consent of GSKCH 
 Clinical Protocol Template v9.0 
Page 19 of 63 
The experimental dentifrices, when marketed, will be indicated for DH. It is anticipated they 
will be purchased by consumers with DH who desire whiter teeth (less dental stain). However, 
the study objectives relate solely to dental stain and tooth color, both of which are independent 
of DH; thus, study subjects are not specifically required to experience DH nor do the exclusion 
criteria exclude subjects with DH.  Subjects will be stratified according to their baseline tooth 
stain score and smoking status to ensure balance across the three treatment groups. 
An 8-week treatment period is deemed sufficient to observe the anticipated clinical benefits; 4-
week assessments are included should more rapid clinical effects occur. 
The clinical measures used in this study, MLSI and VITA shade guide, are well established in 
the scientific literature for the evaluation of dental stain and tooth color respectively (Joiner and 
Luo, 2017).  VITA shade guides are routinely used by dentists in practice to assess the color of 
natural teeth to enable accurate matching of prosthetic devices (e.g. crowns, partial dentures) to 
the natural dentition.  The VITA shade guide selected for use in this study (VITA Bleachedguide 
3D-MASTER) has the advantage over the classic VITA shade guide in providing a linear 
presentation of tooth shade which will enable more accurate assessment of shade changes 
(Paravina, 2008).  Furthermore, it is accepted by the American Dental Association for use in 
determining the efficacy of tooth whitening products (ADA, 2020). 
The VITA EasyShade instrument, whilst being a more recent approach to the assessment of 
tooth color, has been shown to provide precise measurement of tooth color in a previous clinical 
study (Dozić et al., 2007) and offers the potential for objective, examiner-independent 
evaluation of tooth color (Knezovic Zlataric et al., 2016).  It is included in this study is to 
provide further information on tooth color-specific variables (e.g. L*, a*, b*, WID and ΔE) that 
could provide greater understanding on the tooth-cleaning properties of the experimental 
dentifrices. 
Whilst the study products are not contra-indicated for pregnancy (their use would not be 
expected to cause harm either to the mother or foetus), pregnant females will be excluded from 
this study due to the increased prevalence and severity of gingivitis and periodontal disease 
along with increased amounts of calculus and oral debris observed with pregnancy, both of 
which could impact dental stain and tooth color (Samant et al., 1976).  The severity of these 
conditions is known to vary during the course of pregnancy (Samant et al., 1977), thus 
pregnancy would be a confounding factor for the objectives of this study.  Pregnant females and 
those intending to become pregnant will be excluded.  Pregnancy will be monitored by subject-
reported pregnancy status. 
4.3 
Justification for Dose 
Subjects will brush with their assigned dentifrices twice daily for 2 minutes as per the American 
Dental Association recommendations for effective toothbrushing (ADA, 2022) and the UK 
National Health Service teeth cleaning guide (NHS, 2019). 
On each brushing occasion, the toothbrush will be dosed with a ribbon of dentifrice (covering 
the entire length of the toothbrush), in line with the proposed product labelling for the 
experimental dentifrices and the current product labelling for the marketed reference dentifrice. 
No dose modification is permitted in this study.  Any variation from the product usage 
instructions should be communicated to study site personnel and recorded as a deviation. 
300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI


GSK Consumer Healthcare 
 
Clinical Protocol 
 
 
Protocol Number: 300024 
 
Property of GSK Consumer Healthcare - Confidential  
May not be used, divulged, published or otherwise disclosed without the consent of GSKCH 
 Clinical Protocol Template v9.0 
Page 20 of 63 
4.4 
End of Study Definition 
A subject is considered to have completed the study if they have completed all phases of the 
study, including the last visit or the last scheduled procedure shown in the Schedule of Activities. 
The end of this study is defined as the date of the last subject last visit date. 
5 
STUDY POPULATION 
5.1 
Type and Planned Number of Subjects 
Healthy volunteers of either sex and any gender, aged 18 – 65 years will be recruited with 
sufficient levels of dental stain and appropriate tooth color to allow for evaluation of change 
(reduction) in these parameters during the study.  Subjects will be recruited from the study site’s 
database. 
Sufficient subjects will be screened to randomize approximately 300 subjects (equally 
distributed across the three treatment groups) to ensure approximately 270 evaluable subjects 
complete the entire study. 
An enrolled subject is one who has agreed to participate in the clinical study following 
completion of the informed consent process directly or via their legally authorized 
representative and successfully met eligibility criteria to proceed beyond the screening visit as 
applicable for the protocol design.  
This study can fulfill its objectives only if appropriate subjects are enrolled.  The following 
eligibility criteria are designed to select subjects for whom participation in the study is 
considered appropriate.  All relevant medical and non-medical conditions should be taken into 
consideration when deciding whether a subject is suitable for this protocol.   
Subject eligibility to participate in the clinical study should be reviewed and documented by an 
appropriate member of the investigator’s study team before subjects are included in the study. 
5.2 
Inclusion Criteria 
An individual must meet all the following inclusion criteria to be eligible to be included into 
the study: 
1. Provision of a signed and dated informed consent document indicating that the subject has 
been informed of all pertinent aspects of the study before any assessment is performed. 
2. Subject is of either sex and any gender who, at the time of screening, is between the ages 
of 18-65 years, inclusive. 
3. Subject who is willing and able to comply with scheduled visits, product usage 
requirements, study procedures and lifestyle restrictions. 
4. Subject in good general and mental health with, in the opinion of the investigator or 
medically qualified designee, no clinically significant or relevant abnormalities in medical 
history (for example, a medical condition confirmed to be causing xerostomia),or upon 
oral examination, that would impact the subject’s safety, wellbeing or the outcomes of the 
study, if they were to participate in the study, or affect the subject’s ability to understand 
and follow study procedures and requirements. 
5. Subject with generally good oral health with: 
a. At least 16 natural (vital) teeth including 11 of the 12 anterior teeth. 
300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI


GSK Consumer Healthcare 
 
Clinical Protocol 
 
 
Protocol Number: 300024 
 
Property of GSK Consumer Healthcare - Confidential  
May not be used, divulged, published or otherwise disclosed without the consent of GSKCH 
 Clinical Protocol Template v9.0 
Page 21 of 63 
b. Facial surfaces of all anterior teeth (maxillary and mandibular) and lingual surfaces 
of anterior teeth (mandibular only) gradable for MLSI with no significant calculus 
or large restorations as judged by the clinical examiner. 
c. Presence of extrinsic dental stain (formed on the surface of the teeth) which, in the 
opinion of the clinical examiner, originates from the diet and/or use of tobacco 
products. 
d. Facial surfaces of central and lateral maxillary incisors gradable for tooth shade (free 
of cervical margin defects and restorations which could impact assessment), as 
judged by the clinical examiner.  
e. Baseline Total MLSI (A x I)  15 for the facial surfaces of the 12 anterior teeth. 
f. Baseline mean tooth shade (VITA Bleachedguide 3D-MASTER)  11 on the facial 
surfaces of the 4 maxillary incisors. 
5.3 
Exclusion Criteria 
An individual who meets any of the following exclusion criteria will be excluded from the study: 
1. Subject who is an employee of the investigational site, either directly involved in the 
conduct of the study or a member of their immediate family; or an employee of the 
investigational site otherwise supervised by the investigator; or an employee of the 
sponsor directly involved in the conduct of the study or a member of their immediate 
family. 
2. Subject who has participated in other studies (including non-medicinal studies) involving 
investigational product(s) within 30 days of study entry and/or during study participation 
or who has previously been enrolled in this study. 
3. Subject with, in the opinion of the investigator or medically qualified designee, an acute or 
chronic medical or psychiatric condition or laboratory abnormality that may increase the 
risk associated with study participation or study product administration or may interfere 
with the interpretation of study results and, in the judgment of the investigator or 
medically qualified designee, would make the subject inappropriate for entry into this 
study. 
4. Subject who is pregnant (self-reported) or intending to become pregnant during the study. 
5. Subject who is breastfeeding. 
6. Subject with known or suspected intolerance or hypersensitivity to the study products or 
any of their stated ingredients (or closely related compounds).  
7. Subject who is unwilling or, in the opinion of the investigator or medically qualified 
designee, unable to comply with the requirements and/or lifestyle restrictions of the study.  
8. Subject with a recent history (within the last year) of alcohol or other substance abuse. 
9. Subject with OST examination findings at Screening which, in the opinion of the 
investigator, could interfere with the conduct of the study (for example, stomatitis, open 
sores, lesions, cavitied caries lesions, redness or swelling. 
10. Subject using daily oral care products and/or taking daily doses of medications/treatments 
which, in the opinion of the investigator or medically qualified designee, could interfere 
with study outcomes, specifically: 
a) currently daily use of mouthwashes containing ingredients known to cause tooth 
stain (for example, chlorhexidine or cetylpyridinium chloride),  
300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI


GSK Consumer Healthcare 
 
Clinical Protocol 
 
 
Protocol Number: 300024 
 
Property of GSK Consumer Healthcare - Confidential  
May not be used, divulged, published or otherwise disclosed without the consent of GSKCH 
 Clinical Protocol Template v9.0 
Page 22 of 63 
b) past or current use of minocycline, 
c) use of tetracycline or doxycycline within 30days of screening and/or during the 
study, 
d) medications known to cause tooth stain (for example, drugs or supplements 
containing metal ions known to increase enamel staining). 
11. Subject who has used any professionally-dispensed tooth whitening products 6 months 
prior to baseline or any over-the-counter products (including peroxide- or covarine blue-
containing dentifrice, but not other daily use whitening dentifrices) 3 months prior to 
baseline. 
12. Specific exclusions for assessment teeth: 
a. Non-vital tooth. 
b. Tooth with evidence of current or recent carious lesions. 
c. Tooth used as an abutment for fixed or partial dentures 
d. Tooth adjacent to fixed retainers and fixed or removable orthodontic appliances. 
e. Tooth with surface irregularities, cracked enamel, discoloration due to trauma or 
orthodontic treatment, tetracycline stain, restorations or hyper-/hypoplastic areas, 
which, in the opinion of the clinical examiner, grading of extrinsic dental stain and 
tooth shade. 
f. Tooth with a crown or veneer. 
g. Tooth with exposed dentine which, in the opinion of the investigator, could impact 
grading of extrinsic dental stain and tooth shade. 
13. General oral exclusions: 
a. Generalized severe gingivitis or advanced periodontal disease; treatment of 
periodontal disease (including surgery) within 12 months of screening; scaling or root 
planning within 3 months of screening. 
b. Any oral condition requiring immediate care. 
c. Having received a dental prophylaxis within 8 weeks of screening. 
14. Subject who, in the opinion of the investigator, should not participate in the study. 
5.4 
Randomization Criteria 
Subjects who satisfy the study selection criteria will be stratified will be stratified according to 
their baseline Total MLSI (A x I) (low < 45; high ≥ 45) and smoking status (smoker; non-
smoker) and randomized to study treatment.  
The two stratification factors will give rise to four strata. 
• Stratum 1: Baseline Total MLSI (A x I) < 45, Smoker 
• Stratum 2: Baseline Total MLSI (A x I) < 45, Non-smoker 
• Stratum 3: Baseline Total MLSI (A x I) ≥ 45, Smoker 
• Stratum 4: Baseline Total MLSI (A x I) ≥45, Non-smoker 
5.5 
Lifestyle Considerations 
The site may contact subjects to remind them of lifestyle restrictions and approaching scheduled 
visits. 
300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI


GSK Consumer Healthcare 
 
Clinical Protocol 
 
 
Protocol Number: 300024 
 
Property of GSK Consumer Healthcare - Confidential  
May not be used, divulged, published or otherwise disclosed without the consent of GSKCH 
 Clinical Protocol Template v9.0 
Page 23 of 63 
5.5.1 
Oral Hygiene Restrictions 
• Visit 1 onwards: Eligible subjects will not be permitted to use chewing gum from 
screening to the end of the study. 
• Visits 2, 3 & 4: Subjects will abstain from all oral hygiene procedures (including tooth 
brushing) for at least 6 hours prior to and during their clinical/instrumental 
assessment visits. 
• Visit 1 onwards: Subjects should not use any other oral care products (for example, 
dentifrices, toothbrushes, oral rinses, tongue cleaners, whitening/bleaching products, 
interdental cleaning products) than those provided during the study.  
Dental floss can be used to remove impacted food from the anterior teeth; subjects 
may floss posterior teeth provided they do not abut an assessment tooth.  
5.5.2 
Dietary Restrictions 
• Visits 2, 3 & 4: Subjects will abstain from eating and drinking (with the exception of 
small amounts of water required for taking medication) for at least 2 hours prior to 
and during their clinical/instrumental assessment visits. 
5.5.3 
Use of Cosmetics 
• Visits 2, 3 & 4: Subjects will refrain from applying lipstick or colored lip coverings 
prior to and during their clinical/instrumental assessment visits. 
5.5.4 
Tobacco Product Restrictions 
• Visit 1 onwards: Subjects will not be permitted to use chewing tobacco from 
screening to the end of the study. 
• Visits 1-4: Subjects will not be permitted to smoke, vape or use tobacco products 
during their scheduled visits to the study site. 
5.5.5 
Medication and Treatment Restrictions 
• Visits 1-4: Subjects will be asked to delay elective dental treatment (for example, 
dental prophylaxis) for the duration of the study. They will be required to inform site 
staff of any emergency treatment they receive during the study. 
• Visits 3 & 4: Subjects will be asked to inform site staff of changes to their 
medications/treatments for the duration of the study. Should a subject commence a 
course of medication which, in the opinion of the investigator or medically qualified 
designee, could impact study outcomes, the subject may be withdrawn.  
5.5.6 
Contraception 
There are no contraception requirements for subjects participating in this study.  At each visit, 
female subjects of child-bearing potential should verbally confirm they are not currently 
pregnant or planning to become pregnant. 
5.6 
Screen Failures 
Screen failures are defined as subjects who consent to participate in the clinical study but are 
not subsequently randomized. To ensure transparent reporting of screen failure subjects, a 
minimal set of screen failure information will be collected, including demography, reason for 
300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI


GSK Consumer Healthcare 
 
Clinical Protocol 
 
 
Protocol Number: 300024 
 
Property of GSK Consumer Healthcare - Confidential  
May not be used, divulged, published or otherwise disclosed without the consent of GSKCH 
 Clinical Protocol Template v9.0 
Page 24 of 63 
screen failure (e.g. withdrawal of consent), eligibility criteria, any protocol deviations and any 
adverse events or incidents as applicable.  
Individuals who do not meet the criteria for participation in this study (screen failure) may not 
be re-screened. 
5.7 
Sponsor’s Qualified Medical Personnel 
Contact information for the sponsor's appropriately qualified medical/dental personnel for the 
study is documented in the Study Contact List located in the investigator study master file held 
at the study site. 
The contact number is only to be used by site staff seeking advice on medical/ dental questions 
or problems in the event that the established communication pathways between the study site 
and the sponsor’s study team are not available. 
The contact number is not intended for direct use by study subjects.  To facilitate access to 
appropriately qualified medical/dental personnel on study-related medical/dental questions or 
problems, subjects will be provided with a contact card.  The contact card will provide, as a 
minimum, protocol identifiers, the subject’s study identification number, contact information 
for the study site, and contact details in the event that the study site cannot be reached to provide 
advice on a medical question or problem identified by a healthcare professional other than the 
investigator. 
5.8 
Clinical Examiner Qualifications  
Clinical examiner(s) involved in the screening, safety and efficacy assessments will be 
appropriately qualified dental professionals, registered to practice in the US.  
Oral examinations to determine subject eligibility and to monitor the safety/performance of 
study products will be performed by appropriately trained clinical examiner(s), with prior 
relevant clinical experience.  Clinical examiner(s) will also be experienced in use of the VITA 
EasyShade instrument for intra-oral measurement of tooth shade. 
6 
INVESTIGATIONAL/STUDY PRODUCTS 
6.1 
Investigational/Study Product Supplies 
The following study products will be supplied by the sponsor’s Clinical Supplies Group. 
300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI


GSK Consumer Healthcare 
 
Clinical Protocol 
 
 
Protocol Number: 300024 
 
Property of GSK Consumer Healthcare - Confidential  
May not be used, divulged, published or otherwise disclosed without the consent of GSKCH 
 Clinical Protocol Template v9.0 
Page 25 of 63 
Table 6-1 
Investigational/Study Product Supplies 
Product 
Description 
Experimental  
Dentifrices 
Reference 
Dentifrice 
5% KNO3 dentifrice 
with 1% alumina and 
5% STP 
5% KNO3 dentifrice 
with 1% alumina,  
5% STP and 2% high 
cleaning silica 
Regular Fluoride 
Dentifrice 
Product Name 
N/A 
N/A 
Aquafresh Cavity 
Protection  
(US market) 
Fluoride 
Content 
0.2542% NaF (1100 ppm fluoride) 
Pack Design 
One carton containing 2 tubes of dentifrice 
Dispensing 
Details 
Visit 2 (Baseline): 2 cartons; Visit 3 (Week 4): 2 cartons  
Product Master 
Formulation 
Code (MFC) 
 
 
 
Dose/Product 
Application 
Subjects will dose the toothbrush provided with a strip of dentifrice  
(a full brush head) on each brushing occasion 
Route of 
Administration 
Topical oral use 
Usage 
Instructions 
Subjects will brush twice daily (morning and evening) for 2 timed minutes 
with their allocated product. 
Return 
Requirements 
Used and unused study product to be returned to the sponsor. 
 
The following sundry items will be supplied by the sponsor’s Global Clinical Supplies Group. 
Table 6-2 
Sundry Items 
Item 
Pack Design 
Dispensing 
Details 
Return/Disposal Details 
Used Samples 
Unused 
Samples 
Parodontax Complete 
Protection Soft-Bristled 
Toothbrush (US market) 
Individual 
toothbrush in 
commercial pack  
Visit 2:  
1 brush 
Visit 3:  
1 brush 
Destroy at site 
using site disposal 
procedures 
Return 
to 
sponsor 
Countdown Timer 
Individual 
toothbrush in 
commercial pack 
At Visit 2:  
1 timer 
Subject to keep or 
destroy at site 
using site disposal 
procedures 
Return 
to 
sponsor 
300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI
CCI
CCI
CCI


GSK Consumer Healthcare 
 
Clinical Protocol 
 
 
Protocol Number: 300024 
 
Property of GSK Consumer Healthcare - Confidential  
May not be used, divulged, published or otherwise disclosed without the consent of GSKCH 
 Clinical Protocol Template v9.0 
Page 26 of 63 
Detailed instructions for the return of study product/study supplies for the accountability checks 
and subsequent destruction which will be provided by the sponsor during the study in time for 
study close out visit. 
6.1.1 
Medical Devices 
The toothbrushes to be used in this study are medical devices. 
6.1.2 
Dosage Form and Packaging 
The study products are dentifrices, intended for topical oral use, and will be applied by 
toothbrushing using a manual toothbrush. 
The experimental dentifrices will be manufactured and filled into plain white tubes by the 
sponsor; the reference dentifrice will be supplied in its commercial pack. All study dentifrices 
will be overwrapped in white vinyl (to mask their identity and obscure the branding of the 
marketed product) with a study label affixed. The content of the product labels will be in 
accordance with all applicable regulatory requirements and will be the responsibility of the 
sponsor’s Global Clinical Supplies Group. Each study label will contain, but not be limited to, 
protocol number, directions for use and storage requirements.  
Each subject will receive sufficient tubes of their assigned study dentifrice for usage during the 
8-week treatment period. Sundry items will be supplied in their commercial packaging for 
dispensing by study staff as specified in Table 6.2.  
Care should be taken with the supplied products and their labels so that they are maintained in 
good condition.  It is important that all labels remain intact and legible for the duration of the 
study. Subjects should be instructed to not remove or deface any part of the study label. 
All products supplied are for use only in this clinical study and should not be used for any other 
purpose. 
6.1.3 
Preparation and Dispensing  
Subjects will be assigned to study treatment in accordance with the randomization schedule 
generated by an approved sponsor vendor, prior to the start of the study, using validated 
software. 
The product dispensing area will be separate from the clinical examination area. Study 
dentifrices will be dispensed to the subject, by trained site personnel.  These staff members will 
not be involved in any safety/product performance assessments or any other aspect of the study 
that could be influenced by the knowledge of product a subject has been assigned to. An 
additional member of the site staff will verify the dispensing procedure has been completed 
accurately for each subject. 
6.2 
Administration 
Only subjects enrolled in the study may receive study products and only authorized site staff 
may supply or administer study products. All study products must be stored in a secure, 
environmentally controlled, and monitored (manual or automated) area in accordance with the 
labeled storage conditions with access limited to the authorized site staff only. 
Subjects will be instructed to self-administer their assigned study dentifrice according to the 
usage instructions provided to the subject.  Additionally, subjects will undergo supervised 
brushing at Visits 2-4 to ensure compliance with brushing instructions.  The reference dentifrice 
300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI


GSK Consumer Healthcare 
 
Clinical Protocol 
 
 
Protocol Number: 300024 
 
Property of GSK Consumer Healthcare - Confidential  
May not be used, divulged, published or otherwise disclosed without the consent of GSKCH 
 Clinical Protocol Template v9.0 
Page 27 of 63 
is commercially available and the application instructions described in this protocol are 
consistent with it’s label instructions.  The two experimental dentifrices are intended for 
commercialization and the application instructions here are consistent with the intended label 
instructions. 
To help ensure subjects understand the amount of dentifrice they should use each time they 
brush, brushing instructions and diary completion requirements: 
• staff will demonstrate dispensing a full ribbon of dentifrice along the length of the 
toothbrush head to each randomized subject and supervise their first brushing with study 
dentifrice and diary completion at the end of the baseline visit (Visit 2), after all clinical 
assessments have been completed. 
• staff will supervise a brushing with study dentifrice and diary completion at the end of 
the Week 4 visit (Visit 3), after all clinical assessments have been completed. 
On-site administration of study products will also be recorded in the CRF. 
Instructions on usage of the study products are detailed in the Section 15.1. 
Subjects should ensure they do not brush their teeth for at least 6 hours prior to attending site at 
Visits 2-4. 
6.2.1 
Product Usage Errors 
In this study, product usage errors may result, in this study, from the administration or 
consumption of:  
• the wrong product, 
• by the wrong subject,  
• at the wrong time,  
• or at the wrong dosage.  
Such errors occurring to a study subject are to be captured in the CRF.  In the event of a product 
usage error, the sponsor should be notified immediately and under no circumstance should 
this exceed 24 hours. 
Product usage errors are reportable irrespective of the presence of an associated AE, including: 
• Usage errors involving subject exposure to any of the study products; 
• Potential product errors or uses outside of what is foreseen in the protocol that do or 
do not involve the participating subject. 
If a study product usage error is accompanied by an AE, as determined by the investigator, the 
usage error and, any associated adverse event(s) are to be captured in the CRF AE form.  
6.2.2 
Overdose 
An overdose is a deliberate or inadvertent administration of a product at an amount higher than 
specified in the protocol. 
Overdose is not likely to occur in this study. 
Overdose per se is not an AE. However, any clinical sequelae of an overdose should be reported 
as an AE (and serious adverse event (SAE), if appropriate). For reporting, follow the AE and 
SAE reporting instructions. 
300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI


GSK Consumer Healthcare 
 
Clinical Protocol 
 
 
Protocol Number: 300024 
 
Property of GSK Consumer Healthcare - Confidential  
May not be used, divulged, published or otherwise disclosed without the consent of GSKCH 
 Clinical Protocol Template v9.0 
Page 28 of 63 
6.3 
Investigational/Study Product Storage  
The investigator or designee must confirm appropriate temperature conditions have been 
maintained during transit for all study products received and any discrepancies are reported and 
resolved before use according to the supplied shipping documentation. 
The investigator, or designee, will ensure that all study products are stored in a secured, 
environmentally monitored (manual or automated) area with controlled access (authorized site 
staff only) in accordance with the labeled storage conditions and Clinical Study Supplies 
Checklist, and in accordance with applicable regulatory requirements.  
Site systems must be capable of measuring and documenting (for example, via a log), at a 
minimum, daily minimum and maximum temperatures for all site storage locations (as 
applicable, including frozen, refrigerated, and/or room-temperature products).  This should be 
captured from the time of first product receipt throughout the study.  Even for continuous 
monitoring systems, a log or site procedure that ensures active daily evaluation for excursions 
should be available.  The operation of the temperature-monitoring device and storage unit (for 
example, refrigerator), as applicable, should be regularly inspected to ensure it is maintained in 
working order.  
Any excursions from the product-label storage conditions should be reported to appropriate site 
staff upon discovery and communicated to sponsor as soon as possible.  The site should actively 
pursue options for returning the product to the storage conditions as described in the labeling, 
as soon as possible.  Excursions from the storage requirements, including any actions taken, 
must be documented as a protocol deviation and reported to the sponsor. 
Once an excursion is identified, the affected product (or products) must be quarantined and not 
used until the sponsor provides documentation of permission to use. Use of any of the affected 
product(s) prior to sponsor approval will be considered a protocol deviation.   
Site staff will instruct subjects on the proper storage requirements for all take-home products.  
6.4 
Study Product Accountability 
All products supplied are for use only in this clinical study and should not be used for any other 
purpose. 
All study products must be received by a designated person at the study sites, handled and stored 
safely and properly, and kept in a secured location to which only authorized site staff have 
access. Upon receipt, all study products should be stored according to the instructions specified 
on the product labels. Study products are to be dispensed only to subjects enrolled in the study 
in accordance with the protocol, by authorized site staff. 
The study site must maintain adequate records documenting the receipt, use, loss, or other 
disposition of all the product supplies. All study products will be accounted for using the 
investigational/study product accountability form/record. The investigator is responsible for 
study product accountability, reconciliation, and record maintenance.  
Subjects should return their used and unused study products to the clinical site at Visits 3 and 4 
in accordance with the study schedule.  Study product return will be documented.  Subjects will 
complete diaries to detail their usage of study products which will be used to monitor usage 
compliance. 
300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI


GSK Consumer Healthcare 
 
Clinical Protocol 
 
 
Protocol Number: 300024 
 
Property of GSK Consumer Healthcare - Confidential  
May not be used, divulged, published or otherwise disclosed without the consent of GSKCH 
 Clinical Protocol Template v9.0 
Page 29 of 63 
The accountability records must be available for inspection by the study monitor during the 
study. Monitoring of product accountability will be performed by the monitor during site visits 
and at the completion of the study.  
6.4.1 
Destruction of Investigational/Study Product Supplies  
At the end of the study, the Principal Investigator or an appropriate designee, and a 
representative of the sponsor (study monitor) will inventory all used and unused study products 
and sundry items.  The study product accountability record for returned study products will then 
be completed. All study product (used and unused) for this clinical study will be returned for 
destruction to the sponsor’s Clinical Supplies Department or designated vendor using the return 
instructions provided. Detailed instructions for the return of study product/study supplies for 
the accountability checks and subsequent destruction will be provided by the sponsor during 
the study in time for study close out visit. 
6.5 
Blinding and Allocation/Randomization 
All subjects will be centrally randomized to one of the three study products using an Interactive 
Response Technology (IRT). Before the study is initiated, training, login information and 
directions for the IRT will be provided. Study products will be dispensed according to the 
instruction received through the IRT at the appropriate study visits. 
Returned study products should not be re-dispensed to any subject. 
The investigator’s knowledge of the product allocation should not influence the decision to 
enroll a subject or affect the order in which subjects are enrolled. 
While this study is described as examiner-blind (the clinical examiner(s) performing the 
efficacy assessments will be blinded to the product received).  To ensure the examiner(s) 
remains blinded throughout the study, the examiner(s) will not be permitted in any area where 
study product is stored, dispensed, or in use staff involved in the preparation and dispensing of 
study products will work in a separate area, and subjects will be instructed not to remove study 
products from the opaque bags provided/cartons outside of the dispensing room, while at the 
study site. Dispensing staff will not be involved in any efficacy/safety assessment procedures 
during the study. 
Site staff, study statistician(s), data management staff and other employees of the sponsor and 
vendors acting on behalf of the sponsor, who may influence study outcomes will be blinded to 
the product allocation.   
Prior to randomization, subjects will be stratified on their baseline MLSI score and smoking 
status as detailed in Section 5.4. 
6.6 
Breaking the Blind 
At the initiation of the study, the study site will be instructed on the method for breaking the 
blind.  The method will be an electronic process. 
The electronic system will be programmed with blind-breaking instructions. In case of an 
emergency, the investigator has the sole responsibility for determining if unblinding of a 
subject’s product assignment is warranted. Subject safety must always be the first consideration 
in making such a determination. If the investigator decides that unblinding is warranted, the 
investigator should make every effort to contact the sponsor prior to unblinding a subject’s 
product assignment unless this could delay emergency treatment of the subject. 
300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI


GSK Consumer Healthcare 
 
Clinical Protocol 
 
 
Protocol Number: 300024 
 
Property of GSK Consumer Healthcare - Confidential  
May not be used, divulged, published or otherwise disclosed without the consent of GSKCH 
 Clinical Protocol Template v9.0 
Page 30 of 63 
If a subject’s product assignment is unblinded, the sponsor must be notified within 24 hours 
after breaking the blind. The date and reason that the blind was broken must be recorded in the 
source documentation and case report form, as applicable. 
Any AE associated with breaking the blind must be recorded and reported as specified in this 
protocol. The study site may also be required be required to inform the Institutional Review 
Board (IRB) if the blind is broken.  
6.7 
Compliance 
To facilitate subject compliance with product usage requirements:  
• First use of their assigned study dentifrice will be carried out under supervision at the 
study site at the end of the baseline visit (Visit 2); study staff will demonstrate the correct 
amount of dentifrice to dispense and how to use the timer to ensure a 2-minute brushing 
time. A further supervised brushing will be carried out at the study site at the end of 
Week 4 procedures (Visit 3). 
• Subjects will be provided with a diary at baseline (Visit 2) and Week 4 (Visit 3) to record 
each completed brushing with study product. 
• Subjects will attend each study visit with all tubes of dentifrice provided (used and 
unused) for a visual check of product usage, and with their completed diary for review 
by study staff. Any suspected over or under use, the number of any missed or additional 
brushings will be documented as deviations in the CRF; subjects will be re-instructed in 
the correct use of product and diary completion, as required 
• Subjects will also use the diary to note any issues with their study product, any oral 
problems, illnesses and new medications/ treatments. Details relevant to safety or 
efficacy should be reviewed by the investigator (or suitably qualified designee) and 
transcribed to the CRF, as appropriate; AEs must be documented in the CRF.  
The number of any missed or additional applications or doses will be captured as protocol 
deviations. Subjects will be re-instructed in the correct usage requirements and diary completion 
as needed. 
A record of the number of dentifrice tubes dispensed to and taken by each subject must be 
maintained and reconciled with study intervention and compliance records. Intervention start 
and stop dates, including dates for intervention delays and/or dose reductions will also be 
recorded in the CRF. 
6.8 
Concomitant Medication/Treatment(s) 
Any medications, treatments or vaccine (including over-the-counter or prescription medicines, 
vitamins, and/or herbal supplements) taken during the study, from signing the informed consent, 
must be recorded in the CRF with indication, reason for use, unit dose, daily dose, and start and 
stop dates of administration.  All subjects will be questioned about medications/treatments at 
each site visit. 
Medication/treatments taken 28 days prior to signing the informed consent form and until first 
study product application will be documented as a prior medication/treatment.  
Medications/treatments taken after first study product application will be documented as 
concomitant medication/treatments. 
300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI


GSK Consumer Healthcare 
 
Clinical Protocol 
 
 
Protocol Number: 300024 
 
Property of GSK Consumer Healthcare - Confidential  
May not be used, divulged, published or otherwise disclosed without the consent of GSKCH 
 Clinical Protocol Template v9.0 
Page 31 of 63 
7 
DISCONTINUATION OF STUDY INTERVENTION AND 
SUBJECT DISCONTINUATION/WITHDRAWAL 
7.1 
Subject Discontinuation/Withdrawal  
A subject may withdraw from the study at any time at their own request or may be withdrawn 
at any time at the discretion of the investigator or sponsor for safety, behavioral reasons, or the 
inability of the subject to comply with the protocol-required schedule of study visits or 
procedures.   
The following circumstances require discontinuation of study product and/or premature subject 
withdrawal: 
• Protocol violation that may impact the subject’s safety 
• Withdrawal of informed consent 
• Subject lost to follow-up  
• Unblinding of the subject  
• Pregnancy 
If a subject is discontinued or prematurely withdraws from the study, the reason(s) for 
discontinuation or withdrawal and the associated date must be documented in the relevant 
section(s) of the CRF.  
7.2 
Lost to Follow up 
If a subject fails to return to the site for a required study visit, the site must attempt to contact 
the subject and reschedule the missed visit as soon as possible and counsel the subject on the 
importance of maintaining the assigned visit schedule and ascertain whether the subject wishes 
to and/or should continue in the study. 
A subject will be considered lost to follow up if they repeatedly fail to return for scheduled 
visits and is unable to be contacted by the study site. Before a subject is deemed lost to follow 
up, the investigator or designee must make every effort to regain contact with the subject (where 
possible, 3 telephone calls and, if necessary, a certified letter to the subject’s last known mailing 
address or local equivalent methods). These contact attempts should be documented. If contact 
is made with the subject, the investigator should inquire about the reason for withdrawal, request 
that the subject return all products provided and, if appropriate, request that the subject return 
for a final visit and follow-up with the subject regarding any unresolved adverse events (AEs). 
Final safety assessments may be carried out when the subject returns to the study site, at the 
investigator’s discretion, which could include an oral examination. 
Should the subject continue to be unreachable, they will be considered to have withdrawn from 
the study and lost to follow up.  
Lack of completion of all or any of the early termination procedures will not be viewed as 
protocol deviations so long as the subject’s safety was preserved. 
If the subject withdraws from the study and withdraws consent for disclosure of future 
information, no further evaluations should be performed, and no additional data should be 
collected.  The sponsor may retain and continue to use any data collected before such 
withdrawal of consent. 
300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI


GSK Consumer Healthcare 
 
Clinical Protocol 
 
 
Protocol Number: 300024 
 
Property of GSK Consumer Healthcare - Confidential  
May not be used, divulged, published or otherwise disclosed without the consent of GSKCH 
 Clinical Protocol Template v9.0 
Page 32 of 63 
8 
STUDY PROCEDURES 
This section lists the procedures to be completed at each planned study visit.  The timing of 
each procedure is listed in the Schedule of Activities section. 
Adherence to the study design requirements, including all procedures is essential and required 
for study conduct. 
8.1 
Visit 1/Screening 
Screening procedures will be conducted by the Investigator, or suitably qualified designee. 
The following screening procedures will be completed, in the following order (wherever 
possible), and the findings recorded in the CRF: 
 
1. Informed Consent 
2. Demographics 
3. Review of medical history (including smoking/tobacco use status) and prior/concomitant 
medication/treatment  
4. Full OST and OHT examinations 
5. Review of the inclusion/exclusion criteria 
6. Subject eligibility 
 
8.1.1 
Screening Procedures 
8.1.1.1 
Informed Consent 
The investigator, or designee, must obtain informed consent from each subject participating in 
this study after adequate explanation of the aims, methods, objectives, and potential hazards of 
the study. An ingredients listing for the study dentifrices will be provided to each subject during 
the consent process to enable them to confirm they are not aware of any allergy or 
hypersensitivity to any of the ingredients listed.  Two copies of the informed consent form (ICF) 
will be signed and dated by the subject, the subject will retain one copy and the other will be 
kept at site. 
The investigator, or designee, must also explain to the subjects that they are completely free to 
refuse to enter the study or to withdraw from it at any time.  Appropriate forms for documenting 
a signed and dated consent will be provided by either the investigator or by the sponsor. 
The investigator, or designee, should sign and date each copy of the ICF to confirm that the 
consent process was completed correctly after the subject has signed.   
The time the subject signed the ICF will be captured as this is the point from which all AEs will 
be captured. The date and time of consent will be recorded in the CRF. 
If, during a subject’s participation in the study, any new information becomes available that 
may affect the subject’s willingness to participate in the study, each ongoing subject should 
receive a copy of this new information and be re-consented into the study. Each subject should 
be provided with a copy of the signed and dated amended consent form. The date of re-consent 
will be recorded on the CRF. 
300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI


GSK Consumer Healthcare 
 
Clinical Protocol 
 
 
Protocol Number: 300024 
 
Property of GSK Consumer Healthcare - Confidential  
May not be used, divulged, published or otherwise disclosed without the consent of GSKCH 
 Clinical Protocol Template v9.0 
Page 33 of 63 
After signing the ICF, subjects will undergo the screening assessments to confirm that they 
meet all the inclusion criteria and none of the exclusion criteria. If the subject is confirmed 
eligible by the investigator (or designee) to participate in the study the subject is considered 
enrolled in the study. 
8.1.1.2 
Demographics 
The following demographic information will be recorded in the CRF: year of birth, gender and 
race.  Ethnicity and race of subjects will be recorded in accordance with FDA Guidance (US 
FDA, 2005). 
8.1.1.3 
Medical History and Prior Medication/Treatment 
Details of relevant medical and surgical history (in the last year), including allergies or drug 
sensitivity, will be documented in the CRF. 
Prior medications/treatments, including prescription and non-prescription drugs, dietary 
supplements and herbal remedies, taken in the last 28 days and prior to signing the informed 
consent form, will be documented in the CRF. 
8.1.1.4 
Oral Examinations 
Following review of the oral care products the subject is currently using (subject-reported 
product names) to confirm they do not contain any ingredients that could interfere with study 
outcomes, the clinical examiner(s) will perform the following examinations/assessments. 
• OST examination. 
• OHT examination. 
• Confirm eligibility of the anterior teeth against the dentition exclusions described in 
Section 5.3. 
Oral examinations/assessments should only be performed by suitably qualified examiner(s) as 
described in Section 5.8. 
To facilitate subject flow, clinical assessments may be recorded on a paper source document 
and later transcribed into the CRF.  
8.1.1.5 
Inclusion/Exclusion Criteria 
Inclusion and exclusion criteria information will be documented in the CRF. 
8.1.1.6 
Subject Eligibility 
The investigator and/or medically qualified designee will review the inclusion/exclusion criteria, 
medical history, prior and current medications/treatments and the findings of the oral 
examinations to confirm subject eligibility to participate in the clinical trial. This will be 
documented in the CRF. 
To prepare for study participation, subjects will be instructed in the Lifestyle Guidelines and 
any Concomitant Medication/Treatment(s) requirements of the protocol. 
300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI


GSK Consumer Healthcare 
 
Clinical Protocol 
 
 
Protocol Number: 300024 
 
Property of GSK Consumer Healthcare - Confidential  
May not be used, divulged, published or otherwise disclosed without the consent of GSKCH 
 Clinical Protocol Template v9.0 
Page 34 of 63 
8.2 
Study Period 
8.2.1 
Visit 2/Day 0 - Baseline  
Procedures will be conducted by the Investigator, or suitably qualified designee. 
Subjects will undergo, in the following order (wherever possible). 
 
1. MLSI is assessed on the facial surfaces of the six maxillary anterior teeth and six 
mandibular anterior teeth (tooth numbers 6-11 and 22-27), and the lingual surfaces of the 
six mandibular anterior teeth (tooth numbers 22-27), including a repeat assessment if 
required.  At the examiner’s discretion, the examiner my use floss and/or a wetted 
toothbrush to remove debris from the teeth prior to the assessment if required. 
2. Clinical assessment of tooth shade is performed on the facial surfaces of the central and 
lateral maxillary incisors (tooth numbers 7-10) through use of the VITA Bleachedguide 
3D-MASTER instrument including a repeat assessment if required. 
3. Tooth color is assessed through use of the VITA EasyShade instrument. 
4. Review of the inclusion/exclusion criteria. 
5. Subject eligibility assessed.  Subjects who do not meet the criteria for participation will be 
discontinued. 
6. Qualifying subjects will be stratified and randomized to treatment groups. 
7. Study products will be dispensed, including sundry items, and diary.   
8. Instruct subject in product usage requirements/diary completion and demonstrate 
dispensing ribbon of dentifrice on to toothbrush head; supervise first brushing and first 
diary entry. 
9. AEs and incidents recorded. 
Randomized subjects will be appointed to attend the study site for their Week 4 assessments 
and reminded of the Lifestyle Guidelines and to bring their study product and completed diary 
with them to the next visit.  
To facilitate subject flow, clinical and instrumental assessments may be recorded on a paper 
source document and later transcribed into the CRF.  
 
8.2.2 
Visit 3/Week 4 (Day 28 ± 3) 
Procedures will be conducted by the Investigator, or suitably qualified designee. 
Subjects will undergo, in the following order (wherever possible), and findings recorded in the 
CRF: 
 
1. Changes in concomitant medication or non-drug treatments/procedures will be 
documented.  
2. Spontaneous reporting of adverse events and those elicited by asking subjects to respond 
to a non-leading question such as “How do you feel?” will be assessed. 
3. Subject will return study products and diary for visual inspection to evaluate product 
compliance and adherence to protocol.  Subject continuance in the study confirmed. 
4. Subject undergoes an OST examination. 
300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI


GSK Consumer Healthcare 
 
Clinical Protocol 
 
 
Protocol Number: 300024 
 
Property of GSK Consumer Healthcare - Confidential  
May not be used, divulged, published or otherwise disclosed without the consent of GSKCH 
 Clinical Protocol Template v9.0 
Page 35 of 63 
5. MLSI is assessed on the facial surfaces of the six maxillary anterior teeth and six 
mandibular anterior teeth (tooth numbers 6-11 and 22-27), and the lingual surfaces of the 
six mandibular anterior teeth (tooth numbers 22-27), including a repeat assessment if 
required.  At the examiner’s discretion, the examiner my use floss and/or a wetted 
toothbrush to remove debris from the teeth prior to the assessment if required. 
6. Clinical assessment of tooth shade is performed on the facial surfaces of the central and 
lateral maxillary incisors (tooth numbers 7-10) through use of the VITA Bleachedguide 
3D-MASTER instrument including a repeat assessment if required. 
7. Tooth color is assessed through use of the VITA EasyShade instrument. 
8. Resupply of allocated study products will be dispensed, including sundry items, and diary. 
9. Re-instruct subject in product usage requirements/diary completion; supervise on-site 
brushing and diary entry. 
10. AEs and incidents recorded. 
Subjects will be appointed to attend the study site for their Week 8 assessments and reminded 
of the Lifestyle Guidelines and to bring their study product and completed diary with them to 
the next visit.  
To facilitate subject flow, clinical and instrumental assessments may be recorded on a paper 
source document and later transcribed into the CRF.  
 
8.2.3 
Visit 4 /Week 8 (Day 56 ± 3) 
Procedures will be conducted by the Investigator, or suitably qualified designee. 
Subjects will undergo, in the following order (wherever possible). 
 
1. Changes in concomitant medication and/or non-drug treatments/procedures will be 
documented.  
2. Spontaneous reporting of adverse events and those elicited by asking subjects to respond 
to a non-leading question such as “How do you feel?” will be assessed. 
3. Subject will return study products and diary for visual inspection to evaluate product 
compliance and adherence to protocol.  Subject continuance in the study confirmed. 
4. Subject undergoes OST and OHT examinations. 
5. MLSI is assessed on the facial surfaces of the six maxillary anterior teeth and six 
mandibular anterior teeth (tooth numbers 6-11 and 22-27), and the lingual surfaces of the 
six mandibular anterior teeth (tooth numbers 22-27), including a repeat assessment if 
required.  At the examiner’s discretion, the examiner my use floss and/or a wetted 
toothbrush to remove debris from the teeth prior to the assessment if required. 
6. Clinical assessment of tooth shade is performed on the facial surfaces of the central and 
lateral maxillary incisors (tooth numbers 7-10) through use of the VITA Bleachedguide 
3D-MASTER instrument including a repeat assessment if required. 
7. Tooth color is assessed through use of the VITA EasyShade instrument. 
8. AEs and incidents recorded. 
9. Study conclusion. 
To facilitate subject flow, clinical and instrumental assessments may be recorded on a paper 
source document and later transcribed into the CRF. 
300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI


GSK Consumer Healthcare 
 
Clinical Protocol 
 
 
Protocol Number: 300024 
 
Property of GSK Consumer Healthcare - Confidential  
May not be used, divulged, published or otherwise disclosed without the consent of GSKCH 
 Clinical Protocol Template v9.0 
Page 36 of 63 
8.2.4 
Study Procedures 
8.2.4.1 
Diary Review 
The diary should be reviewed at every visit by the investigator, or suitably qualified designee, 
and the subject. Any subject comment captured in the diary which is considered an adverse 
event will be assessed and reported as defined in the Adverse Event and Serious Adverse Events 
section of this protocol.  
Any additional comments relating to medications/treatments provided in the diary will be 
reviewed by the investigator or medically qualified designee with the subject and entered into 
the CRF as appropriate.  
Additional and missed product applications will be considered deviations from the protocol and 
will be recorded on the Deviations Log and as a deviation in the CRF. 
8.2.4.2 
Study Conclusion 
The Study Conclusion page of the CRF will be completed for all subjects whether they 
completed all study procedures or if they were discontinued from the study early.  If the subject 
was discontinued early, at any point during the study, the primary reason for withdrawal should 
be recorded on the Study Conclusion page. 
If a subject has any clinically significant, study-related abnormalities or AEs at the end of the 
study, the sponsor’s medical monitor (or designated representative) should be notified, and the 
subject may be asked to remain at the clinical site or be asked to return for a follow-up visit to 
ensure any issue is resolved or deemed not clinically significant.  
8.2.4.3 
Follow-up Visit / Phone Call 
The study site may contact a subject to follow up an AE post-study completion/withdrawal and, 
in some circumstances, request they return to the site for additional follow-up visits (final safety 
assessments). If needed, additional clinical examinations may be carried out at such visits. 
9 
STUDY ASSESSMENTS 
Every effort should be made to ensure that protocol-required examinations and assessments are 
completed as described.  However, it is anticipated that there may be circumstances, outside the 
control of the investigator that may make it unfeasible to complete an assessment.  In these 
cases, the investigator must take all steps necessary to ensure the safety and well-being of the 
subject.  When a protocol-required assessment cannot be performed, the investigator (or 
designee) will document the reason for the missed assessment as a protocol deviation and any 
corrective and preventative actions that they have taken to ensure the required processes are 
adhered to as soon as possible.  The sponsor must be informed of any missed assessments in a 
timely manner.  The outcome of all examinations and assessments should be recorded in the 
CRF. 
9.1 
Screening Assessments 
Screening examinations and assessments will be performed by appropriately trained clinical 
examiners at the times, and in the order, defined in the Study Procedures section of this 
protocol. 
300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI


GSK Consumer Healthcare 
 
Clinical Protocol 
 
 
Protocol Number: 300024 
 
Property of GSK Consumer Healthcare - Confidential  
May not be used, divulged, published or otherwise disclosed without the consent of GSKCH 
 Clinical Protocol Template v9.0 
Page 37 of 63 
9.1.1 
OST Examination 
The screening clinician will perform an initial oral soft tissue examination in agreement with 
Section 9.3.1 in order to record any abnormalities and assess the subject’s suitability and 
eligibility for enrollment into the study. 
9.1.2 
OHT Examination 
The screening clinician will perform a visual examination of the oral hard tissues in agreement 
with Section 9.3.2 in order to record any abnormalities and assess the subject’s suitability and 
eligibility for enrollment into the study. 
9.2 
Efficacy Assessments 
The following efficacy assessments will be performed by appropriately trained clinical 
examiner(s), at the times and in the order defined in the Study Procedures section of this 
protocol. 
If in the opinion of the examiner a subject is between defined grades/scores, a conservative 
approach should be used to provide the final score.  The same approach should be applied 
throughout the study to ensure consistency in the grading of the scores at all timepoints.  
9.2.1 
Macpherson Modification of the Lobene Stain Index (MLSI) 
Extrinsic dental stain will be assessed on the facial surfaces of the 6 maxillary and 6 mandibular 
anterior teeth (6-11 and 22-27), and the lingual surfaces of the 6 mandibular anterior teeth (22-
27) at baseline, Week 4 and Week 8 (Visits 2-4), using the MacPherson modification 
(Macpherson et al., 2000) of the Lobene stain index (Lobene, 1968) (MLSI).  
All assessments should be performed by a single, trained clinical examiner, with consistent 
lighting to standardize of the assessment conditions. If required the examiner will brush the 
subject’s anterior teeth with a wetted toothbrush and/or floss to remove any debris which could 
impact the accuracy of the stain assessment.  Teeth will be air dried prior to and during the 
assessment as needed.  
The facial surfaces of each assessable tooth is divided into four regions. The ‘gingival’ region 
is defined as a crescent-shaped band, approximately 2 mm wide, adjacent to the free margin of 
the gingiva and extending to the crest of the interdental papillae of the adjacent teeth. The ‘body’ 
of the tooth is then sub-divided into three regions on the facial surfaces. 
 
The facial and lingual surfaces of each assessable tooth will be divided into 2 regions, with a 
total of 4 sites per tooth surface (Figure 9-1). 
• Gingival Region: Defined as a crescent-shaped band (~ 2 mm wide) adjacent to the free 
margin of the gingiva and extending to the crest of the inter-dental papillae of the adjacent 
teeth (1 site).  
• Body Region: The remainder of the tooth surface (the body) is further sub-divided into 3 
sites. 
• Distal facial, body facial, mesial facial sites 
• Distal lingual, body lingual, mesial lingual sites 
 
 
300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI


GSK Consumer Healthcare 
 
Clinical Protocol 
 
 
Protocol Number: 300024 
 
Property of GSK Consumer Healthcare - Confidential  
May not be used, divulged, published or otherwise disclosed without the consent of GSKCH 
 Clinical Protocol Template v9.0 
Page 38 of 63 
Figure 9-1 MLSI Assessment Sites: Body (B), Gingival (G), Mesial (M), Distal (D) 
 
 
Area (A) and intensity (I) of extrinsic dental stain is scored separately for the four ‘gingival’ 
and ‘body’ sites, as follows.  
 
Score 
Area 
Intensity 
0 
No stain  
No stain 
1 
Stain covering up to one third of region 
Light stain 
2 
Stain covering up to two thirds of region 
Moderate stain 
3 
Stain covering more than two thirds of region 
Heavy stain 
9.2.1.1 
Repeatability of the MLSI Assessment 
To assess the repeatability of the MLSI assessments, replicate examinations will be performed 
by the same clinical examiner.  Ten subjects will be randomly selected for repeat MLSI 
assessments at each assessment time point (Visits 2, 3 and 4), a total of 30 repeat assessments 
over the duration of the study.  Replicate assessments will be separated by a minimum of 10 
minutes (maximum 60 minutes) from the original assessment for a given subject and, where 
possible, separated by at least one subject.   
The scores of the initial assessment will not be visible to the examiner or scribe when the repeat 
assessment is carried out.   
9.2.2 
Tooth Shade (Color) Assessment 
Tooth shade (color) of the facial surfaces of the four central and lateral maxillary incisors (tooth 
numbers 7-10) will be assessed by a single, trained clinical examiner using the VITA 
Bleachedguide 3D-MASTER.  The arch tooth position will be parallel to the floor.   
Assessment conditions should be standardized: color corrected lighting in the range of 
5000 Kelvin; a grey bib will be placed over the subject’s clothing; subjects will be asked not 
to wear lipstick; assessments will be performed in the same room (necessary) at approximately 
the same time of day (if possible); outside light will be controlled by covering the windows or 
using a windowless room. Color determination should be made within 5-7 seconds of starting 
an assessment to avoid eye fatigue. 
The VITA Bleachedguide 3D-MASTER (Paravina, 2008) uses a value-ranked ordered scale 
from 1 (the lightest) to 29 (the darkest).  The shade level of each tooth surface is scored visually 
by the clinical examiner with reference to the Bleachedguide.   
A single VITA Bleachedguide will be used for all assessments throughout the study wherever 
possible. 
300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI


GSK Consumer Healthcare 
 
Clinical Protocol 
 
 
Protocol Number: 300024 
 
Property of GSK Consumer Healthcare - Confidential  
May not be used, divulged, published or otherwise disclosed without the consent of GSKCH 
 Clinical Protocol Template v9.0 
Page 39 of 63 
9.2.2.1 
Repeatability of the Tooth Color Shade Assessment 
To assess the repeatability of the tooth shade assessments, replicate examinations will be 
performed by the same clinical examiner using the same VITA Bleachedguide instrument.  Ten 
subjects will be randomly selected for repeat shade assessments at each assessment time point 
(Visits 2, 3 & 4), a total of 30 repeat shade assessments over the duration of the study.  Replicate 
assessments will be separated by a minimum of 10 minutes (maximum 60 minutes) from the 
original assessment for a given subject and, where possible, separated by at least one subject.   
The scores of the initial assessment will not be visible to the examiner or scribe when the repeat 
assessment is carried out. 
9.2.3 
VITA EasyShade Assessment 
Tooth shade (Bleachedguide shade) and color coordinates (L*, a*, b*) will be measured 
instrumentally for the facial surfaces of the four central and lateral maxillary incisors (tooth 
numbers 7-10) using the VITA EasyShade instrument. The clinical examiner will take a single 
reading from the middle section of each assessable tooth, in accordance with the manufacturer’s 
instructions.  The spectrophotometer should be calibrated using the calibration block supplied, 
in accordance with the manufacturer’s instructions.   
The collected data will be used to calculate the ΔE* and WID (del Mar Pérez et al., 2016) values 
as: 
∆𝐸∗= √∆𝐿∗2 + ∆𝑎∗2 + ∆𝑏∗2 
𝑊𝐼𝐷= 0.511𝐿∗−2.324𝑎∗−1.100𝑏∗ 
 
9.3 
Safety and Other Assessments 
The following safety assessments will be performed by appropriately trained clinical 
examiner(s), at the times and in the order defined in the Study Procedures section of this 
protocol.  Additionally, to help prevent COVID-19 transmission within the study, the 
measurement of the temperature of subjects and/or questioning of the subjects may be utilized 
at any site visit at the examiner’s discretion. 
9.3.1 
Oral Soft Tissue (OST) Examination 
This procedure will be conducted by a qualified, experienced clinical examiner.  The OST 
examination will be accomplished by direct observation and palpation with retraction aids, as 
appropriate. The examination will cover the oral labial mucosa (including lips), buccal mucosa, 
mucogingival folds, gingival mucosa, hard palate, soft palate, tonsillar area, pharyngeal area, 
tongue, sublingual area, submandibular area and salivary glands.  Findings from the 
examination will be recorded in the CRF as either normal or abnormal, with details of any 
abnormalities. The results of the OST examination performed at screening will be used to 
determine subject eligibility. Any new OST abnormality or worsening of a pre-existing 
condition observed by the clinical examiner or reported by the subject after the screening 
examination will be recorded as an AE. 
Where possible, this procedure should be conducted by a single clinical examiner.   
300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI


GSK Consumer Healthcare 
 
Clinical Protocol 
 
 
Protocol Number: 300024 
 
Property of GSK Consumer Healthcare - Confidential  
May not be used, divulged, published or otherwise disclosed without the consent of GSKCH 
 Clinical Protocol Template v9.0 
Page 40 of 63 
9.3.2 
Oral Hard Tissue (OHT) Examination 
This procedure should be conducted by a qualified, experienced clinical examiner.  The OHT 
examination will be accomplished by direct observation, using retraction aids as appropriate 
and will identify any grossly carious lesions, signs of erosive wear, enamel irregularities, tooth 
fracture, gross generalized dental caries decay, decalcification and faulty restorations. The 
presence of any implants, fixed or removable dentures, fixed or removable orthodontic 
braces/bands, fixed orthodontic retainers, full crowns or veneers will be recorded. Observations 
will be listed as either absent or present, and conditions noted as present will be described in 
the eCRF. Any change observed by the clinical examiner or reported by the subject after the 
screening examination will be recorded as an AE. 
The results of the OHT examination performed at Screening will be used to determine subject 
eligibility. 
Where possible, this procedure should be conducted by a single clinical examiner.  
9.3.3 
Pregnancy Testing 
Urine pregnancy testing of subjects of child-bearing potential is not required for this study (see 
Section 4.2 for details).  Subjects of child-bearing potential will be asked to provide verbal 
confirmation of pregnancy status at screening (Visit 1) and to inform site staff if they find they 
are pregnant while participating in the study.  In case of a positive confirmed pregnancy, the 
subject will be withdrawn from the study. 
10 
ADVERSE EVENT AND SERIOUS ADVERSE EVENTS 
The investigator and any qualified designees are responsible for detecting, documenting, and 
reporting events that meet the definition of an AE or SAE and remain responsible for following 
up AEs that are serious, considered related to the study product or the study, or that caused the 
subject to discontinue the study product or study. 
10.1 
Definition of an Adverse Event (AE) 
An AE is any untoward medical occurrence in a clinical study subject, temporally associated 
with the use of a study product including any washout or lead-in product (or medical device), 
whether or not considered related to the study product, including any washout or lead-in product 
(or medical device). 
NOTE: An AE can therefore be any unfavorable and unintended sign (including an abnormal 
laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the 
use of a study product including any washout or lead-in product (or medical device). 
Events Meeting the AE Definition:   
• Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or 
other safety assessments (e.g. ECG, radiological scans, vital sign measurements), 
including those that worsen from baseline, considered clinically significant in the 
medical and scientific judgment of the investigator (i.e., not related to progression of 
underlying disease). 
• Exacerbation of a chronic or intermittent pre-existing condition including either an 
increase in frequency and/or intensity of the condition. 
300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI


GSK Consumer Healthcare 
 
Clinical Protocol 
 
 
Protocol Number: 300024 
 
Property of GSK Consumer Healthcare - Confidential  
May not be used, divulged, published or otherwise disclosed without the consent of GSKCH 
 Clinical Protocol Template v9.0 
Page 41 of 63 
• New conditions detected or diagnosed after study product administration even though 
it may have been present before the start of the study. 
• Signs, symptoms, or the clinical sequelae of a suspected drug-drug interaction. 
• Signs, symptoms, or the clinical sequelae of a suspected overdose of either study 
product or a concomitant medication. Overdose per se will not be reported as an 
AE/SAE unless it is an intentional overdose taken with possible suicidal/self-harming 
intent. Such overdoses should be reported regardless of sequelae. 
• "Lack of efficacy" or "failure of expected pharmacological action" per se will not be 
reported as an AE. Such instances will be captured in the efficacy assessments. 
However, the signs, symptoms, and/or clinical sequelae resulting from lack of 
efficacy will be reported as AE if they fulfill the definition of an AE.  
Events NOT meeting the AE definition:  
• Any clinically significant abnormal laboratory findings (if applicable) or other abnormal 
safety assessments which are associated with the underlying disease, unless judged by 
the investigator to be more severe than expected for the subject’s condition.  
• The disease/disorder being studied or expected progression, signs, or symptoms of the 
disease/disorder being studied, unless more severe than expected for the subject’s 
condition.  
• Medical or surgical procedure (e.g. endoscopy, appendectomy) is not the AE. The 
condition that leads to the procedure is an AE (e.g. appendicitis). 
• Situations where an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospital). 
• Anticipated day-to-day fluctuations of pre-existing disease(s) or condition(s) present or 
detected at the start of the study that do not worsen.  
10.2 
Definition of a Serious Adverse Event (SAE) 
A Serious Adverse Event (SAE) is a particular category of an adverse event where the adverse 
outcome is serious. If an event is not an AE per definition above, then it cannot be an SAE even 
if serious conditions are met (e.g. hospitalization for signs/symptoms of the disease under study, 
death due to progression of disease). 
A serious adverse event is any untoward medical occurrence at any dose that: 
• Results in death 
• Is life-threatening  
▪ The term 'life-threatening' in the definition of 'serious' refers to an event in which 
the subject was at risk of death at the time of the event. It does not refer to an 
event, which hypothetically might have caused death, if it were more severe; 
• Requires inpatient hospitalization or prolongation of existing hospitalization  
▪ In general, hospitalization signifies that the subject has been detained (usually 
involving at least an overnight stay) at the hospital or emergency ward for 
observation and/or treatment that would not have been appropriate in the 
physician’s office or outpatient setting. Complications that occur during 
hospitalization are AEs. If a complication prolongs hospitalization or fulfills any 
other serious criteria, the event is serious. When in doubt as to whether 
300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI


GSK Consumer Healthcare 
 
Clinical Protocol 
 
 
Protocol Number: 300024 
 
Property of GSK Consumer Healthcare - Confidential  
May not be used, divulged, published or otherwise disclosed without the consent of GSKCH 
 Clinical Protocol Template v9.0 
Page 42 of 63 
“hospitalization” occurred, or was necessary, the AE should be considered 
serious. 
▪ Hospitalization for elective treatment of a pre-existing condition that did not 
worsen from baseline is not considered an AE. 
• Results in persistent or significant disability/incapacity 
▪ The term disability means a substantial disruption of a person’s ability to conduct 
normal life functions. 
▪ This definition is not intended to include experiences of relatively minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, 
influenza, and accidental trauma (e.g. sprained ankle) which may interfere with or 
prevent everyday life functions but do not constitute a substantial disruption 
• Results in congenital anomaly/birth defect 
• Other situations: 
▪ Medical or scientific judgment should be exercised in deciding whether SAE 
reporting is appropriate in other situations such as important medical events that 
may not be immediately life-threatening or result in death or hospitalization but 
may jeopardize the subject or may require medical or surgical intervention to 
prevent one of the other outcomes listed in the above definition. These events 
should usually be considered serious. 
▪ Examples of such events include invasive or malignant cancers, intensive 
treatment in an emergency room or at home for allergic bronchospasm, blood 
dyscrasias or convulsions that do not result in hospitalization, or development of 
drug dependency or drug abuse. 
Note: Classification of an AE as ‘serious’ is based on the outcome of the event and is a factor 
in determining reporting requirements. 
10.3 
Time Period and Frequency for Collecting AE and SAE 
Information 
All AEs, and therefore all SAEs will be collected immediately after a subject provides consent 
to participate in the study by the completion (signature) of the ICF and until 5 days following 
last administration of the study product (or last procedure).  
Medical occurrences that began before obtaining informed consent will be recorded in the 
Medical History/Current Medical Conditions section of the CRF not the AE section. 
Details recorded by the subject on a diary or similar document that meet the definition of an AE 
must also be discussed with the subjects and transcribed in the AE section of the CRF.  
All SAEs will be recorded and reported to the sponsor or designee immediately and under no 
circumstance should this exceed 24 hours. The investigator will submit any updated SAE data 
to the sponsor within 24 hours of it being available. 
Investigators are not obligated to actively seek AEs or SAEs after the conclusion of the study 
participation. However, if the investigator learns of any SAE, including a death, at any time 
after a subject has been discharged from the study, and they consider the event to be reasonably 
related to the study product or study participation, the investigator must promptly notify the 
sponsor. 
300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI


GSK Consumer Healthcare 
 
Clinical Protocol 
 
 
Protocol Number: 300024 
 
Property of GSK Consumer Healthcare - Confidential  
May not be used, divulged, published or otherwise disclosed without the consent of GSKCH 
 Clinical Protocol Template v9.0 
Page 43 of 63 
10.4 
Reporting Procedures 
The investigator and any designees are responsible for detecting, documenting and reporting 
events that meet the definition of an AE and remain responsible for following up on AEs that 
are serious, considered related to the study product(s), participation in the study, or a study 
procedure, or that caused the subject to discontinue the study product or study.  
Spontaneous reporting of adverse events and those elicited by asking subjects to respond to 
non-leading such as “How do you feel” will be assessed and any AE’s recorded in the CRF and 
reported appropriately. 
The investigator (or medically qualified designee) is to report all directly observed AEs and all 
AEs spontaneously reported by the study subject. In addition, each study subject will be 
questioned about AEs.  
Each AE is to be assessed to determine if it meets the criteria for a SAE.  If an SAE occurs, 
expedited reporting will follow local and international regulations, as appropriate. 
When an AE occurs, it is the responsibility of the investigator (or medically qualified designee) 
to review all documentation (e.g. hospital progress notes, laboratory, and diagnostics reports) 
related to the event. 
The investigator or site staff will then record all relevant information regarding an AE in the 
CRF and all details relating to an SAE in the paper SAE Form provided. 
It is not acceptable for the investigator (or medically qualified designee) to send photocopies 
of the subject’s medical records to the sponsor in lieu of completion of the AE CRF page/SAE 
form. 
There may be instances when copies of medical records for certain cases are requested by the 
sponsor.  In this instance, all subject identifiers, except for the subject number, will be redacted 
on the copies of the medical records prior to submission to the sponsor. 
The investigator (or medically qualified designee) will attempt to establish a diagnosis of the 
event based on signs, symptoms, and/or other clinical information.  The diagnosis will be the 
documented as the AE/SAE where known and not the individual signs/symptoms. (e.g. upper 
respiratory tract infection, seasonal allergy, etc. instead of runny nose). 
AEs elicited by the investigator (or medically qualified designee) in a standard manner at the 
study visits should also be recorded in the AE section of the CRF and/or using the SAE form 
(subject to the classification of the AE). Care will be taken not to introduce bias when 
questioning a subject about any changes in their health. Open-ended and non-leading verbal 
questioning should be used. 
10.4.1 
Reporting of an Adverse Event 
All AEs will be reported on the AE page of the CRF by the investigator or site staff.  It should 
be noted that the form for collection of SAE information is not the same as the AE CRF.  Where 
the same data are collected, the AE CRF page and the SAE form must be completed in a 
consistent manner.  For example, the same AE term should be used on both.  AEs should be 
reported using concise medical terminology on the CRF as well as on the form for collection of 
SAE information. 
300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI


GSK Consumer Healthcare 
 
Clinical Protocol 
 
 
Protocol Number: 300024 
 
Property of GSK Consumer Healthcare - Confidential  
May not be used, divulged, published or otherwise disclosed without the consent of GSKCH 
 Clinical Protocol Template v9.0 
Page 44 of 63 
10.4.2 
Reporting of a Serious Adverse Event 
In addition to recording the details of each AE on the AE CRF page, an SAE form should be 
completed, as fully as possible. Hard copies of the ‘paper’ SAE form will be provided in the 
investigator study master file. Original SAE forms will be retained in the investigator study 
master file. 
It is essential to enter the following information:  
• Protocol and subject identifiers 
• Subject demography 
• Description of events, with diagnosis if available 
• Investigator opinion of relationship to study product (or study procedure, if 
appropriate) 
• Criterion for seriousness. 
The following are desirable and are of particular relevance for investigator and the sponsor 
assessment of the SAE report: 
• Date of onset of AE  
• Date AE stopped, if relevant 
• Study product start date 
• Study product end date if relevant 
• Action taken in relation to the study product 
• Outcome if known 
The SAE form, completed as fully as possible, must be scanned and e-mailed to the Case 
Management Group mailbox 
 ), with copy to the 
appropriate  CH Study Manager, with the study number and subject number in the subject line 
of the email immediately and under no circumstance should this exceed 24 hours after study 
site personnel learn of the event. The investigator will submit any updated SAE data to the 
sponsor, immediately and under no circumstance should this exceed 24 hours of it being 
available.  
The initial report will be followed up with more information as relevant, or as requested by the 
CH study manager. 
The CH Study Manager will be responsible for forwarding the SAE form to other CH personnel 
as appropriate. 
10.5 
Evaluating Adverse Events  
10.5.1 
Assessment of Intensity 
The investigator or medically qualified designee will make an assessment of intensity for each 
AE reported during the study and will assign it to one of the following categories: 
• Mild:  An event that is easily tolerated by the subject, causing minimal discomfort and 
not interfering with everyday activities. 
• Moderate:  An event that is sufficiently discomforting to interfere with normal everyday 
activities 
• Severe:  An event that prevents normal everyday activities.  
300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
PPD
CCI


GSK Consumer Healthcare 
 
Clinical Protocol 
 
 
Protocol Number: 300024 
 
Property of GSK Consumer Healthcare - Confidential  
May not be used, divulged, published or otherwise disclosed without the consent of GSKCH 
 Clinical Protocol Template v9.0 
Page 45 of 63 
NOTE: An AE that is assessed as severe should not be confused with an SAE. Severe is a 
category utilized for rating the intensity of an event; and both non-serious AEs and SAEs can 
be assessed as severe. For example, a headache may be severe (interferes significantly with the 
subject's usual function) but would not be classified as serious unless it met one of the criteria 
for SAEs, listed above. An event is defined as ‘serious’ when it meets at least 1 of the predefined 
outcomes as described in the definition of an SAE, NOT when it is rated as severe. 
10.5.2 
Assessment of Causality 
The causality assessment is one of the criteria used when determining regulatory reporting 
requirements.  
For each AE (serious and non-serious), the investigator (or medically qualified designee) must 
provide an assessment of causality on the AE CRF page and the SAE form (subject to the 
classification of the AE). The investigator will also document in the medical notes that they 
have reviewed the AE and assessed causality, where applicable.  
A “reasonable possibility” of a relationship conveys that there are facts, evidence, and/or 
arguments to suggest a causal relationship, rather than a relationship cannot be ruled out. 
Generally, the facts (evidence) or arguments to suggest a causal relationship should be provided. 
The investigator will use clinical judgment to determine the relationship and will also consult 
the Safety Statement, in the determination of their assessment.  Alternative causes, such as 
underlying disease(s), concomitant therapy, other risk factors, and the temporal relationship of 
the event to the study product will be considered and investigated. 
For each AE/SAE, the investigator must document in the medical notes that they have reviewed 
the AE/SAE and has provided an assessment of causality. 
The investigator’s assessment of causality must be provided for all AEs (serious and non-
serious); the investigator must record the causal relationship in the CRF, as appropriate, and 
report such an assessment in accordance with the SAE reporting requirements if applicable. 
There may be situations when an SAE has occurred, and the investigator has minimal 
information to include in the initial report to the sponsor.  However, it is very important that 
the investigator always make an assessment of causality for every event prior to the initial 
transmission of the SAE data to the sponsor. The investigator may change their opinion of 
causality in light of follow-up information and send an SAE follow-up report with the updated 
causality assessment.  
10.6 
Follow-up of AEs and SAEs  
After the initial AE/SAE report, the investigator is required to proactively follow up with each 
subject and provide further information on the subject’s condition. 
All AEs (serious and non-serious) will be followed until resolution, until the condition stabilizes, 
until the event is otherwise explained, or until the subject is lost to follow-up.   
The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as may be indicated or as requested by the sponsor to elucidate 
as fully as possible the nature and/or causality of the AE. This may include additional laboratory 
tests or investigations, histopathological examinations, or consultation with other health care 
professionals. 
300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI


GSK Consumer Healthcare 
 
Clinical Protocol 
 
 
Protocol Number: 300024 
 
Property of GSK Consumer Healthcare - Confidential  
May not be used, divulged, published or otherwise disclosed without the consent of GSKCH 
 Clinical Protocol Template v9.0 
Page 46 of 63 
New or updated information will be recorded on the AE CRF page and on the SAE form (subject 
to the classification of the AE). 
The investigator will submit any updated SAE data to the sponsor within 24 hours of receipt of 
the information. 
Investigators are not obliged to actively seek AEs in former subjects.  However, if the 
investigator learns of a SAE, including death, at any time after a subject has been discharged 
from the study, and considers the event reasonably related to the study product or study 
participation, the investigator will promptly notify the sponsor by emailing the information to 
the Case Management Group mailbox at 
), with copy 
to the appropriate CH Study Manager. 
The investigator will submit any updated SAE data to the sponsor within the designated 
reporting time frames. 
10.7 
Withdrawal Due to an Adverse Event  
Withdrawal due to AEs should be distinguished from withdrawal due to other causes, according 
to the definition of an AE noted earlier, and recorded on the appropriate AE CRF page.  
When a subject withdraws because of an SAE, the SAE must be reported in accordance with 
the reporting requirements defined. 
10.8 
Regulatory Reporting Requirements for SAEs 
The sponsor has a legal responsibility to notify, as appropriate, the local regulatory authority 
and other regulatory authorities about the safety of a product under clinical investigation.  
Prompt notification of SAEs by the investigator to the sponsor is essential so that legal 
obligations and ethical responsibilities towards the safety of subjects are met. 
The sponsor will comply with country specific regulatory requirements relating to safety 
reporting to the regulatory authority, IRB/EC and investigators. 
Both the investigator and the sponsor will comply with all local medical device reporting 
requirements  
Investigator safety reports must be prepared for suspected unexpected serious adverse reactions 
(SUSAR) according to local regulatory requirements and sponsor policy and forwarded to 
investigators as necessary. 
An investigator who receives an investigator safety report describing a SAE or other specific 
safety information e.g. summary or listing of SAE from the sponsor will review and then file it 
along with the Investigator’s Brochure in the investigator study master file, and will notify the 
IRB/IEC, if appropriate according to local requirements. 
10.9 
Pregnancy 
10.9.1 
Time Period for Collecting Pregnancy Information 
Pregnancy information will be collected on all pregnancies reported while a female subject is 
participating in the study from the signing of informed consent until 5 days after last 
administration of study product. 
300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
PPD
CCI


GSK Consumer Healthcare 
 
Clinical Protocol 
 
 
Protocol Number: 300024 
 
Property of GSK Consumer Healthcare - Confidential  
May not be used, divulged, published or otherwise disclosed without the consent of GSKCH 
 Clinical Protocol Template v9.0 
Page 47 of 63 
10.9.2 
Action to be Taken if Pregnancy Occurs 
The investigator will record pregnancy information on the appropriate form scan and e-mail it 
to the Case Management Group mailbox 
), with copy 
to the appropriate CH Study Manager. Original pregnancy information forms will be retained 
in the investigator study master file.  
The subject will be followed to determine the outcome of the pregnancy. Information on the 
status of the mother and infant / neonate (including concomitant medications taken by the 
mother during the pregnancy) will be forwarded by the investigator to the Case Management 
Group mailbox at 
 with copy to the appropriate CH 
Study Manager. Generally, follow-up will be no longer than 6 to 8 weeks following the 
estimated delivery date. Any termination of the pregnancy will be reported. 
While pregnancy itself is not considered to be an AE, abnormal pregnancy outcomes (e.g. 
spontaneous abortion, fetal death, stillbirth, congenital anomalies, ectopic pregnancy) are, and 
should be recorded as an SAE. 
Any female subject who becomes pregnant while participating will be withdrawn from the study. 
10.10 
Medical Device Incidents 
Both the investigator and the sponsor will comply with all local medical device reporting 
requirements. 
Medical devices are being provided by the sponsor for use in this study; the medical device in 
this study is the supplied toothbrush.  
10.10.1 Definition of an Incident 
A medical device incident is any malfunction or deterioration in the characteristics and/or 
performance of a device as well as any inadequacy in the labeling or the instructions for use 
which, directly or indirectly, might lead to or might have led to the death of a subject/user/other 
person or to a serious deterioration in their state of health. 
Not all incidents lead to death or serious deterioration in health. The nonoccurrence of such a 
result might have been due to other fortunate circumstances or to the intervention of health care 
personnel. 
It is sufficient that: 
An incident associated with a device happened and 
• The incident was such that, if it occurred again, might lead to death or a serious 
deterioration in health. 
• A serious deterioration in state of health can include any of the following: 
• Life-threatening illness 
• Permanent impairment of body function or permanent damage to body structure 
• Condition necessitating medical or surgical intervention to prevent one of the above  
• Fetal distress, fetal death, or any congenital abnormality or birth defects 
Examples of incidents: 
• A subject, user, caregiver, or healthcare professional is injured as a result of a medical 
device failure or its misuse. 
300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
PPD
PPD
CCI


GSK Consumer Healthcare 
 
Clinical Protocol 
 
 
Protocol Number: 300024 
 
Property of GSK Consumer Healthcare - Confidential  
May not be used, divulged, published or otherwise disclosed without the consent of GSKCH 
 Clinical Protocol Template v9.0 
Page 48 of 63 
• A subject’s study treatment is interrupted or compromised by a medical device 
failure. 
• A misdiagnosis due to medical device failure leads to inappropriate treatment. 
• A subject’s health deteriorates due to medical device failure. 
10.11 
Reporting of Incidents and Malfunctions 
All incidents must be reported to the sponsor immediately and under no circumstance should 
this exceed 24 hours of the investigator or designee becoming aware of the situation. 
Any medical device incident occurring during the study will be documented in the subject's 
medical records, if in accordance with the investigator's normal clinical practice, and on the 
appropriate Incident Report Form.  In addition, for incidents fulfilling the definition of an AE 
(serious and non-serious), the appropriate AE CRF page and SAE form will be completed and 
reported as per the AE and SAE reporting sections. 
The Incident Report Form will be completed as thoroughly as possible and signed by the 
investigator before transmittal to the sponsor.  It is very important that the investigator describes 
any corrective or remedial actions taken to prevent recurrence of the incident. 
The completed Incident Report Form should be scanned and emailed to the Case Management 
Group mailbox 
), with copy to the appropriate  CH 
Study Manager,  with the study number and subject number in the subject line of the email 
immediately and under no circumstance should this exceed 24 hours after study site 
personnel learn of the event. If there is an SAE, the completed SAE form should be sent together 
with this report form.  However, if a copy of the SAE report is sent with this form, this does not 
replace the procedure to report an SAE.  The original Incident Report Form will be retained in 
the investigator study master file.  
The initial report will be followed up with more information as relevant, or as requested by the 
CH study manager. 
The investigator will follow the following directions regarding the reporting of a device failure 
(malfunction): 
• Notify the sponsor immediately (by following the process described above). 
• Schedule the subject to return to the site promptly to return the failed device. 
• Record any incidents on the CRF and Incident Report Form following instructions given 
in the section above. 
• For any incident/malfunction occurring with a medical device (including those that are 
part of combination products) supplied by the sponsor, return the failed device to the 
sponsor as soon as possible, including documentation of the details of the failure. 
• For any incident/malfunction occurring with a medical device (including those that are 
part of combination products) supplied by the Investigator site, report the incident to the 
device manufacturer and follow the manufacturer instructions for the return of the failed 
device (whilst keeping the sponsor informed). 
10.12 
Follow-up of Medical Device Incidents 
Medical device incidents involving an AE will be followed and reported in the same manner as 
other AEs. This applies to all subjects, including those who discontinue study product or are 
withdrawn from the study. 
300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
PPD
CCI


GSK Consumer Healthcare 
 
Clinical Protocol 
 
 
Protocol Number: 300024 
 
Property of GSK Consumer Healthcare - Confidential  
May not be used, divulged, published or otherwise disclosed without the consent of GSKCH 
 Clinical Protocol Template v9.0 
Page 49 of 63 
The investigator is responsible for ensuring that follow-up includes any supplemental 
investigations as indicated to elucidate the nature and/or causality of the incident. 
New or updated information will be recorded on the originally completed Incident Report form 
with all changes signed and dated by the investigator. 
10.13 
Regulatory Reporting Requirements for Medical Device Incidents 
To fulfill regulatory reporting obligations worldwide, the investigator is responsible for the 
detection and documentation of events meeting the definitions of incident or malfunction that 
occur during all periods of the study in which the medical device is used.  
The investigator will promptly report all incidents occurring with any medical device provided 
for use in the study in order for the sponsor to fulfill the legal responsibility to notify appropriate 
regulatory authorities and other entities about certain safety information relating to medical 
devices being used in clinical studies. 
The investigator, or responsible person according to local requirements (e.g. the head of the 
medical institution), will comply with the applicable local regulatory requirements relating to 
the reporting of incidents to the IRB/IEC. 
11 
DATA MANAGEMENT 
As used in this protocol, the term CRF is understood to refer to either a paper form or an 
electronic data record or both, depending on the data collection method.  
For this study, subject data will be entered into an electronic CRF (eCRF), using a validated 
system. Data relating to SAEs, pregnancy and incidents will also be collected on paper forms. 
The investigator is responsible for verifying that data entries are accurate and correct by 
physically or electronically signing the CRF. 
The source documents (e.g. hospital records, clinical and office charts, laboratory notes, 
memoranda, subject diaries, questionnaires, evaluation checklists, pharmacy dispensing records, 
recorded data from automated instruments, microfiches, photographic negatives, microfilm or 
magnetic media, x-rays, subject files and records kept at the pharmacy, at the laboratory and at 
the medico-technical departments involved in the clinical study) which contain the source of 
data recorded in the CRF should be specified.  The CRF and or diary can be used as a source 
document at the discretion of data management. 
Each subject will be assigned and identified by a unique Screening Subject Number. Any 
reference made to an individual subject within the study must be done using their unique 
Screening Subject Number. 
11.1 
Case Report Form 
A CRF is a printed, optical, or electronic document designed to record the protocol required 
information to be reported to the sponsor on each trial subject. 
For each subject who has given informed consent/assent the CRF must be completed and signed 
by the Principal Investigator (or authorized designee) to certify that the data are complete and 
correct.  The investigator must maintain accurate documentation (source data) that supports the 
information entered in the CRF. 
300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI


GSK Consumer Healthcare 
 
Clinical Protocol 
 
 
Protocol Number: 300024 
 
Property of GSK Consumer Healthcare - Confidential  
May not be used, divulged, published or otherwise disclosed without the consent of GSKCH 
 Clinical Protocol Template v9.0 
Page 50 of 63 
Management of clinical data will be performed in accordance with Third Party BDM Vendor 
applicable standards and data cleaning procedures with oversight by the sponsor to ensure 
integrity of the data, for example, to correct errors and inconsistencies in the data.  
To protect the privacy of subjects, no Personal Information (PI) (including the subject's name 
or initials or full birth date) is to be recorded in the CRF or as part of the query text. 
All CRF pages should be completed during a subject assessment when the CRF has been 
designated as the source.  Data that is sourced elsewhere should be entered into the CRF in an 
agreed upon timeframe between the Investigator and sponsor.   
The sponsor will obtain and retain all CRFs and associated study data as applicable at the 
completion of the study.  
11.2 
Data Handling 
Documentation of all data management activities should allow step-by-step retrospective 
assessment of data quality and study performance.  
Any changes or corrections to data will be performed in the Electronic Data Capture (EDC) 
System, and it will include rationale for changes. The EDC system has an audit trail, which will 
provide a complete record of the changes and corrections endorsed by the Investigator. 
Adverse events will be coded using Medical Dictionary for Regulatory Activities (MedDRA) 
and any concomitant medications terms (if applicable) using a validated medication dictionary, 
WHODrug.   
11.2.1 
Data Queries 
Programmed edit checks will be generated automatically, as the data are being entered into the 
system. Reports and listings on the CRF data will also be run, in addition to the queries already 
programmed and generated by the system, to raise manual queries as needed for site 
clarification or correction. The sponsor’s third party vendor will raise queries as needed on 
safety data to code the terms (AEs and Drugs or concomitant medication) appropriately.  
The study monitor will perform ongoing review of the CRFs in accordance with the monitoring 
plan, to confirm that data entered into the CRF by authorized site personnel are accurate, 
complete, and verifiable from source documents; that the safety and rights of participants are 
being protected; and that the study is being conducted in accordance with the currently approved 
protocol and any other study agreements, ICH GCP, and all applicable regulatory requirements. 
Any queries will be generated in the EDC System to the Investigator or designee, enabling the 
errors to be addressed in parallel with Data Management review. The study monitor can also 
run reports and listings on the CRFs, to raise manual queries as needed for site clarification or 
correction. 
12 
STATISTICAL CONSIDERATIONS AND DATA ANALYSES 
12.1 
Sample Size Determination 
The study will be powered sufficiently (>90%) to provide evidence of superiority for an 
Experimental Dentifrice compared to the Reference Dentifrice for both stain removal and 
whitening after 8 weeks under the graphical approach method (with initial two-sided alpha 
300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI


GSK Consumer Healthcare 
 
Clinical Protocol 
 
 
Protocol Number: 300024 
 
Property of GSK Consumer Healthcare - Confidential  
May not be used, divulged, published or otherwise disclosed without the consent of GSKCH 
 Clinical Protocol Template v9.0 
Page 51 of 63 
allocation of 5% for testing within each Experimental Dentifrice) to adjust for multiple 
comparisons and preserve a two-sided 10% family wise error rate as described in section 12.3. 
Table 12-1 
Sample Size Power by Endpoint at 5% and 2.5% Significance Levels 
with 90 Subjects per Arm 
Endpoint at  
Week 8 
Assumptions 
Independent power from 
90 subjects per arm for 
each endpoint by two-
sided significance level 
3 
Power from 
graphical 
approach to 
achieve 
statistical 
significance at 
5% level 4 
Mean 
Difference 
Standard 
Deviation 
(SD) 
5% 
2.5% 
Within Experimental 
Dentifrice change from 
baseline in mean Total 
MLSI (Area x Intensity) 1 
0.6 
0.4 
>99.9% 
>99.9% 
>99.9% 
Comparison with 
Reference Dentifrice in 
change from baseline in 
mean Total MLSI (Area x 
Intensity) 1 
0.3 
0.4 
99.8% 
99.7% 
99.8% 
Within change from 
baseline in the mean 
VITA shade score 2 
2 
2 
>99.9% 
>99.9% 
>99.9% 
Comparison with 
Reference Dentifrice in 
change from baseline in 
the mean VITA shade 
score 2 
1 
2 
91.5% 
86.1% 
90.2% 
1) Estimates of mean difference and SD were based on results from previous GSKCH studies of similar design 
 
2) Estimates of mean difference and SD were based on results from a previous GSKCH study of similar design 
 Within treatment study reductions in the mean VITA shade score are expected to be greater in this 
study due to greater baseline VITA shade scores and an 8 week primary assessment instead of 4 weeks. As such, the 
SD is also assumed to increase, so an effect size (mean difference/SD) of 0.5 is assumed. 
3) Based on carrying out a two tailed one-sample (within Experimental Dentifrice) or two-sample (Comparison with 
Reference Dentifrice) t-test at the 5% significance level using PASS software version 19.0.1. 
4) Simulation using SAS 9.4 software based on stated assumptions for all endpoints and graphical approach analysis 
detailed in section 12.3. 
As detailed in the independent sample size calculations in Table 12-1, the minimum required 
sample size assessment depends almost entirely on the mean VITA shade score reduction 
comparison between Experimental and Reference Dentifrices. Simulation shows that under the 
graphical approach methodology (Section 12.3) and the above underlying assumptions for an 
Experimental Dentifrice, the power to show statistical significance in all 4 comparisons for that 
Experimental Dentifrice (reduction from baseline and superior reduction compared to 
Reference Dentifrice in both mean Total MLSI [Area x Intensity] and mean VITA shade score) 
is > 90%. 
Approximately 100 subjects per group (approximately 300 in total) will be randomized to 
account for a drop-out rate of up to 10% prior to Week 8. 
300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI
CCI
CCI


GSK Consumer Healthcare 
 
Clinical Protocol 
 
 
Protocol Number: 300024 
 
Property of GSK Consumer Healthcare - Confidential  
May not be used, divulged, published or otherwise disclosed without the consent of GSKCH 
 Clinical Protocol Template v9.0 
Page 52 of 63 
12.2 
Populations for Analysis 
12.2.1 
Definitions of Analysis Populations 
The Safety population will include all randomized subjects who complete at least one use of 
study product. This population will be based on the study product the subject received. All 
assessments of safety will be based on this analysis population. 
The modified Intent-To-Treat (mITT) population will include all randomized subjects who 
complete at least one use of study product and have at least one post baseline efficacy 
assessment. This population will be based on the study product to which the subject was 
randomized. All assessments of efficacy will be primarily based on this analysis population. 
The per protocol (PP) population is defined as all subjects in the mITT population who have at 
least one assessment of efficacy considered unaffected by protocol violations. 
12.2.2 
Exclusions of Data from Analysis  
Exclusion of any data from the analyses will be determined during a Blinded Data Review 
(BDR) Meeting prior to database lock. Any reasons for exclusion from an analysis population 
will be listed, if applicable. 
A PP analysis will be performed on the mean Total MLSI (Area x Intensity) and mean VITA 
shade score endpoints if there is more than 10% difference in the number of subjects between 
the PP and mITT populations. A decision on whether a PP analysis will be performed will be 
made prior to study unblinding (release of the randomization codes). 
12.3 
Statistical Analyses 
Additional details of the proposed statistical analyses will be documented in the statistical 
analysis plan (SAP), which will be written following finalization of the protocol and prior to 
study unblinding. This section is a summary of the planned statistical analyses of the most 
important endpoints including primary and key secondary endpoints. 
12.3.1 
Primary Analyses  
The hypothesis testing of the mean Total MLSI (Area x Intensity) and mean VITA shade score 
within each Experimental Dentifrice will employ the graphical approach shown in Figure 12.1, 
as per Bretz et al (Bretz et al., 2009) in order to maintain an overall two-sided familywise error 
rate at 5% within each Experimental Dentifrice (10% overall). 
For stratification purposes, the Total MLSI (Area x Intensity) will be derived as the sum of the 
MLSI (Area x Intensity) scores for each of evaluated regions (gingival and body) of the facial 
surfaces of each anterior tooth (4 values per assessed tooth surface).   
For efficacy evaluation, the mean Total MLSI (Area x Intensity) for a subject will be derived 
as the mean of the Total MLSI (Area x Intensity) scores across all anterior teeth assessed (facial 
surfaces of the maxillary and mandibular anterior teeth and the lingual surfaces of the 
mandibular teeth, 4 values per assessed tooth surface). 
The mean VITA shade score for a subject will be derived as the mean of the VITA shade scores 
across all teeth assessed.  
  
300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI


GSK Consumer Healthcare 
 
Clinical Protocol 
 
 
Protocol Number: 300024 
 
Property of GSK Consumer Healthcare - Confidential  
May not be used, divulged, published or otherwise disclosed without the consent of GSKCH 
 Clinical Protocol Template v9.0 
Page 53 of 63 
Figure 12-1 
Graphical Approach Showing Allocation and Propagation of Alpha 
Between Hypotheses Within Each Experimental Dentifrice  
 
The above hypotheses tests will be conducted based on separate Mixed Models with Repeated 
Measures (MMRM) for the change from baseline in the mean Total MLSI (Area x Intensity) 
and mean VITA shade score. Fixed effects will be included for smoking status, study product, 
visit and study product x visit interaction. The respective baseline result will be included as a 
covariate. Subject will be included as a repeated measure with unstructured covariance matrix. 
Kenward Rogers degrees of freedom approach will be applied. The least square means for each 
study product at week 8 will be presented based on observed margins and used to test for < 0 
change from baseline. The differences between least square means for each Experimental 
Dentifrice compared to the Reference Dentifrice at week 8 will be presented and used to test 
for a difference between products. The adjusted two-sided p-values and simultaneous 95% 
confidence intervals (following graphical testing approach) will be provided for all 
comparisons.  
The assumption of normality and homogeneity of variance in the MMRM will be investigated. 
In case of violation of these assumptions, a suitable nonparametric test (adjusted for the 
randomization stratification) will be performed for each comparison at week 8 and results will 
be provided to support the MMRM results. 
The mean Total MLSI (Area x Intensity) and mean VITA shade score values across the study 
and change from baseline will be summarised descriptively. 
300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI


GSK Consumer Healthcare 
 
Clinical Protocol 
 
 
Protocol Number: 300024 
 
Property of GSK Consumer Healthcare - Confidential  
May not be used, divulged, published or otherwise disclosed without the consent of GSKCH 
 Clinical Protocol Template v9.0 
Page 54 of 63 
12.3.2 
Secondary and Exploratory Analyses 
There will be no adjustment for multiplicity in the analyses described in this section. 
The within and between study product comparisons for the mean Total MLSI (Area x Intensity) 
and mean VITA shade score after 4 weeks will be based on the same respective MMRM as 
used for the primary analyses but based on the least square means comparisons at week 4. 
The within and between study product comparisons for the other secondary and exploratory 
efficacy endpoints (see Section 3) after 4 and 8 weeks will be based on the same MMRM as 
used for the primary analyses (replacing the respective baseline for the endpoint as a covariate) 
and the least square means comparisons at weeks 4 and 8. These other secondary and 
exploratory endpoint values across the study and change from baseline will also be summarised 
descriptively. 
12.3.3 
Safety Analyses 
The Safety population will be used for safety analyses. Safety analyses will be performed 
according to study product received.  
Safety analyses will focus on: 
• Exposure and compliance with study product 
• Adverse Events (AEs) 
All AEs will be reviewed by the Clinical Research Scientist, or designee, prior to database lock 
and unblinding and will be coded using the MedDRA. During this review stage, AEs will be 
further categorized as oral or non-oral. AEs will be regarded as ‘treatment’ emergent if they 
occur on or after the first use of study product at the Baseline visit.  
The following AEs summaries (number of distinct AEs and frequency/proportion of subjects 
affected will be presented by study product group and overall:  
• Treatment emergent AEs 
• Treatment emergent AEs by System Organ Class (SOC) and Preferred Term (PT);  
• Treatment emergent AEs by Oral/Non-Oral and PT;  
• Treatment emergent treatment related AEs by Oral/Non-Oral and PT; 
• Treatment emergent treatment related serious AEs by SOC and PT; 
A listing of all AEs will be presented for all subjects in the Safety population. Separate listings 
will be presented for any deaths, serious AEs and AEs leading to study or product 
discontinuation. 
• Oral Soft Tissue and Examinations 
• Oral Hard Tissue and Examinations 
A list of medical device incidents will also be included as part of the safety analyses.  No 
specific risks or anticipated adverse device effects are expected to be observed within this study, 
however all AEs and medical device incidents will be assessed to evaluate the tolerability and 
safety of the treatments. 
12.3.4 
Other Analyses 
The repeat stain and color assessments will be compared to the original assessments and will 
not be used in any efficacy analysis. The first and second assessments on each tooth site will be 
cross tabulated. A weighted Kappa coefficient (κ), along with the 95% CI will be calculated 
300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI


GSK Consumer Healthcare 
 
Clinical Protocol 
 
 
Protocol Number: 300024 
 
Property of GSK Consumer Healthcare - Confidential  
May not be used, divulged, published or otherwise disclosed without the consent of GSKCH 
 Clinical Protocol Template v9.0 
Page 55 of 63 
to assess the intra-examiner reliability. Fleiss-Cohen weighted kappa will be calculated for the 
repeatability analysis. Reliability will be deemed  
• Excellent if κ > 0.75 
• Fair to good if 0.4 ≤ κ ≤ 0.75 
• Poor if κ <0.4 
All subjects who have repeatability data will be included in this analysis.  
12.3.5 
Demographic and Baseline Characteristics 
Demographic and randomized stratification data will be summarized descriptively. 
12.3.6 
Study Product Compliance and Use of Other Therapies 
12.3.6.1 Study Product Compliance 
Number of brushings, brushing compliance (%), number of missed brushings, number of 
additional brushings will be summarized using descriptive statistics by cumulative visit.  
Number of brushings is defined as: [(date of Visit N – date of Visit 2) multiplied by 2 – number 
of missing brushings + number of additional brushings].  
Brushing compliance (%) is defined as: [100 x (Number of brushings / Expected number of 
brushings)], where expected number of brushings is defined as: [(date of Visit N – date of Visit 
2) multiplied by 2]. 
12.3.6.2 Prior and Concomitant Medications 
Prior and Concomitant Medications will be listed only. 
12.3.6.3 Handling of Dropouts and Missing Data  
The use of MMRM analyses account for missing data assuming a missing at random assumption, 
i.e., there is a systematic relationship between the propensity of missing values and the observed 
data, but not the missing data.  
It is therefore assumed that a subject with missing data would have obtained a similar efficacy 
result compared to a subject using the same study product with the same smoking status and 
similar non-missing results at other timepoints (baseline and post-baseline). Sensitivity analyses 
may be added to the SAP prior to unblinding in case of high drop-out rates and/or exclusion 
from PP population.  
12.3.7 
Interim Analysis  
No interim analysis is planned for this study. 
13 
STUDY GOVERNANCE CONSIDERATIONS 
13.1 
Quality Control  
In accordance with applicable regulations including GCP, and the sponsor’s procedures, the 
sponsor or designee (i.e. third-party vendor) monitors will contact the site prior to the start of 
the study to review with the site staff the protocol, study requirements, and their responsibilities 
to satisfy regulatory, ethical, and the sponsor’s requirements. 
300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI


GSK Consumer Healthcare 
 
Clinical Protocol 
 
 
Protocol Number: 300024 
 
Property of GSK Consumer Healthcare - Confidential  
May not be used, divulged, published or otherwise disclosed without the consent of GSKCH 
 Clinical Protocol Template v9.0 
Page 56 of 63 
When reviewing data collection procedures, the discussion will include identification, 
agreement and documentation of data items for which the CRF will serve as the source 
document. 
The sponsor or designee will monitor the study and site activity to verify that the: 
• Data are authentic, accurate, and complete. 
• Safety and rights of subjects are being protected. 
• Study is conducted in accordance with the currently approved protocol and any other 
study agreements, GCP, and all applicable regulatory requirements. 
The extent and nature of monitoring will be described in a written monitoring plan on file with 
the sponsor. The investigator (or designee) agrees to allow the monitor direct access to all 
relevant documents and agrees to co-operate with the monitor to ensure that any problems 
detected in the course of these monitoring visits are resolved. 
13.2 
Quality Assurance 
To ensure compliance with GCP and all applicable regulatory requirements, the sponsor may 
conduct a quality assurance assessment and/or audit of the site records, and the regulatory 
agencies may conduct a regulatory inspection at any time during or after completion of the 
study.  
In the event of an assessment, audit or inspection, the investigator (and institution) must agree 
to grant the advisor(s), auditor(s) and inspector(s) direct access to all relevant documents and 
to allocate their time and the time of their staff to discuss the conduct of the study, any 
findings/relevant issues and to implement any corrective and/or preventative actions to address 
any findings/issues identified. 
The investigator(s) will notify the sponsor or its agents immediately of any regulatory 
inspection notification in relation to the study. Furthermore, the investigator will cooperate with 
the sponsor or its agents to prepare the study site for the inspection and will allow the sponsor 
or its agent, whenever feasible, to be present during the inspection. The investigator will 
promptly apply copies of the inspection finding to the sponsor or its agent. Before response 
submission to the regulatory authority, the investigator will provide the sponsor or its agents 
with an opportunity to review and comment on responses to any such findings.  
The sponsor will be available to help investigators prepare for an inspection. 
13.3 
Regulatory and Ethical Considerations 
13.3.1 
Institutional Review Board/ Ethics Committee  
It is the responsibility of the investigator to have prospective approval of the study protocol, 
protocol amendments and informed consent documents, investigator brochure/safety statement 
(including any updates) and other relevant documents, e.g. recruitment advertisements, if 
applicable, from the IRB/EC.  All correspondence with the IRB/EC should be retained in the 
investigator file.  Copies of IRB/EC approvals should be forwarded to the sponsor prior to the 
initiation of the study, and also when subsequent amendments to the protocol are made. 
The only circumstance in which an amendment may be initiated prior to IRB/EC approval is 
where the change is necessary to eliminate apparent immediate hazards to the subjects.  In that 
300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI


GSK Consumer Healthcare 
 
Clinical Protocol 
 
 
Protocol Number: 300024 
 
Property of GSK Consumer Healthcare - Confidential  
May not be used, divulged, published or otherwise disclosed without the consent of GSKCH 
 Clinical Protocol Template v9.0 
Page 57 of 63 
event, the investigator must notify the IRB/EC and the sponsor in writing immediately after the 
implementation. 
13.3.2 
Ethical Conduct of the Study 
The study will be conducted in accordance with the protocol and legal and regulatory 
requirements, as well as the general principles set forth in the International Ethical Guidelines 
for Biomedical Research Involving Human Subjects (Council for International Organizations 
of Medical Sciences 2002), International Ethical Guidelines for Health-Related Research 
Involving Humans (ICH, Nov 2016), guidelines for GCP (ICH, 1997), and the Declaration of 
Helsinki (World Medical Association, 2013).  
In addition, the study will be conducted in accordance with the protocol, the ICH guideline on 
GCP, and applicable local regulatory requirements and laws. 
13.3.3 
Subject Information and Consent 
All parties will ensure protection of subject personal data and will not include subject names or 
other identifiable data in any reports, publications, or other disclosures, except where required 
by laws.  
When study data are compiled for transfer to the sponsor and other authorized parties, subject 
names, addresses, and other identifiable data will be replaced by numerical codes based on a 
numbering system provided by the sponsor in order to de-identify study subjects.   
The study site will maintain a confidential list of subjects who participated in the study, linking 
each subject’s numerical code to his or her actual identity.  In case of data transfer, the sponsor 
will maintain high standards of confidentiality and protection of subjects’ personal data 
consistent with applicable privacy laws. 
The informed consent documents must be in compliance with ICH GCP, local regulatory 
requirements, and legal requirements, including applicable privacy laws. 
The informed consent documents used during the informed consent process must be reviewed 
and approved by the sponsor, approved by the IRB/EC before use, and available for inspection. 
The investigator must ensure that each study subject, is fully informed about the nature and 
objectives of the study and possible risks associated with participation.  
13.3.4 
Subject Recruitment  
Advertisements approved by IRBs/ECs and investigator databases may be used as recruitment 
procedures.  Use of ethics committee approved, generic, prescreening questionnaire to assess 
basic subject characteristics to determine general eligibility for this study is allowed.  This 
generic questionnaire may be used by sites as a phone script and/or to review internal databases 
to identify subjects.   
The sponsor will have an opportunity to review and approve the content of any study 
recruitment materials directed to potential study subjects before such materials are used.  
13.3.5 
Reporting of Safety Issues and Serious Breaches of the Protocol or 
ICH GCP  
The sponsor defines a serious breach as a breach likely to affect to a significant degree the safety 
and rights of a subject or the reliability and robustness of the data generated in human subject 
research studies.  
300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI


GSK Consumer Healthcare 
 
Clinical Protocol 
 
 
Protocol Number: 300024 
 
Property of GSK Consumer Healthcare - Confidential  
May not be used, divulged, published or otherwise disclosed without the consent of GSKCH 
 Clinical Protocol Template v9.0 
Page 58 of 63 
In the event of any prohibition or restriction imposed (i.e., clinical hold) by an applicable 
competent authority in any area of the world, or if the investigator is aware of any new 
information that might influence the evaluation of the benefits and risks of the investigational 
product, the sponsor should be informed immediately.  
In addition, the investigator will inform the sponsor immediately of any urgent safety measures 
taken by the investigator to protect the study subjects against any immediate hazard, and of any 
serious breaches of this protocol or of ICH GCP that the investigator becomes aware of. 
13.4 
Posting of Information on Publicly Available Clinical Trial 
Registers 
Study information from this protocol will be posted on publicly available clinical trial registers 
before enrollment of subjects begins in accordance with applicable sponsor processes. 
The sponsor intends to make anonymized subject-level data from this trial available to external 
researchers for scientific analyses or to conduct further research that can help advance medical 
science or improve patient care. This helps ensure the data provided by trial participants are 
used to maximum effect in the creation of knowledge and understanding 
13.5 
Provision of Study Results to Investigators 
Where required by applicable regulatory requirements, an investigator signatory will be 
identified for the approval of the clinical study report.  The investigator will be provided 
reasonable access to statistical tables, figures, and relevant reports and will have the opportunity 
to review the complete study results at the sponsor’s site or other mutually-agreeable location. 
The sponsor will also provide the investigator with the full summary of the study results.  The 
investigator is encouraged to share the summary results with the study subjects, as appropriate. 
The procedures and timing for public disclosure of the results summary and for development of 
a manuscript for publication will be in accordance with the sponsor’s Policy. 
A manuscript will be progressed for publication in the scientific literature if the results provide 
important scientific or medical knowledge. 
13.6 
Records Retention 
Following closure of the study, the investigator must maintain all site study records (except for 
those required by local regulations to be maintained elsewhere), in a safe and secure location.   
The records (study/ site master file) must be maintained to allow easy and timely retrieval, when 
needed (e.g. for a sponsor audit or regulatory inspection) and must be available for review in 
conjunction with assessment of the facility, supporting systems, and relevant site staff. 
Where permitted by local laws/regulations or institutional policy, some or all of these records 
can be maintained in a format other than hard copy (e.g. microfiche, scanned, electronic); 
however, caution needs to be exercised before such action is taken.  
The investigator must ensure that all reproductions are legible and are a true and accurate copy 
of the original and meet accessibility and retrieval standards, including re-generating a hard 
copy, if required.  Furthermore, the investigator must ensure there is an acceptable back-up of 
these reproductions and that an acceptable quality control process exists for making these 
reproductions. 
300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI


GSK Consumer Healthcare 
 
Clinical Protocol 
 
 
Protocol Number: 300024 
 
Property of GSK Consumer Healthcare - Confidential  
May not be used, divulged, published or otherwise disclosed without the consent of GSKCH 
 Clinical Protocol Template v9.0 
Page 59 of 63 
The investigator must assure that the subject’s anonymity will be maintained.  On CRFs or other 
documents submitted to the sponsor, subjects should not be identified by their names or initials, 
but by an identification code. The investigator should keep a separate log of subjects’ codes, 
names and addresses.  Documents not for submission to the sponsor, e.g. subjects’ written 
consent forms, should be maintained by the investigator in strict confidence. 
Records and documents, including signed ICF, pertaining to the conduct of this study must be 
retained by the investigator as per the signed contractual agreement, from the issue of the final 
Clinical Study Report (CSR) or equivalent summary, unless local regulations or institutional 
policies require a longer retention period. The minimum retention time will meet the strictest 
standard applicable to that site for the study, as dictated by any institutional requirements or 
local laws or regulations, the sponsor’s standards/procedures, and/or institutional requirements.   
No study document should be destroyed without a prior written agreement between the sponsor 
and the investigator. The investigator must notify the sponsor of any changes in the archival 
arrangements, including, but not limited to, archival at an off-site facility or transfer of 
ownership of the records in the event the investigator is no longer associated with the site. 
13.7 
Conditions for Terminating the Study  
Premature termination of this study may occur because of a regulatory authority decision, 
change in opinion of the IRB/EC, or study product safety problems, or at the discretion of the 
sponsor.  In addition, the sponsor retains the right to discontinue development of the 
experimental dentifrices at any time.  
If a study is prematurely terminated, the sponsor will promptly notify the investigator.  After 
notification, the investigator must promptly contact all participating subjects and should assure 
appropriate therapy/ follow-up for the subjects.  As directed by the sponsor, all study materials 
must be collected and all CRF’s completed to the greatest extent possible. Where required by 
the applicable regulatory requirements, the sponsor should inform the regulatory authority(ies) 
and the investigator should promptly inform the IRB/EC and provide the IRB/EC a detailed 
written explanation of the termination or suspension.  
If the IRB/EC terminates or suspends its approval/favorable opinion of a trial, the investigator 
should promptly notify the sponsor and provide the sponsor with a detailed written explanation 
of the termination or suspension. 
Upon completion or premature discontinuation of the study, the sponsor’s  monitor will conduct 
site closure activities with the investigator or site staff, as appropriate, in accordance with 
applicable regulations including GCP, and the sponsor’s Standard Operating Procedures. 
14 
REFERENCES 
[ADA (2020)] Home Use Tooth Bleaching Products. 
[ADA (2022)] Toothbrushes. https://www.ada.org/resources/research/science-and-research-
institute/oral-health-topics/toothbrushes: Extracted 26 April 2022. 
[Ash A, Mulholland F, Burnett GR, et al. (2014)] Structural and compositional changes in the 
salivary pellicle induced upon exposure to SDS and STP. Biofouling; 30(10): 1183-97. 
[Bretz F, Maurer W, Brannath W, et al. (2009)] A graphical approach to sequentially rejective 
multiple test procedures. Statistics in medicine; 28(4): 586-604. 
300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI


GSK Consumer Healthcare 
 
Clinical Protocol 
 
 
Protocol Number: 300024 
 
Property of GSK Consumer Healthcare - Confidential  
May not be used, divulged, published or otherwise disclosed without the consent of GSKCH 
 Clinical Protocol Template v9.0 
Page 60 of 63 
[del Mar Pérez M, Ghinea R, Rivas MJ, et al. (2016)] Development of a customized whiteness 
index for dentistry based on CIELAB color space. Dental Materials; 32(3): 461-7. 
[Dozić A, Kleverlaan CJ, El‐Zohairy A, et al. (2007)] Performance of five commercially 
available tooth color‐measuring devices. J. Prosthodont.; 16(2): 93-100. 
[Featherstone JD (1999)] Prevention and reversal of dental caries: role of low level fluoride. 
Community dentistry and oral epidemiology; 27(1): 31-40. 
[Gillam DG (1996)] Efficacy of a potassium nitrate mouthwash in alleviating cervical dentine 
sensitivity (CDS). Journal of Clinical Periodontology; 23(11): 993-7. 
[Gómez‐Polo C, Gómez‐Polo M, Martínez Vazquez De Parga JA, et al. (2015)] 3D 
Master Toothguide according to L*, C*, and h* coordinates. Color Research & Application; 
40(5): 518-24. 
[ICH (1997)] GENERAL CONSIDERATIONS FOR CLINICAL TRIALS E8. 
[ICH (Nov 2016)] Topic E6 (R2) Guideline for Good Clinical Practice. 
[Joiner A, Luo W (2017)] Tooth colour and whiteness: A review. Journal of dentistry; 67: S3-
S10. 
[Knezovic Zlataric D, Illeš D, Alajbeg IŽ, et al. (2016)] In vivo evaluations of inter-observer 
reliability using VITA Easyshade® Advance 4.0 Dental Shade-Matching Device. Acta 
stomatologica Croatica: International journal of oral sciences and dental medicine; 50(1): 34-
9. 
[Lippert F (2013)] An introduction to toothpaste - its purpose, history and ingredients. 
Monographs in oral science; 23: 1-14. 
[Lobene R (1968)] Effect of dentifrices on tooth stains with controlled brushing. J Am Dent 
Assoc; 77: 849-55. 
[Macpherson LM, Stephen KW, Joiner A, et al. (2000)] Comparison of a conventional and 
modified tooth stain index. J Clin Periodontol; 27(11): 854-9. 
[Marinho VC, Higgins J, Logan S, et al. (2003)] Fluoride toothpastes for preventing dental 
caries in children and adolescents. Cochrane database of systematic reviews; (1). 
[Milleman KR, Milleman JL, Young S, et al. (2017)] Randomized Controlled Trial to Explore 
the Effect of Experimental Low Abrasivity Dentifrices on Enamel Gloss and Smoothness, and 
the Build-up of Extrinsic Tooth Stain. J Clin Dent; 28(2): 1-8. 
[NHS (2019)] Teeth cleaning guide https://www.nhsinform.scot/healthy-living/dental-
health/your-teeth/teeth-cleaning-guide: Extracted 26 March 2019. 
[Pader (2012)] Dentifrices',  Kirk-Othmer Encyclopedia of Chemical Technology: John Wiley 
and Sons. 
[Paravina RD (2008)] New shade guide for tooth whitening monitoring: visual assessment. J. 
Prosthet. Dent.; 99(3): 178-84. 
[Samant A, Malik C, Chabra S, et al. (1977)] Gingivitis and periodontal disease in pregnancy. 
Obstetrical & Gynecological Survey; 32(3): 140-1. 
300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI
CCI


GSK Consumer Healthcare 
 
Clinical Protocol 
 
 
Protocol Number: 300024 
 
Property of GSK Consumer Healthcare - Confidential  
May not be used, divulged, published or otherwise disclosed without the consent of GSKCH 
 Clinical Protocol Template v9.0 
Page 61 of 63 
[Samant A, Malik C, Chabra S, et al. (1976)] Gingivitis and periodontal disease in pregnancy. 
47(7): 415-8. 
[Schiff T, Dotson M, Cohen S, et al. (1994)] Efficacy of a dentifrice containing potassium 
nitrate, soluble pyrophosphate, PVM/MA copolymer, and sodium fluoride on dentinal 
hypersensitivity: A twelve-week clinical study. Journal of Clinical Dentistry; 5(SPEC. ISS.): 
87-92. 
[Seong J, Hall C, Young S, et al. (2017)] A randomised clinical in situ study to evaluate the 
effects of novel low abrasivity anti-sensitivity dentifrices on dentine wear. J Dent; 57: 20-5. 
[Shellis RP, Addy M, Rees GD (2005)] In vitro studies on the effect of sodium 
tripolyphosphate on the interactions of stain and salivary protein with hydroxyapatite. Journal 
of Dentistry; 33(4): 313-24. 
[Tung FF, Goldstein GR, Jang S, et al. (2002)] The repeatability of an intraoral dental 
colorimeter. J. Prosthet. Dent.; 88(6): 585-90. 
[US FDA (2005)] GUIDANCE FOR INDUSTRY: COLLECTION OF RACE AND 
ETHNICITY DATA IN CLINICAL TRIALS. 
[Watts A, Addy M (2001)] Tooth discolouration and staining: A review of the literature. 
British Dental Journal; 190(6): 309-16. 
[World Medical Association (2013)] Declaration of Helsinki, 64th General Assembly, 
Fortaleza. 
[Young S, Mason S, Milleman JL, et al. (2017)] A randomized clinical study to evaluate the 
effect of an ultra low abrasivity dentifrice on extrinsic stain. American Journal of Dentistry; 
30(5): 255-61. 
15 
APPENDICIES 
15.1 
Product Usage Instructions Sheet 
 
INSTRUCTIONS FOR PRODUCT USE 
Brush twice a day (morning and evening). 
Each time you brush: 
• Dispense a ribbon of toothpaste covering the length of the toothbrush head (see below 
picture). Only the supplied toothbrush may be used. 
• Set your timer for 2 minutes, and then brush your teeth in your usual manner for 2 timed 
minutes. 
 
300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI
CCI


GSK Consumer Healthcare 
 
Clinical Protocol 
 
 
Protocol Number: 300024 
 
Property of GSK Consumer Healthcare - Confidential  
May not be used, divulged, published or otherwise disclosed without the consent of GSKCH 
 Clinical Protocol Template v9.0 
Page 62 of 63 
 
 
• Record each brushing on the diary card. Note any changes to these brushing procedures 
and reasons for changes (e.g. missed brushings, extra brushings) in the ‘Comments’ 
column. 
• Record any changes in your smoking habits, health, medications (prescription and over 
the counter medications), or treatments on the diary card. 
• Bring your diary card (completed and not completed), toothpaste and toothbrush to the 
next study visit. 
 
15.2 
ABBREVIATIONS 
The following is a list of abbreviations that may be used in the protocol. 
Table 15-1 
Abbreviations 
 
Abbreviation 
Term 
AE 
adverse event 
BDR 
blinded data review 
CI 
confidence interval 
CRF 
case report form 
EC 
ethics committee 
eCRF 
Electronic Case Report Form 
EudraCT 
European Clinical Trials Database 
FDA 
Food and Drug Administration (United States) 
GCP 
Good Clinical Practice 
ICH 
International Conference on Harmonisation 
ID 
identification 
IEC 
Independent Ethics Committee 
IRB 
institutional review board 
LSLV 
last subject last visit  
KNO3 
Potassium nitrate 
MedDRA 
medical Dictionary for Regulatory Activities 
MLSI 
Modified Lobene Stain Index 
MMRM 
Mixed Models with Repeated Measures 
300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI


GSK Consumer Healthcare 
 
Clinical Protocol 
 
 
Protocol Number: 300024 
 
Property of GSK Consumer Healthcare - Confidential  
May not be used, divulged, published or otherwise disclosed without the consent of GSKCH 
 Clinical Protocol Template v9.0 
Page 63 of 63 
Abbreviation 
Term 
N/A 
not applicable 
PI 
principal investigator 
PI 
Personal information 
SAE 
serious adverse event 
SOP 
standard operating procedure 
SRSD 
single reference study document 
SS 
safety statement 
STP 
Sodium tripolyphosphate 
US 
United States 
 
300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
CCI


Signature Page for  300024 TMF-236430 v3.0
Signature Page for TMF-236430 v3.0
Reason for signing: Approved
Name: 
Role: A
Date of signature: 
GMT+0000
300024 | Protocol  07 Sep 2022 | TMF-236430 | 3.0
PPD
PPD

SAP_001.pdf: 
Potassium Nitrate Dentifrices 
300024 
Property of GSK Consumer Healthcare 
Confidential 
May not be used, divulged, published, or otherwise disclosed 
without the consent of GSK 
 Statistical Analysis Plan Template v6.0 
Page 1 of 37 
STATISTICAL ANALYSIS PLAN 
A RANDOMIZED, CONTROLLED, SINGLE-BLIND CLINICAL STUDY 
TO INVESTIGATE THE TOOTH STAIN REMOVAL EFFICACY OF 
TWO EXPERIMENTAL POTASSIUM NITRATE DENTIFRICES IN 
SUBJECTS WITH EXTRINSIC DENTAL STAIN COMPARED TO A 
STANDARD DENTIFRICE CONTROL WHEN USED TWICE DAILY 
FOR 8 WEEKS 
Protocol Number: 300024 
Phase: 
N/A 
This document contains confidentiality statements that are not relevant for 
this publicly available version
CCI


Potassium Nitrate Dentifrices 
300024 
 
 
 
 
GlaxoSmithKline Consumer Healthcare Confidential 
 Statistical Analysis Plan Template v6.0 
Page 2 of 37 
Document History 
 
Document 
Version Date 
Summary of Changes (New analysis or 
Change in planned analysis) 
Original Analysis Plan 
V1.0 04-OCT-2022 
Not applicable (N/A) 
 
 
 
CCI


Potassium Nitrate Dentifrices 
300024 
 
 
 
 
GlaxoSmithKline Consumer Healthcare Confidential 
 Statistical Analysis Plan Template v6.0 
Page 3 of 37 
Table of contents 
Document History ............................................................................................................... 2 
Table of contents ................................................................................................................. 3 
List of Tables ....................................................................................................................... 4 
List of Figures ...................................................................................................................... 4 
Abbreviations.............................................................................................................................. 5 
1 
Summary of Key Protocol Information ............................................................................... 6 
1.1 
Study Design ............................................................................................................ 7 
1.2 
Study Objectives ...................................................................................................... 9 
1.3 
Study Products ....................................................................................................... 11 
1.4 
Sample Size Calculation ........................................................................................ 11 
2 
Planned Analyses ............................................................................................................... 13 
2.1 
Interim Analysis ..................................................................................................... 13 
2.2 
Final Analyses ....................................................................................................... 13 
3 
Considerations for data analyses and Data Handling Conventions ................................... 13 
3.1 
Baseline Definition ................................................................................................ 13 
3.2 
Subgroups/Stratifications ....................................................................................... 13 
3.3 
Centers Pools ......................................................................................................... 14 
3.4 
Timepoints and Visit Windows ............................................................................. 14 
4 
Data Analysis ..................................................................................................................... 14 
4.1 
Populations for Analysis ........................................................................................ 14 
4.1.1 
Subject Disposition ............................................................................... 14 
4.1.2 
Protocol Deviations ............................................................................... 15 
4.1.3 
Analysis Populations ............................................................................. 16 
4.2 
Subject Demographics and Other Baseline Characteristics ................................... 17 
4.2.1 
Demographic and Baseline Characteristics ........................................... 17 
4.2.2 
General Medical History ....................................................................... 17 
4.3 
Treatments (Study Product, Rescue Medication, other Concomitant 
Therapies, Compliance) ......................................................................................... 17 
4.3.1 
Study Product Compliance and Exposure ............................................. 17 
4.3.2 
Prior and Concomitant Medication ....................................................... 18 
4.4 
Analysis of Efficacy .............................................................................................. 18 
4.4.1 
Primary Efficacy Endpoint .................................................................... 19 
CCI


Potassium Nitrate Dentifrices 
300024 
 
 
 
 
GlaxoSmithKline Consumer Healthcare Confidential 
 Statistical Analysis Plan Template v6.0 
Page 4 of 37 
4.4.2 
Secondary Efficacy Endpoints .............................................................. 21 
4.4.3 
Exploratory Efficacy Variables ............................................................. 26 
4.4.4 
Handling of Missing Values/Censoring/Discontinuations .................... 27 
4.5 
Analysis of Safety .................................................................................................. 27 
4.5.1 
Adverse Events and Serious Adverse Events ........................................ 28 
4.5.2 
Other Safety Variables .......................................................................... 28 
4.6 
Analysis of Other Variables ................................................................................... 29 
5 
Changes to the Protocol Defined Statistical Analysis Plan ............................................... 30 
Appendix 1: List of Data Displays .................................................................................... 31 
 
List of Tables 
Table 1-1 
Schedule of Activities ............................................................................. 8 
Table 1-2 
Study Objectives and Endpoints ............................................................. 9 
Table 1-3 
Study Products ...................................................................................... 11 
Table 1-4 
Sample Size Power by Endpoint at 5% and 2.5% Significance 
Levels with 90 Subjects per Arm .......................................................... 12 
 
List of Figures 
Figure 4-1 
Graphical Approach Showing Allocation and Propagation of Alpha 
Between Hypotheses Within Each Experimental Dentifrice ................ 19 
Figure 4-2 
MLSI Assessment Sites: Body (B), Gingival (G), Mesial (M), 
Distal (D) ............................................................................................... 20 
 
CCI


Potassium Nitrate Dentifrices 
300024 
 
 
 
 
GlaxoSmithKline Consumer Healthcare Confidential 
 Statistical Analysis Plan Template v6.0 
Page 5 of 37 
Abbreviations 
 
Abbreviation 
Term 
AE 
Adverse Event 
A × I 
Area × Intensity 
BDRM 
Blinded Data Review Meeting 
CH 
Consumer Healthcare 
CI 
Confidence Interval 
COVID-19 
Coronavirus Disease of 2019 
eCRF 
Electronic Case Report Form 
GSK 
GlaxoSmithKline 
GSKCH 
GlaxoSmithKline Consumer Healthcare 
ICF 
Informed Consent Form 
ITT 
Intent-To-Treat 
KNO3 
Potassium Nitrate 
MedDRA 
Medical Dictionary for Regulatory Activities 
mITT 
Modified Intend-To-Treat 
MLSI 
Total Modified Lobene Stain Index 
MMRM 
Mixed Model with Repeated Measures 
N/A 
Not Applicable 
NA 
Not Applicable 
NaF 
Sodium Fluoride 
OHT 
Oral Hard Tissue 
OST 
Oral Soft Tissue 
PP 
Per-Protocol 
PT 
Preferred Term 
SAE 
Serious Adverse Event 
SAP 
Statistical Analysis Plan 
SD 
Standard Deviation 
SE 
Standard Error 
SOC 
System Organ Class 
STP 
Sodium Tripolyphosphate 
TEAEs 
Treatment Emergent Adverse Events 
WHODD 
World Health Organization Drug Dictionary 
CCI


Potassium Nitrate Dentifrices 
300024 
 
 
 
 
GlaxoSmithKline Consumer Healthcare Confidential 
 Statistical Analysis Plan Template v6.0 
Page 6 of 37 
The purpose of this Statistical Analysis Plan (SAP) is to describe the planned analyses and 
outputs to be included in the Clinical Study Report for Protocol 300024 (version 3.0, dated 
07-Sep-2022). 
1 
Summary of Key Protocol Information 
This will be a single-center, 8-week, randomized, controlled, single-blind (clinical examiner[s] 
and VITA EasyShade operator), three treatment-arm, parallel design, stratified clinical study in 
healthy volunteers with a propensity to form dental stain. It has been designed to investigate 
changes in tooth stain and color, following twice-daily use of two experimental dentifrices, after 
four- and eight-weeks twice daily use; a regular fluoride dentifrice will be included as reference 
dentifrice. Sufficient subjects will be screened to randomize approximately 300 subjects to 
study treatment to ensure approximately 270 subjects complete the study. 
At screening (Visit 1, Day 0), subjects will give their written informed consent to participate in 
the study. Demography, relevant medical history, and current medications/treatments will be 
recorded, followed by oral soft tissue (OST) and oral hard tissue (OHT) examinations. Subjects 
meeting the relevant study criteria, will be considered eligible to proceed for baseline 
assessments on the same day. 
At baseline (Visit 2, Day 0) subjects, having refrained from oral hygiene procedures for at least 
6 hours, will undergo clinical assessment of the stain on the facial surfaces of their six maxillary 
anterior teeth and six mandibular anterior teeth (tooth numbers 6-11 and 22-27) and the lingual 
surfaces of their six mandibular anterior teeth using the MacPherson modification of the Lobene 
Stain Index (MLSI). The shade (color) of the facial surfaces of the central and lateral maxillary 
incisors (tooth numbers 7-10) will then be assessed clinically using the VITA Bleachedguide 
3D-MASTER and the color of the same surfaces will be evaluated using the VITA EasyShade 
instrument. Subjects who fulfil all inclusion/exclusion criteria will be enrolled into the study. 
Qualifying subjects with a Total MLSI (A × I) ≥ 15 for the facial surfaces of the 12 anterior teeth 
and a mean tooth shade ≥ 11 on the facial surfaces of the 4 maxillary incisors, who meet all 
other entry criteria, will be stratified according to their baseline Total MLSI (A × I) (low < 45; 
high ≥ 45) and smoking status (smoker; non-smoker) and randomized to study treatment.  
Randomized subjects will brush twice daily (morning and evening) with their assigned study 
dentifrice for the next 8 weeks and record each brushing in the diary provided; significant 
changes in diet or smoking status should also be noted in the diary. Subjects, having refrained 
from oral hygiene procedures for at least 6 hours, will return to the clinic after 4- and 8-weeks 
treatment (Visits 3 and 4, respectively) for clinical and instrumental assessments of dental stain 
and tooth shade/color.  
The clinical examiner will perform replicate MLSI and tooth shade assessments (as described 
in Sections 4.6) at Visits 2 to 4. The clinical examiner may brush the subject’s anterior teeth 
with water and/or floss between the anterior teeth prior to MLSI assessments, if required, to 
remove any debris on the teeth. 
CCI


Potassium Nitrate Dentifrices 
300024 
 
 
 
 
GlaxoSmithKline Consumer Healthcare Confidential 
 Statistical Analysis Plan Template v6.0 
Page 7 of 37 
Safety and oral tolerability of the study products will be monitored over the 8-week usage period 
by review of reported Adverse Events (AEs). 
1.1 
Study Design 
This will be a single-center, 8-week, randomized, controlled, single-blind (clinical examiner[s] 
and VITA EasyShade operator), three treatment-arm, parallel design, stratified clinical study in 
healthy volunteers with clinically confirmed dental stain (originating from the diet and/or 
smoking) on the surfaces of their anterior teeth. 
Potential subjects will attend a screening visit (Visit 1, Day 0) to determine their suitability to 
participate. Having obtained their written informed consent, relevant details of their medical 
history and current medications will be recorded, followed by OST and OHT examinations. 
Subjects meeting the relevant study criteria, will be considered as eligible to proceed for 
baseline assessments on the same day. 
At the baseline visit (Visit 2, Day 0), eligible subjects will undergo clinical and instrumental 
assessments of extrinsic dental stain (MLSI: facial surfaces of the six maxillary anterior teeth 
and six mandibular anterior teeth, and the lingual surfaces of the six mandibular anterior teeth) 
and tooth color (VITA Bleachedguide 3D-MASTER and VITA EasyShade instrument: facial 
surfaces of the central and lateral maxillary incisors). Qualifying subjects will be stratified by 
baseline Total MLSI (A ×I) (calculated for the facial surfaces of the six maxillary anterior teeth 
and six mandibular anterior teeth only) and smoking status and randomized to one of the three 
study treatments. Randomized subjects will be instructed to brush twice daily (for 2 minutes, 
morning and evening) with their assigned study dentifrice for the next 8 weeks. Extrinsic dental 
stain and tooth color assessments will be repeated after 4- and 8-weeks treatment. Table 1-1 
presents the schedule of activities.  
 
 
CCI


Potassium Nitrate Dentifrices 
300024 
 
 
 
 
GlaxoSmithKline Consumer Healthcare Confidential 
 Statistical Analysis Plan Template v6.0 
Page 8 of 37 
Table 1-1 
Schedule of Activities 
Procedure/Assessment 
Screening 
Treatment Period 
Visit 1 
Screening 
(Day 0)4 
Visit 2 
Baseline 
(Day 0)4 
 
Visit 3 
Week 4 
(Day 28 
±3 
days) 
 
Visit 4 
Week 8 
Day 56 
±3 
days) 
Informed consent 
X 
 
4 Weeks 
 
4 Weeks 
 
Demographics 
X 
 
 
 
Medical History / current oral 
care products / current and prior 
medication review 
X 
 
 
 
Review changes in health and 
concomitant 
medications/treatments 
 
 
X 
X 
OST Examination 
X 
 
X 
X 
OHT Examination 
X 
 
 
X 
Clinical assessment of extrinsic 
dental stain (MLSI)2 
 
X 
X 
X 
Clinical assessment of tooth 
color (VITA Bleachedguide) 
 
X 
X 
X 
Instrumental assessment of 
tooth color (VITA EasyShade) 
 
X 
X 
X 
Repeatability assessments3 
 
X 
X 
X 
Inclusion/exclusion criteria 
review 
X 
X 
 
 
Subject eligibility 
X 
X 
 
 
Subject continuance 
 
 
X 
X 
Randomization and stratification 
 
X 
 
 
Dispense study products, diary 
and sundry items 
 
X 
X 
 
Supervised tooth brushing 
 
X 
X 
 
Return of study dentifrice, 
toothbrush and completed diary 
 
 
X 
X 
Adverse events review1 
 
X 
X 
X 
Medical device incidents review1 
 
X 
X 
X 
Study conclusion 
 
 
 
X 
Abbreviations: OST: Oral Soft Tissue, OHT: Oral Hard Tissue, MLSI: Modified Lobene Stain Index 
Footnotes: 
1. Adverse Events (AEs), Serious Adverse Events (SAEs) and medical device incidents collected 
immediately after subject provides consent to participate in the study by the completion of the Informed 
Consent Form (ICF) until 5 days after last use of the study dentifrice (or last procedure). Medical 
device in this study is the supplied toothbrush. 
2. Brushing and/or flossing of the subject’s assessment teeth will be performed prior to this 
assessment by the examiner if required (at the examiner’s discretion). 
CCI


Potassium Nitrate Dentifrices 
300024 
 
 
 
 
GlaxoSmithKline Consumer Healthcare Confidential 
 Statistical Analysis Plan Template v6.0 
Page 9 of 37 
3. Repeatability assessments for VITA Bleachedguide and MLSI assessments will be performed on a 
subset of subjects 
4. Note Visits 1 & 2 will occur on the same day. 
1.2 
Study Objectives 
Study objectives and endpoints are defined in Table 1-2: 
Table 1-2 
Study Objectives and Endpoints 
Objectives 
Endpoints 
Primary Objective 
Primary Endpoint 
To evaluate the change in extrinsic 
dental stain after 8 weeks twice daily use 
of a ‘5% KNO3/1% alumina/5% STP’ 
dentifrice, a ‘5% KNO3/1% alumina/ 5% 
STP/2% silica’ dentifrice and a regular 
fluoride dentifrice, as measured by Total 
Modified Lobene Stain Index (Total MLSI 
[Area × Intensity]). 
Change from baseline in mean Total MLSI 
(Area × Intensity) score at week 8. 
Secondary Objectives 
Secondary Endpoints 
Efficacy 
 
To evaluate the change in extrinsic 
dental stain after 4 weeks twice daily use 
of a ‘5% KNO3/1% alumina/5% STP’ 
dentifrice, a ‘5% KNO3/1% alumina/ 5% 
STP/2% silica’ dentifrice and a regular 
fluoride dentifrice, as measured by Total 
Modified Lobene Stain Index (Total MLSI 
[Area × Intensity]). 
Change from baseline in mean Total MLSI 
(Area × Intensity) score at week 4. 
To compare the change in extrinsic 
dental stain after 4 & 8 weeks twice daily 
use of either a ‘5% KNO3/1% alumina/5% 
STP’ dentifrice or a ‘5% KNO3/1% 
alumina/ 5% STP/2% silica’ dentifrice, 
compared to a regular fluoride dentifrice, 
as measured by Total MLSI (Area × 
Intensity). 
Change from baseline in mean Total MLSI 
(Area × Intensity) score at weeks 4 & 8. 
To evaluate and compare the change in 
tooth shade (color) after 4 and 8 weeks 
twice daily use of either a ‘5% KNO3/1% 
alumina/5% STP’ dentifrice or a ‘5% 
KNO3/1% alumina/ 5% STP/2% silica’ 
dentifrice, compared to a regular fluoride 
Change from baseline in mean VITA shade 
score (examiner assessed) at weeks 4 & 8. 
CCI


Potassium Nitrate Dentifrices 
300024 
 
 
 
 
GlaxoSmithKline Consumer Healthcare Confidential 
 Statistical Analysis Plan Template v6.0 
Page 10 of 37 
Objectives 
Endpoints 
dentifrice, as measured by the VITA 
Bleachedguide 3D-MASTER. 
To evaluate and compare the changes in 
dental stain at specific tooth sites (along 
gingival margin, inter-proximally and on 
the body of the tooth) after 4 and 8 
weeks twice daily use of either a ‘5% 
KNO3/1% alumina/5% STP’ dentifrice or 
a ‘5% KNO3/1% alumina/ 5% STP/2% 
silica’ dentifrice, compared to a regular 
fluoride dentifrice, as measured by Total 
MLSI (Area × Intensity). 
Change from baseline in mean MLSI (Area × 
Intensity) in: 
• Gingival sites 
• Interproximal sites  
• Body sites 
To evaluate and compare change in 
extrinsic dental stain after 4 and 8 weeks 
twice daily use of either a ‘5% KNO3/1% 
alumina/5% STP’ dentifrice or a ‘5% 
KNO3/1% alumina/ 5% STP/2% silica’ 
dentifrice, compared to a regular fluoride 
dentifrice, as measured by MLSI (Area) 
and MLSI (Intensity). 
Change from baseline in mean MLSI (Area) 
and MLSI (Intensity) 
Exploratory Objectives 
Exploratory Endpoints 
To evaluate and compare the change in 
tooth color co-ordinates after 4 and 8 
weeks twice daily use of either a ‘5% 
KNO3/1% alumina/5% STP’ dentifrice or 
a ‘5% KNO3/1% alumina/ 5% STP/2% 
silica’ dentifrice, compared to a regular 
fluoride dentifrice, as measured using the 
VITA EasyShade. 
Change from baseline in mean tooth shade, 
L*, a*, b*, WID and ΔE* determined using the 
VITA EasyShade instrument at weeks 4 & 8 
Safety 
 
To assess the safety and tolerability of 
the two experimental KNO3 dentifrices. 
Treatment emergent adverse events 
CCI


Potassium Nitrate Dentifrices 
300024 
 
 
 
 
GlaxoSmithKline Consumer Healthcare Confidential 
 Statistical Analysis Plan Template v6.0 
Page 11 of 37 
1.3 
Study Products 
Table 1-3 presents the study products. 
Table 1-3 
Study Products 
Product Description 
Experimental 
Dentifrice 1 
Experimental 
Dentifrice 2 
Reference Dentifrice 
5% KNO3 dentifrice 
with 1% alumina and 
5% STP 
5% KNO3 dentifrice 
with 1% alumina, 5% 
STP and 2% high 
cleaning silica 
Regular Fluoride 
Dentifrice 
Product Name 
N/A 
N/A 
Aquafresh Cavity 
Protection 
(US market) 
Fluoride Content 
0.2542% NaF (1100 ppm fluoride) 
Pack Design  
One carton containing 2 tubes of dentifrice 
Dispensing Details 
Visit 2 (Baseline): 2 cartons; Visit 3 (Week 4): 2 cartons 
Product Master 
Formulation Code 
(MFC) 
 
 
 
Dose/Product 
Application 
Subjects will dose the toothbrush provided with a strip of dentifrice (a full 
brush head) on each brushing occasion 
Route of 
Administration 
Topical oral use 
Usage Instructions 
Subjects will brush twice daily (morning and evening) for 2 timed minutes 
with their allocated product. 
Return Requirements 
Used and unused study product to be returned to the sponsor. 
KNO3: Potassium Nitrate, STP: Sodium Tripolyphosphate, N/A: Not Applicable, NaF: Sodium Fluoride 
All dentifrices will be applied in the same manner and will be brushed on to the teeth, twice 
daily (morning and evening) for 2 timed minutes. 
1.4 
Sample Size Calculation 
The study will be powered sufficiently (>90%) to provide evidence of superiority for an 
Experimental Dentifrice compared to the Reference Dentifrice for both stain removal and 
whitening after 8 weeks under the graphical approach method (with initial two-sided alpha 
allocation of 5% for testing within each Experimental Dentifrice) to adjust for multiple 
comparisons and preserve a two-sided 10% family wise error rate as described in Figure 4-1. 
CCI
CCI
CCI
CCI


Potassium Nitrate Dentifrices 
300024 
 
 
 
 
GlaxoSmithKline Consumer Healthcare Confidential 
 Statistical Analysis Plan Template v6.0 
Page 12 of 37 
Table 1-4 
Sample Size Power by Endpoint at 5% and 2.5% Significance Levels 
with 90 Subjects per Arm 
Endpoint at Week 8 
Assumptions 
Independent power from 
90 subjects per arm for 
each endpoint by two-
sided significance level3 
Power from 
graphical 
approach to 
achieve 
statistical 
significance at 
5% level4 
Mean 
Difference 
Standard 
Deviation 
(SD) 
5% 
2.5% 
Within Experimental 
Dentifrice change from 
baseline in mean Total 
MLSI (Area × Intensity)1 
0.6  
0.4 
>99.9%  
>99.9%  
>99.9% 
Comparison with 
Reference Dentifrice in 
change from baseline in 
mean Total MLSI (Area 
× Intensity)1 
0.3  
0.4 
99.8%  
99.7% 
99.8% 
Within change from 
baseline in the mean 
VITA shade score2 
2 
2 
>99.9%  
>99.9%  
>99.9% 
Comparison with 
Reference Dentifrice in 
change from baseline in 
the mean VITA shade 
score2 
1  
2 
91.5%  
86.1%  
90.2% 
1) Estimates of mean difference and SD were based on results from a previous GSKCH study of 
similar design 
 
2) Estimates of mean difference and SD were based on results from previous GSKCH studies of 
similar design 
 Within treatment study reductions in the mean VITA shade score are 
expected to be greater in this study due to greater baseline VITA shade scores and an 8 week primary 
assessment instead of 4 weeks. As such, the SD is also assumed to increase, so an effect size (mean 
difference/SD) of 0.5 is assumed. 
3) Based on carrying out a two tailed one-sample (within Experimental Dentifrice) or two-sample 
(Comparison with Reference Dentifrice) t-test at the 5% significance level using PASS software 
version 19.0.1. 
4) Simulation using SAS9.4 software based on stated assumptions for all endpoints and graphical 
approach analysis as described in Figure 4-1 
As detailed in the independent sample size calculations in Table 1-4, the minimum required 
sample size assessment depends almost entirely on the mean VITA shade score reduction 
comparison between Experimental and Reference Dentifrices. Simulation shows that under the 
graphical approach methodology and the above underlying assumptions for an Experimental 
Dentifrice, the power to show statistical significance in all 4 comparisons for that Experimental 
Dentifrice (reduction from baseline and superior reduction compared to Reference Dentifrice 
in both mean Total MLSI [A×I] and mean VITA shade score) is > 90%. 
CCI
CCI
CCI


Potassium Nitrate Dentifrices 
300024 
 
 
 
 
GlaxoSmithKline Consumer Healthcare Confidential 
 Statistical Analysis Plan Template v6.0 
Page 13 of 37 
Approximately 100 subjects per group (approximately 300 in total) will be randomized to 
account for a drop-out rate of up to 10% prior to Week 8. 
2 
Planned Analyses 
2.1 
Interim Analysis 
No interim analysis is planned. 
2.2 
Final Analyses 
The final planned primary analyses will be performed after the completion of the following 
sequential steps: 
1. All subjects have completed the study as defined in the protocol 
2. All required database cleaning activities including any external data reconciliation have 
been completed and database has been locked. 
3. All criteria for unblinding the randomization codes have been met and the randomization 
codes have been distributed. 
3 
Considerations for data analyses and Data Handling 
Conventions 
3.1 
Baseline Definition 
For all endpoints, the baseline value will be the Day 0 (Visit 2) pre-brushing assessment with a 
non-missing value. 
3.2 
Subgroups/Stratifications 
Subjects who satisfy the study selection criteria will be stratified according to their baseline 
Total MLSI (A × I) (low < 45; high ≥ 45) and smoking status (smoker; non-smoker) and 
randomized to study treatment. 
For stratification purposes, the Total MLSI (A × I) will be derived as the sum of the MLSI (A 
× I) scores for each of evaluated regions (gingival and body) of the facial surfaces of each 
anterior tooth (4 values per assessed tooth surface). 
The two stratification factors will give rise to four strata. 
• Stratum 1: Baseline Total MLSI (A × I) < 45, Smoker 
• Stratum 2: Baseline Total MLSI (A × I) < 45, Non-smoker 
• Stratum 3: Baseline Total MLSI (A × I) ≥ 45, Smoker 
• Stratum 4: Baseline Total MLSI (A × I) ≥ 45, Non-smoker 
CCI


Potassium Nitrate Dentifrices 
300024 
 
 
 
 
GlaxoSmithKline Consumer Healthcare Confidential 
 Statistical Analysis Plan Template v6.0 
Page 14 of 37 
In the event of mis-stratification, the correct strata according to CRF information will be used 
in the analysis i.e. derived stratification variable from ADSL will be used for analysis. 
3.3 
Centers Pools 
Since this is single center study, pooling of centres is not applicable. 
3.4 
Timepoints and Visit Windows 
The timepoints and visits for this study are defined in the Table 1-1 “Schedule of Activities”. 
Any deviation from the study schedule may be reviewed on case-by-case basis at the Blinded 
Data Review Meeting (BDRM) to determine whether the data should be excluded from the Per-
Protocol (PP) analyses. 
4 
Data Analysis 
Data analysis will be performed by 
 with oversight from GSK CH. The statistical 
analysis software used will be SAS version 9.4 or higher. For the implementation of graphical 
approach as described in Section 4.4, SAS IML or gMCP package in R will be used. 
Prior to database closure a BDRM will be conducted in which various aspects of the trial will 
be discussed and agreed. 
One aspect that will be considered prior to or during BDRM is the assessment of the number of 
subjects who have dropped or discontinued from the study due to pandemic related events (e.g., 
Coronavirus Disease of 2019 [COVID-19]) and the potential need of a sensitivity analysis. Any 
major changes to planned analyses will need an amendment to SAP. 
Except as described below, all listings will be produced for all randomized subjects. 
4.1 
Populations for Analysis 
4.1.1 Subject Disposition 
Screen failures are defined as subjects who consent to participate in the clinical study but are 
not subsequently randomized. An enrolled subject is a subject who has signed informed consent 
and is eligible to proceed beyond the screening visit. 
The number of subjects screened, enrolled, and randomized subjects will be presented in 
Table 14.1.1. 
The number and percentage of screen failure subjects (subjects not randomized) with reasons 
why subjects are not randomized including percentage of subjects not randomized due to 
COVID-19 pandemic will be displayed. Percentages for screen failure subjects will be based 
on the total number of subjects screened. 
CCI
CCI


Potassium Nitrate Dentifrices 
300024 
 
 
 
 
GlaxoSmithKline Consumer Healthcare Confidential 
 Statistical Analysis Plan Template v6.0 
Page 15 of 37 
The number and percentage of randomized subjects who complete and discontinue the study, 
broken 
down 
by 
reason 
for 
discontinuation 
including 
percentage 
of 
subjects 
discontinued/withdrew from study due to COVID-19 pandemic, by study product and overall 
will also be displayed. The percentages will be based on the number of subjects randomized. 
Table 14.1.1 will also present the number and percentage of subjects in each of the defined 
analysis populations (as defined in Section 4.1.3) by study product and overall. Percentages will 
be based on the number of subjects randomized. 
Subject disposition including demographic data (age, sex, race and ethnicity), screening date, 
study product start date and time, subject status (completer, Yes/No), study completion 
/withdrawal date, duration (in days) in the study (defined as [(date of completion or withdrawal 
– start date of study product) + 1], and the primary reason for withdrawal will be listed (Listing 
16.2.1.1) by study product. 
Subject disposition information will be listed for non-randomized subjects (Listing 16.2.1.2), 
displaying subject number, demographic information (age, sex, race and ethnicity), screening 
date, reason for screen failure and any further details of reason for screen failure and 
discontinuation status due to COVID-19 pandemic. 
4.1.2 Protocol Deviations 
Protocol deviations will be tracked by the study team throughout the conduct of the study. Data 
will be reviewed prior to unblinding and closure of the database to ensure all important 
deviations are captured and categorised. Subjects with important protocol deviations liable to 
influence the efficacy outcomes will have affected data excluded from the PP analyses. Subjects 
may also be identified as having important protocol deviations not leading to exclusion of data 
from the PP analyses. 
Important deviations of the protocol procedures may include, but will not necessarily be limited 
to the following: 
• Consent procedures 
• Inclusion/Exclusion criteria 
• Study procedures 
• Non-compliance with product administration 
• Inadmissible concomitant medication 
The specific details of the important protocol deviations will be listed in Protocol Deviation 
Management Plan and assessment process will be specified in the Blind Data Review Plan and 
subjects with important protocol deviations will be identified at the BDRM. 
The number and percentage of subjects with at least one important protocol deviation, at least 
one important protocol deviation not leading to exclusion of data from PP analyses (overall and 
by each deviation reason) and at least one important protocol deviation leading to exclusion of 
CCI


Potassium Nitrate Dentifrices 
300024 
 
 
 
 
GlaxoSmithKline Consumer Healthcare Confidential 
 Statistical Analysis Plan Template v6.0 
Page 16 of 37 
data from the PP analyses (overall and by each deviation reason) will be presented by study 
product (Table 14.1.2) and listed in Listing 16.2.2.1. 
All protocol deviations collected on the protocol deviation case report form page will be listed 
in Listing 16.2.2.2. The listing will present date of deviation, type of deviation, and deviation 
description. 
4.1.3 Analysis Populations 
Four analysis populations are defined. 
Population 
Definition / Criteria 
Analyses Evaluated 
Safety 
Comprise of all randomized subjects who 
complete at least one use of study product. Any 
subject who receives a randomization number will 
be considered to have been randomized. 
This population will be based on the treatment the 
subject actually received. 
Safety 
Modified Intent-
To-Treat (mITT) 
Comprise all randomized subjects who complete 
at least one use of study product and have at 
least one post-baseline efficacy assessment. 
Any subject who receives a randomization 
number will be considered to have been 
randomized. 
This population will be based on the study product 
to which the subject was randomized. 
Demographic 
Baseline Characteristics 
Efficacy Analysis 
 
Per-Protocol 
Comprise all subjects in the mITT population who 
have at least one assessment of efficacy 
considered unaffected by protocol violations. 
Protocol deviations that would exclude subjects 
from the PP population are defined in Section 
4.1.2 (Protocol Deviations). 
This population will be based on the study product 
to which the subject was randomized. 
Efficacy Analysis 
Repeatability 
Assessment 
Comprise of all subjects who have a repeat 
clinical assessment of efficacy at any visit. There 
will be a separate population for repeat MLSI 
assessment and repeat tooth shade assessment: 
MLSI Repeatability population: Subjects with at 
least one initial and repeat assessment of MLSI at 
any visit. 
VITA Shade Repeatability population: Subjects 
with at least one initial and repeat assessment of 
Tooth shade at any visit. 
Repeatability analyses 
NOTES : 
Please refer to Appendix 1: List of Data Displays which details the population to be used for each 
displays being generated. 
CCI


Potassium Nitrate Dentifrices 
300024 
 
 
 
 
GlaxoSmithKline Consumer Healthcare Confidential 
 Statistical Analysis Plan Template v6.0 
Page 17 of 37 
The numbers of subjects included in each of the analysis populations will be summarized (Table 
14.1.1). Subjects excluded from any of the analysis populations will be listed in Listing 16.2.3.1. 
The primary population for assessment of efficacy will be the mITT Population. A PP analysis 
will be performed on the change from baseline for Mean Total MLSI (A×I) and Mean VITA 
shade score endpoints only if more than 10% mITT subjects are excluded from the PP 
Population. A decision on whether a PP analysis will be performed will be made prior to study 
(unblinding release of the randomization codes). 
4.2 
Subject Demographics and Other Baseline Characteristics 
4.2.1 Demographic and Baseline Characteristics 
Descriptive statistics (number of subjects [n], mean, standard deviation [SD], median, minimum 
and maximum for continuous variables and frequency count [n] and percentage [%] of subjects 
for categorical variables) will be presented for demographic variables by study product. These 
variables include age, sex, race, ethnicity, stratification group and will be presented for the 
Safety population (Table 14.1.3.1) and the mITT population (Table 14.1.3.2). 
Demographic information will be listed (Listing 16.2.4.1) for all randomized subjects. 
4.2.2 General Medical History 
Medical and surgical history (in the last year) including allergies or drug sensitivity will be 
listed in Listing 16.2.4.2, with start date and end date or ongoing at the start of study product. 
4.3 
Treatments (Study Product, Rescue Medication, other Concomitant 
Therapies, Compliance) 
Randomization details will be listed, including the randomization number, stratification group, 
the planned study product, the actual study product the subject was randomized to and the 
randomization date (Listing 16.1.7.1) for all randomized subjects. 
4.3.1 Study Product Compliance and Exposure 
Compliance data will also be summarized for the mITT population and will be assessed by 
number of brushings.  
Number of brushings, brushing compliance (%), number of missed brushings, number of 
additional brushings will be summarized using descriptive statistics as separate categories by 
study product in Table 14.2.1 by cumulative visit. 
Number of brushings is defined as: [(date of Visit N – date of Visit 2) multiplied by 2 – number 
of missing brushings + number of additional brushings]. 
CCI


Potassium Nitrate Dentifrices 
300024 
 
 
 
 
GlaxoSmithKline Consumer Healthcare Confidential 
 Statistical Analysis Plan Template v6.0 
Page 18 of 37 
Brushing compliance (%) is defined as: [100 x (Number of brushings / Expected number of 
brushings)], where expected number of brushings is defined as: [(date of Visit N – date of Visit 
2) multiplied by 2]. 
Study product compliance (number of brushings / brushing compliance [%] / number of missed 
brushings / numbers of additional brushings) will be listed in Listing 16.2.5.1 for all randomized 
subjects by study product. 
Supervised study product application (subject number, date of visit and time of the supervised 
procedure) will be listed (Listing 16.2.5.2) for all randomized subjects. 
4.3.2 Prior and Concomitant Medication 
Prior medications/treatments, including prescription and non-prescription drugs, dietary 
supplements and herbal remedies, taken in the last 28 days and prior to signing the informed 
consent form, will be documented in the CRF. The prior and concomitant medications will be 
coded using a validated medication dictionary, World Health Organization Drug Dictionary 
(WHODD). 
Prior medications and prior non-drug treatments will be listed by subject, with drug name, 
WHODD Drug Synonym, reason, route, dose, frequency, start date and end date both relative 
to study product start date (Listing 16.2.4.3) for all screened subjects. Prior medications are 
defined as those which stopped before the first use of the study product. 
Concomitant medications and concomitant non-drug treatments/significant non-drug therapies 
taken during treatment will be listed similarly (Listing 16.2.4.4) for all randomized subjects 
with either ongoing or end date displayed. Concomitant medications are defined as medications 
that started or stopped on or after the first use of the study product or are ongoing. 
Unknown dates will not be imputed, however if the start or stop date is unknown, then it will 
be assumed to be concomitant medication unless the partial start date or stop date indicates 
differently. 
4.4 
Analysis of Efficacy 
The primary population for assessment of efficacy will be the mITT Population. 
The hypothesis testing of the change from baseline in the mean Total MLSI (A×I) and mean 
VITA shade score at week 8 for each Experimental Dentifrice will employ the graphical 
approach shown in Figure 4-1 (as per Bretz et al., 2009) in order to maintain an overall two-
sided familywise error rate at 5% within each Experimental Dentifrice (10% overall).  
Therefore, the final p-values presented for all these endpoints (primary efficacy endpoint and 
secondary efficacy endpoints 1-3) may be adjusted depending on results of the other endpoints 
and the completion of the graphical approach testing. 
CCI


Potassium Nitrate Dentifrices 
300024 
 
 
 
 
GlaxoSmithKline Consumer Healthcare Confidential 
 Statistical Analysis Plan Template v6.0 
Page 19 of 37 
Figure 4-1 
Graphical Approach Showing Allocation and Propagation of Alpha 
Between Hypotheses Within Each Experimental Dentifrice 
 
For all other secondary and exploratory endpoints, there will be no adjustments for multiplicity 
and unadjusted p-values will be presented. 
4.4.1 Primary Efficacy Endpoint 
4.4.1.1 
Primary Efficacy Endpoint Definition 
The primary endpoints for this study are the change from baseline in the mean Total MLSI 
(A×I) at Week 8 within each study product.  
Extrinsic dental stain will be assessed on the facial surfaces of the 6 maxillary and 6 mandibular 
anterior teeth (6-11 and 22-27), and the lingual surfaces of the 6 mandibular anterior teeth (22- 
27) at baseline, Week 4, and Week 8 (Visits 2-4) using MLSI. 
The facial and lingual surfaces of each assessable tooth will be divided into 2 regions, with a 
total of 4 sites per tooth surface (Figure 4-2). 
• Gingival Region: Defined as a crescent-shaped band (~ 2 mm wide) adjacent to the free 
margin of the gingiva and extending to the crest of the inter-dental papillae of the adjacent 
teeth (1 site). 
CCI


Potassium Nitrate Dentifrices 
300024 
 
 
 
 
GlaxoSmithKline Consumer Healthcare Confidential 
 Statistical Analysis Plan Template v6.0 
Page 20 of 37 
• Body Region: The remainder of the tooth surface (the body) is further sub-divided into 3 
sites.  
• Distal facial, body facial, mesial facial sites 
• Distal lingual, body lingual, mesial lingual sites 
Figure 4-2 
MLSI Assessment Sites: Body (B), Gingival (G), Mesial (M), Distal (D) 
 
Area (A) and intensity (I) of extrinsic dental stain is scored separately for the four ‘gingival’ 
and ‘body’ sites, as follows. 
 
Score 
Area 
Intensity 
0 
No stain 
No stain 
1 
Stain covering up to one third of region 
Light stain 
2 
Stain covering up to two thirds of region 
Moderate stain 
3 
Stain covering more than two thirds of region 
Heavy stain 
The mean Total MLSI (A×I) score for each subject at each visit is calculated as the mean of all 
MLSI (A×I) scores over all non-missing gingival, body, mesial and distal sites on the facial 
surfaces of the six maxillary anterior teeth and six mandibular anterior teeth, and the lingual 
surfaces of the six mandibular anterior teeth. 
Descriptive statistics (n, mean, SD, SE, median, minimum, and maximum) will be presented 
for the mean Total MLSI at each time point (absolute and change from baseline) in 
Table 14.2.2.1.1 for all subjects in mITT population by study product. Raw means (± SE) of the 
mean Total MLSI scores at each time point will be plotted by study product in Figure 14.2.1.1 
for all subjects in mITT population. 
Individual and derived MLSI (A×I) score data will be listed for each subject by visit and study 
product group in Listing 16.2.6.1.1 and Listing 16.2.6.1.2 respectively for all randomized 
subjects. 
4.4.1.2 
Statistical Hypothesis, Model, and Method of Analysis 
The following null and alternative hypotheses will be evaluated: 
• H0: There is no difference between baseline and week 8 
• H1: There is a difference between baseline and week 8 
The following study product comparisons will be analyzed: 
• For Experimental Dentifrice 1, baseline versus week 8 
CCI


Potassium Nitrate Dentifrices 
300024 
 
 
 
 
GlaxoSmithKline Consumer Healthcare Confidential 
 Statistical Analysis Plan Template v6.0 
Page 21 of 37 
• For Experimental Dentifrice 2, baseline versus week 8 
The change from baseline in the mean Total MLSI (A×I) score will be analysed using a Mixed 
Model with Repeated Measures (MMRM). Fixed effects will be included for smoking status, 
study product, visit and study product x visit interaction. The baseline mean Total MLSI (A×I) 
score will be included as a covariate. Subject will be included as a repeated measure with 
unstructured covariance matrix. Kenward Rogers degrees of freedom approach will be applied. 
The least square means for each study product at week 8 will be presented based on observed 
margins and used to test for a non-zero change from baseline. If unstructured covariance matrix 
does not converge, compound symmetry covariance matrix will be used. 
Using the above model, the adjusted mean change from baseline in the mean Total MLSI (A × 
I) score will be reported by study product group along with 95% confidence intervals (CIs) and 
adjusted p-values testing for a non-zero change from baseline will be provided in Table 
14.2.2.2.1. For each Experimental Dentifrice, only adjusted p-values following the graphical 
approach (see Figure 4-1) will be presented. Significance testing will be conducted at the two-
sided 5% significance level.  
The assumption of normality and homogeneity of variance in the MMRM will be investigated. 
In case of violation of these assumptions, a suitable nonparametric test (the Van Elteren test, 
adjusted for the randomization stratification) will be performed for each comparison at week 8 
and results will be provided to support the MMRM results. 
4.4.1.3 
Supportive Analyses 
A PP analysis will be performed on the change from baseline in the mean Total MLSI (A×I) 
score if there is more than 10% difference in the number of subjects between the PP and mITT 
populations. A decision on whether a PP analysis will be performed will be made prior to study 
unblinding (release of the randomization codes). 
A summary of the mean Total MLSI (A×I) will be presented for the PP Population in Table 
14.2.2.1.2. Statistical analysis of the mean Total MLSI score will be presented for the PP 
population in Table 14.2.2.2.2. In addition, the mean profiles of the mean Total MLSI (A×I) 
(Figure 14.2.1.2) at each time point will be plotted by study product for all subjects in the PP 
Population. 
4.4.2 Secondary Efficacy Endpoints 
4.4.2.1 
Secondary Efficacy Endpoint 1 
The Secondary Efficacy Endpoint 1 will be the change from baseline in the mean VITA shade 
score at week 8 within each study product.  
Tooth shade (color) of the facial surfaces of the four central and lateral maxillary incisors (tooth 
numbers 7-10) will be assessed by a single, trained clinical examiner using the VITA 
Bleachedguide 3D-MASTER. The VITA Bleachedguide 3D-MASTER uses a value-ranked 
CCI


Potassium Nitrate Dentifrices 
300024 
 
 
 
 
GlaxoSmithKline Consumer Healthcare Confidential 
 Statistical Analysis Plan Template v6.0 
Page 22 of 37 
ordered scale from 1 (the lightest) to 29 (the darkest). The shade level of each tooth surface is 
scored visually by the clinical examiner with reference to the Bleachedguide. 
The mean VITA shade score for each subject at each visit is calculated as the mean VITA shade 
score over all non-missing facial surfaces of the four central and lateral maxillary incisors. 
Descriptive statistics (n, mean, SD, Standard Error [SE], median, minimum, and maximum) 
will be presented for the mean VITA shade score at each assessment time point (absolute and 
change from baseline) in Table 14.2.3.1.1 for all subjects in mITT Population by study product. 
Raw means (± SE) of mean VITA shade scores at each time point will be plotted by study 
product in Figure 14.2.2.1 respectively for all subjects in mITT population. 
4.4.2.1.1 Statistical Hypothesis, Model and Method of Analysis 
The following null and alternative hypotheses will be evaluated: 
• H0: There is no difference between baseline and week 8 
• H1: There is a difference between baseline and week 8 
The following study product comparisons will be analyzed: 
• For Experimental Dentifrice 1, baseline versus week 8 
• For Experimental Dentifrice 2, baseline versus week 8 
The change from baseline in the mean VITA shade score will be analysed using a MMRM. 
Fixed effects will be included for smoking status, baseline Total MLSI (AxI) stratification (< 
45 or ≥ 45), study product, visit and study product x visit interaction. The baseline mean VITA 
shade score will be included as a covariate. Subject will be included as a repeated measure with 
unstructured covariance matrix. Kenward Rogers degrees of freedom approach will be applied. 
The least square means for each study product at week 8 will be presented based on observed 
margins and used to test for a non-zero change from baseline. If unstructured covariance matrix 
does not converge, compound symmetry covariance matrix will be used. 
Using the above model, the adjusted mean change from baseline in the mean VITA shade score 
will be reported by study product group along with 95% CIs and p-values testing for a non-zero 
change from baseline will be provided in Table 14.2.3.2.1. For each Experimental Dentifrice, 
only adjusted p-values following the graphical approach (see Figure 4-1)  will be presented. 
Significance testing will be conducted at the two-sided 5% significance level.  
The assumption of normality and homogeneity of variance in the MMRM will be investigated. 
In case of violation of these assumptions, a suitable nonparametric test (the Van Elteren test, 
adjusted for the randomization stratification) will be performed for each comparison at week 8 
and results will be provided to support the MMRM results. 
4.4.2.1.2 Supportive Analyses 
A PP analysis will be performed on the change from baseline in the mean VITA shade score if 
there is more than 10% difference in the number of subjects between the PP and mITT 
CCI


Potassium Nitrate Dentifrices 
300024 
 
 
 
 
GlaxoSmithKline Consumer Healthcare Confidential 
 Statistical Analysis Plan Template v6.0 
Page 23 of 37 
populations. A decision on whether a PP analysis will be performed will be made prior to study 
unblinding (release of the randomization codes). 
A summary of the mean VITA shade will be presented for the PP Population in Table 14.2.3.1.2. 
Statistical analysis of the mean VITA shade score will be presented for the PP population in 
Table 14.2.3.2.2. In addition, the mean profiles of the mean VITA shade score (Figure 14.2.2.2) 
at each time point will be plotted by study product for all subjects in the PP Population. 
 
4.4.2.2 
Secondary Efficacy Endpoint 2 
The Secondary Efficacy Endpoint 2 will be the change from baseline in mean Total MLSI (A×I) 
score at week 8 and the comparison of each Experimental Dentifrice to the Reference 
Dentifrice.  
4.4.2.2.1 Statistical Hypothesis, Model and Method of Analysis 
The following null and alternative hypotheses will be evaluated: 
• H0: There is no treatment difference 
• H1: There is a treatment difference 
The following study product comparisons will be analyzed: 
• Experimental Dentifrice 1 versus Reference Dentifrice at week 8 
• Experimental Dentifrice 2 versus Reference Dentifrice at week 8 
The results for this endpoint will be obtained from the MMRM detailed in Section 4.4.1.1. Mean 
differences between each Experimental Dentifrice compared to the Reference Dentifrice in the 
change from baseline in mean Total MLSI (A×I) score at week 8 will be presented along with 
95% CIs and adjusted p-values (following the graphical approach in Figure 4-1) in Table 
14.2.2.2.1. Significance testing will be conducted at the two-sided 5% significance level. 
The assumption of normality and homogeneity of variance in the MMRM will be investigated. 
In case of violation of these assumptions, a suitable nonparametric test (the Van Elteren test, 
adjusted for the randomization stratification) will be performed for each comparison at week 8 
and results will be provided to support the MMRM results. 
4.4.2.3 
Secondary Efficacy Endpoint 3 
The Secondary Efficacy Endpoint 3 will be the change from baseline in mean VITA shade score 
at week 8 and the comparison of each Experimental Dentifrice to the Reference Dentifrice.  
4.4.2.3.1 Statistical Hypothesis, Model and Method of Analysis 
The following null and alternative hypotheses will be evaluated: 
• H0: There is no treatment difference 
CCI


Potassium Nitrate Dentifrices 
300024 
 
 
 
 
GlaxoSmithKline Consumer Healthcare Confidential 
 Statistical Analysis Plan Template v6.0 
Page 24 of 37 
• H1: There is a treatment difference 
The following study product comparisons will be analyzed: 
• Experimental Dentifrice 1 versus Reference Dentifrice at week 8 
• Experimental Dentifrice 2 versus Reference Dentifrice at week 8 
The results for this endpoint will be obtained from the MMRM detailed in Section 4.4.2.1.1. 
Mean differences between each Experimental Dentifrice compared to the Reference Dentifrice 
in the change from baseline in mean VITA shade score at week 8 will be presented along with 
95% CIs and adjusted p-values (following the graphical approach in Figure 4-1) in Table 
14.2.3.2.1. Significance testing will be conducted at the two-sided 5% significance level. 
The assumption of normality and homogeneity of variance in the MMRM will be investigated. 
In case of violation of these assumptions, a suitable nonparametric test (the Van Elteren test, 
adjusted for the randomization stratification) will be performed for each comparison at week 8 
and results will be provided to support the MMRM results. 
4.4.2.4 
Secondary Efficacy Endpoint 4 
The Secondary Efficacy Endpoint 4 will be the change from baseline in mean Total MLSI (A×I) 
score at week 4 for each study product and the comparison of each Experimental Dentifrice to 
the Reference Dentifrice.  
4.4.2.4.1 Statistical Hypothesis, Model and Method of Analysis 
The results for this endpoint will be obtained from the MMRM detailed in Section 4.4.1.1. The 
same results as presented for the week 8 analysis (see Sections 4.4.1.1 and Section 4.4.2.2) will 
also be presented for week 4, however only unadjusted p-values will be presented. 
4.4.2.5 
Secondary Efficacy Endpoint 5 
The Secondary Efficacy Endpoint 5 will be the change from baseline in mean VITA shade score 
at week 4 for each study product and the comparison of each Experimental Dentifrice to the 
Reference Dentifrice.  
4.4.2.5.1 Statistical Hypothesis, Model and Method of Analysis 
The results for this endpoint will be obtained from the MMRM detailed in Section 4.4.2.1.1. 
The same results as presented for the week 8 analysis (see Section 4.4.2.1 and Section 4.4.2.3) 
will also be presented for week 4, however only unadjusted p-values will be presented. 
4.4.2.6 
Secondary Efficacy Endpoint 6 
The Secondary Efficacy Endpoint 6 will be the change from baseline in the mean site MLSI 
(A×I) score at weeks 4 and 8 (Gingival sites, Interproximal sites, and Body sites). 
CCI


Potassium Nitrate Dentifrices 
300024 
 
 
 
 
GlaxoSmithKline Consumer Healthcare Confidential 
 Statistical Analysis Plan Template v6.0 
Page 25 of 37 
The mean Interproximal MLSI (A×I) score for each subject at each visit is calculated as the 
mean MLSI (A×I) score over all interproximal (Mesial + Distal) sites on the facial surfaces of 
the six maxillary anterior teeth and six mandibular anterior teeth, and the lingual surfaces of the 
six mandibular anterior teeth. 
The mean Gingival MLSI (A×I) and mean Body MLSI (A×I) score for each subject at each 
visit is calculated as the respective mean MLSI (A×I) score over Gingival or Body sites on the 
facial surfaces of the six maxillary anterior teeth and six mandibular anterior teeth, and the 
lingual surfaces of the six mandibular anterior teeth. 
Descriptive statistics (n, mean, SD, Standard Error [SE], median, minimum, and maximum) 
will be presented for each site MLSI (A×I) score at each assessment time point (absolute and 
change from baseline) in Table 14.2.4.1 for all subjects in mITT Population by study product. 
4.4.2.6.1 Statistical Hypothesis, Model and Method of Analysis 
The same MMRM model detailed in Section 4.4.1.1 for the mean Total MLSI (A×I) will be 
fitted separately for each mean site MLSI (A×I) score (Gingival sites, Interproximal sites, Body 
sites) but instead using the respective baseline mean site MLSI (A×I) score as a covariate. The 
same results as presented for the mean Total MLSI (A×I) score (see Section 4.4.1.1, Section 
4.4.2.2 and Section 4.4.2.4) will be presented for each mean site MLSI (A×I) score in Table 
14.2.4.2. 
The assumption of normality and homogeneity of variance in the MMRM will be investigated. 
In case of violation of these assumptions, a suitable nonparametric test (the Van Elteren test, 
adjusted for the randomization stratification) will be performed for each comparison at weeks 
4 and 8 and results will be provided to support the MMRM results. 
4.4.2.7 
Secondary Efficacy Endpoint 7 
The Secondary Efficacy Endpoint 7 will be the change from baseline in the mean Total MLSI 
(A) and the mean Total MLSI (I) at 4 and 8 weeks. 
The mean Total MLSI (A) and mean Total MLSI (I) score for each subject at each visit is 
calculated as the respective mean MLSI (A) or mean MLSI (I) score over all gingival, body, 
mesial and distal sites on the facial surfaces of the six maxillary anterior teeth and six 
mandibular anterior teeth, and the lingual surfaces of the six mandibular anterior teeth. 
Descriptive statistics (n, mean, SD, Standard Error [SE], median, minimum, and maximum) 
will be presented for the mean Total MLSI (A) and the mean Total MLSI (I) scores at each 
assessment time point (absolute and change from baseline) in Table 14.2.5.1 for all subjects in 
mITT Population by study product. 
4.4.2.7.1 Statistical Hypothesis, Model and Method of Analysis 
The same MMRM model detailed in Section 4.4.1.1 for the mean Total MLSI (A×I) will be 
fitted separately for mean Total MLSI (A) score and mean Total MLSI (I) score but instead 
CCI


Potassium Nitrate Dentifrices 
300024 
 
 
 
 
GlaxoSmithKline Consumer Healthcare Confidential 
 Statistical Analysis Plan Template v6.0 
Page 26 of 37 
using the baseline mean Total MLSI (A) and baseline mean Total MLSI (I) score as respective 
covariates. The same results as presented for the mean Total MLSI (A×I) score (see Section 
4.4.1.1, Section 4.4.2.2 and Section 4.4.2.4) will be presented in Table 14.2.5.2.  
The assumption of normality and homogeneity of variance in the MMRM will be investigated. 
In case of violation of these assumptions, a suitable nonparametric test (the Van Elteren test, 
adjusted for the randomization stratification) will be performed for each comparison at weeks 
4 and 8 and results will be provided to support the MMRM results. 
4.4.3 Exploratory Efficacy Variables 
There will be no adjustment for multiplicity in the analyses for exploratory efficacy variables. 
4.4.3.1 
Exploratory Efficacy Variable 1 
Exploratory variables are Change from baseline in Mean VITA EasyShade color co-ordinates 
(L*, a*, b*, WID) and ΔE* determined using the VITA EasyShade instrument at weeks 4 and 
8. 
VITA EasyShade color coordinates (L*, a*, b*) will be measured instrumentally for the facial 
surfaces of the four central and lateral maxillary incisors (tooth numbers 7-10) using the VITA 
EasyShade instrument. 
The collected data will be used to calculate the ΔE* and WID values as: 
Δ𝐸* = Square root (Δ𝐿∗2 + Δ𝑎∗2 + Δ𝑏∗2), where Δ𝐿*, Δa*, Δb* are respective change 
from baseline values. Since Δ𝐸* is calculated as change from baseline. There will be no 
change from baseline separately for analysis. 
𝑊𝐼𝐷 = 0.511𝐿∗ − 2.324𝑎∗ − 1.100𝑏∗ 
The mean VITA EasyShade color co-ordinate for L*/a*/b*/WID score for each subject at each 
visit is calculated as the respective mean L*/a*/b*/WID score over all facial surfaces of the four 
central and lateral maxillary incisors (tooth numbers 7-10). Change from baseline values will 
be used for analysis. 
The mean VITA EasyShade color co-ordinate for ΔE* score for each subject at each visit is 
calculated as the mean ΔE* score over all facial surfaces of the four central and lateral maxillary 
incisors (tooth numbers 7-10). Derived ΔE* values will be used for analysis directly since ΔE* 
is calculated as change from baseline already and only derived at post-baseline visits. 
Descriptive statistics (n, mean, SD, SE, median, minimum, and maximum) will be presented 
for each mean VITA EasyShade color co-ordinates (L*, a*, b*, and WID) (absolute and change 
from baseline) and post-baseline ΔE* score at each assessment time point in Table 14.2.6.1 for 
all subjects in mITT Population by study product. Raw means (± SE) of Mean VITA EasyShade 
color co-ordinates (L*, a*, b*, WID and ΔE*) scores at each time point will be plotted by study 
product in Figure 14.2.3 respectively for all subjects in mITT population. 
CCI


Potassium Nitrate Dentifrices 
300024 
 
 
 
 
GlaxoSmithKline Consumer Healthcare Confidential 
 Statistical Analysis Plan Template v6.0 
Page 27 of 37 
Individual Mean VITA EasyShade color co-ordinates (L*, a*, b*, WID and derived ΔE*) score 
data will be listed for each subject by visit and study product group in Listing 16.2.6.3 for all 
randomized subjects. 
4.4.3.1.1 Statistical Hypothesis, Model and Method of Analysis 
Using the same MMRM model mentioned in Section 4.4.2.1.1 (replaced with the respective 
baseline covariate for all apart from ΔE* for which baseline L*, a*, and b* covariates will be 
used) for each color co-ordinates (change from baseline in each of L*/ a*/ b*/ WID and derived 
ΔE*), adjusted mean change from baseline, along with 95% CIs will be reported by study 
product group will be provided for each Mean VITA EasyShade color co-ordinates (L*, a*, b*, 
WID and ΔE*) in Table 14.2.6.2. Also, P-values testing for non-zero change from baseline will 
be presented for study product groups. Mean difference between study product groups, 95% 
CIs and p-values will be provided for each of Mean VITA EasyShade color co-ordinates (L*, 
a*, b*, WID and ΔE*) in Table 14.2.6.2. Significance testing will be conducted at the two-sided 
5% significance level. 
The assumption of normality and homogeneity of variance in the MMRM will be investigated. 
In case of violation of these assumptions, a suitable nonparametric test (the Van Elteren test, 
adjusted for the randomization stratification) will be performed for each comparison at weeks 
4 and 8 and results will be provided to support the MMRM results. 
4.4.4 
Handling of Missing Values/Censoring/Discontinuations 
Missing data will not be replaced or imputed. Subjects who withdraw from the study 
prematurely will be included in the statistical analyses up to the point of discontinuation. 
The use of MMRM analyses account for missing data assuming a missing at random 
assumption, i.e., there is a systematic relationship between the propensity of missing values and 
the observed data, but not the missing data. 
It is therefore assumed that a subject with missing data would have obtained a similar efficacy 
result compared to a subject using the same study product with the same smoking status and 
similar non-missing results at other timepoints (baseline and post-baseline). Sensitivity analyses 
may be added to the SAP prior to unblinding in case of high drop-out rates and/or exclusion 
from PP analyses. 
4.5 
Analysis of Safety 
The safety profile of the study treatments will be assessed with respect to AEs or incidents or 
others such as OST/OHT abnormalities in oral health study. 
CCI


Potassium Nitrate Dentifrices 
300024 
 
 
 
 
GlaxoSmithKline Consumer Healthcare Confidential 
 Statistical Analysis Plan Template v6.0 
Page 28 of 37 
4.5.1 
Adverse Events and Serious Adverse Events 
All AEs will be reviewed by the Clinical Research Scientist or Designee prior to database lock 
and will be coded to a system organ class (SOC) and preferred term (PT) using the Medical 
Dictionary for Regulatory Activities (MedDRA). 
AEs will be classified as oral and non-oral on the AE page of eCRF. 
Treatment emergent adverse events (TEAEs) are defined as new AEs that occur on or after the 
first study product use (if this date is missing a suitable alternative will be used e.g., date of 
randomization). AEs with an onset date/time prior to the first study product use will be 
considered as non-treatment emergent. 
The following summary tables and listings will be presented by study product group. 
• Table of TEAEs by SOC and PT (Table 14.3.1.1). 
• Table of TEAEs by Oral/Non-Oral and PT (Table 14.3.1.2) 
• Table of treatment related TEAEs by SOC and PT (Table 14.3.1.3) 
• Table of treatment related TEAEs by Oral/Non-Oral and PT (Table 14.3.1.4) 
• Table of AEs related to COVID-19 by SOC and PT (Table 14.3.1.5). 
• Listing of all AEs (Listing 16.2.7.1 for all randomized subjects; Listing 16.2.7.2 for non-
randomized subjects) 
• Listing of deaths (Listing 14.3.2.1) 
• Listing of non-fatal SAEs (Listing 14.3.2.2) 
• Listing of TEAEs leading to study or drug withdrawal (Listing 14.3.2.3) 
• Listing of TEAEs classified as Oral (Listing 14.3.2.4) 
• Listing of all AEs related to COVID-19 (Listing 16.2.7.3 for all screened subjects) 
In the event that there is nothing to report, a null table or listing will be produced. 
All Incidents will be listed in Listing 16.2.7.4. In the event that there is nothing to report, a null 
listing will be produced. 
4.5.2 
Other Safety Variables 
Other safety variables are listed below: 
• OST examination 
• OHT examination 
4.5.2.1 
OST Examination 
This procedure will be conducted by a qualified, experienced clinical examiner. The OST 
examination will be accomplished by direct observation and palpation with retraction aids, as 
appropriate. The examination will cover the oral labial mucosa (including lips), buccal mucosa, 
mucogingival folds, gingival mucosa, hard palate, soft palate, tonsillar area, pharyngeal area, 
CCI


Potassium Nitrate Dentifrices 
300024 
 
 
 
 
GlaxoSmithKline Consumer Healthcare Confidential 
 Statistical Analysis Plan Template v6.0 
Page 29 of 37 
tongue, sublingual area, submandibular area, and salivary glands. Findings from the 
examination will be recorded in the CRF as either normal or abnormal, with details of any 
abnormalities. The results of the OST examination performed at screening will be used to 
determine subject eligibility. Any new OST abnormality or worsening of a pre-existing 
condition observed by the clinical examiner or reported by the subject after the screening 
examination will be recorded as an AE. Where possible, this procedure should be conducted by 
a single clinical examiner. 
OST will be summarized (number of subjects and percentages with abnormalities, without 
abnormalities, or OST not examined) by visit and study product in Table 14.3.4.1 for all subjects 
in Safety Population. OST examination will be listed (Listing 16.2.8.1) for all randomized 
subjects. 
4.5.2.2 
OHT Examination 
This procedure should be conducted by a qualified, experienced clinical examiner. The OHT 
examination will be accomplished by direct observation, using retraction aids as appropriate 
and will identify any grossly carious lesions, signs of erosive wear, enamel irregularities, tooth 
fracture, gross generalized dental caries decay, decalcification, and faulty restorations. The 
presence of any implants, fixed or removable dentures, fixed or removable orthodontic 
braces/bands, fixed orthodontic retainers, full crowns or veneers will be recorded. Observations 
will be listed as either absent or present, and conditions noted as present will be described in 
the eCRF. Any change observed by the clinical examiner or reported by the subject after the 
screening examination will be recorded as an AE. The results of the OHT examination 
performed at Screening will be used to determine subject eligibility. Where possible, this 
procedure should be conducted by a single clinical examiner. 
OHT examination will be listed (Listing 16.2.8.2) for all randomized subjects. 
4.6 
Analysis of Other Variables 
Repeat individual MLSI and tooth shade assessments will be performed by the clinical examiner 
at Baseline-Day 0 (Visit 2), Week 4 (Visit 3), and Week 8 (Visit 4). To assess the repeatability 
of the MLSI and tooth shade assessments, replicate examinations will be performed by the same 
clinical examiner. 
Ten subjects will be randomly selected for repeat MLSI and tooth shade assessments at each 
assessment time point (Visits 2, 3, and 4), a total of 30 repeat assessments (for both MLSI and 
tooth shade assessments) over the duration of the study. Replicate assessments will be separated 
by a minimum of 10 minutes (maximum 60 minutes) from the original assessment for a given 
subject and, where possible, separated by at least one subject. 
The scores of the initial assessment will not be visible to the examiner or scribe when the repeat 
assessment is carried out. 
CCI


Potassium Nitrate Dentifrices 
300024 
 
 
 
 
GlaxoSmithKline Consumer Healthcare Confidential 
 Statistical Analysis Plan Template v6.0 
Page 30 of 37 
The repeat dental assessments (MLSI and tooth shade assessments) will be compared to the 
respective original assessments and will be used to investigate intra-examiner variability. The 
repeat assessments will not be used in any efficacy analyses. 
The first and repeat assessments for each tooth site will be cross tabulated for MLSI (by Area 
and Intensity) (Table 14.2.7.1) and for tooth shade assessments (Table 14.2.7.2).  
A weighted Kappa coefficient (κ), along with the 95% CIs will be calculated to assess the 
intra-examiner repeatability across all initial versus repeat assessments performed. Fleiss-
Cohen weighted kappa using the raw scores will be calculated for the repeatability analysis. 
Repeatability will be deemed: 
• Excellent if κ > 0.75 
• Fair to good if 0.4 ≤ κ ≤ 0.75 
• Poor if κ <0.4 
This analysis will be conducted for MLSI using the MLSI Repeatability population and for 
tooth shade assessments using the VITA Shade Repeatability population. Only results with non-
missing initial and repeat assessments of the same value (MLSI area, MLSI intensity or tooth 
shade) at the same tooth site/surface will be presented and analyzed. 
5 
Changes to the Protocol Defined Statistical Analysis Plan 
There were below changes to the originally planned statistical analysis specified from the 
protocol version 3.0 (Dated: 07-SEP-2022). 
Initially it was planned for primary analysis of Mean Total MLSI (A × I) to provide adjusted 
mean difference between study product groups, adjusted 95% CIs and adjusted p-values 
(following graphical testing approach) in Table 14.2.2.2.1. However, adjusted 95% CIs will no 
longer be provided in the table. In place of adjusted CIs, we will provide standard 95% CIs.  
Similarly in secondary endpoint 1 (Mean VITA shade score) related Table 14.2.3.2.1, we will 
provide standard CIs in place of adjusted CIs. 
For secondary and exploratory endpoints not related to MLSI, an additional fixed effect for the 
Total MLSI (AxI) strata (< 45 or ≥ 45) will be included in the MMRMs. 
 
 
CCI


Potassium Nitrate Dentifrices 
300024 
 
 
 
 
GlaxoSmithKline Consumer Healthcare Confidential 
 Statistical Analysis Plan Template v6.0 
Page 31 of 37 
Appendix 1: List of Data Displays 
 
CSR 
Section 
TLF 
Number 
Title 
Population 
Template 
Topline 
14.1 Demographic Data Summary Tables and Figures 
  
Table 
14.1.1 
Subject Disposition 
All Screened 
Subjects 
14.1.1 
Yes 
 
Table 
14.1.2 
Incidence of Important protocol deviations 
All randomized 
subjects 
14.1.2 
 
 
Table 
14.1.3.1 
Demographic and Baseline Characteristics 
mITT Population 
14.1.3.1 
Yes 
 
Table 
14.1.3.2 
Demographic and Baseline Characteristics 
Safety Population 
14.1.3.1 
 
14.2 Efficacy Data Summary Tables and Figures 
  
Table 
14.2.1 
Summary of Brushing Compliance 
mITT Population 
14.2.1 
  
 
Table 
14.2.2.1.1 
Summary of Mean Total MLSI (A×I) Score 
mITT Population 
14.2.2.1.1 
Yes 
 
Table 
14.2.2.1.2 
Summary of Mean Total MLSI (A×I) Score 
PP Population 
14.2.2.1.1 
 
 
Table 
14.2.2.2.1 
Statistical Analysis of Change from Baseline in Mean Total 
MLSI (A×I) Score  
mITT Population 
14.2.2.2.1 
Yes 
 
Table 
14.2.2.2.2 
Statistical Analysis of Change from Baseline in Mean Total 
MLSI (A×I) Score  
PP Population 
14.2.2.2.1 
 
 
Table 
14.2.3.1.1 
Summary of Mean VITA Shade Score 
mITT Population 
14.2.3.1.1 
Yes 
 
Table 
14.2.3.1.2 
Summary of Mean VITA Shade Score 
PP Population 
14.2.3.1.1 
 
 
Table 
14.2.3.2.1 
Statistical Analysis of Change from Baseline in Mean VITA 
shade score  
mITT Population 
14.2.3.2.1 
Yes 
CCI


Potassium Nitrate Dentifrices 
300024 
 
 
 
 
GlaxoSmithKline Consumer Healthcare Confidential 
 Statistical Analysis Plan Template v6.0 
Page 32 of 37 
CSR 
Section 
TLF 
Number 
Title 
Population 
Template 
Topline 
 
Table 
14.2.3.2.2 
Statistical Analysis of Change from Baseline in Mean VITA 
shade score  
PP Population 
14.2.3.2.1 
 
 
Table 
14.2.4.1 
Summary of Mean MLSI (A×I) Score by Sites 
(Interproximal/Gingival/Body) 
mITT Population 
14.2.4.1 
 
 
Table 
14.2.4.2 
Statistical Analysis of Change from Baseline in Mean MLSI 
(A×I) Score by Sites (Interproximal/Gingival/Body) 
mITT Population 
14.2.4.2 
 
 
Table 
14.2.5.1 
Summary of Mean MLSI Score by Area and Intensity 
mITT Population 
14.2.5.1 
 
 
Table 
14.2.5.2 
Statistical Analysis of Change from Baseline in Mean MLSI 
Score by Area and Intensity 
mITT Population 
14.2.5.2 
 
 
Table 
14.2.6.1 
Summary of Mean VITA EasyShade color co-ordinates (L*, a*, 
b*, WID and Delta E*) score 
mITT Population 
14.2.6.1 
Yes 
 
Table 
14.2.6.2 
Statistical Analysis of Change from Baseline in Mean VITA 
EasyShade color co-ordinates (L*, a*, b*, WID and Delta E*) 
score 
mITT Population 
14.2.6.2 
Yes 
 
Table 
14.2.7.1 
Intra-examiner Repeatability Analysis of MLSI Score 
MLSI Repeatability 
Population 
14.2.7.1 
 
 
Table 
14.2.7.2 
Intra-examiner Repeatability Analysis of VITA Shade Score 
Vita Shade 
Repeatability 
Population 
14.2.7.2 
 
 
Figure 
14.2.1.1 
Mean Total MLSI (A*I) Score Mean (±SE) Plot Over Time by 
Product Group 
mITT Population 
14.2.1.1 
 
 
Figure 
14.2.1.2 
Mean Total MLSI (A*I) Score Mean (±SE) Plot Over Time by 
Product Group 
PP Population 
14.2.1.1 
 
CCI


Potassium Nitrate Dentifrices 
300024 
 
 
 
 
GlaxoSmithKline Consumer Healthcare Confidential 
 Statistical Analysis Plan Template v6.0 
Page 33 of 37 
CSR 
Section 
TLF 
Number 
Title 
Population 
Template 
Topline 
 
Figure 
14.2.2.1 
Mean VITA Shade Score Mean (±SE) Plot Over Time by 
Product Group 
mITT Population 
14.2.2.1 
 
 
Figure 
14.2.2.2 
Mean VITA Shade Score Mean (±SE) Plot Over Time by 
Product Group 
PP Population 
14.2.2.1 
 
 
Figure 
14.2.3 
Mean VITA EasyShade color co-ordinates (L*, a*, b*, WID and 
Delta E*) Score Mean (±SE) Plot Over Time by Product Group 
mITT Population 
14.2.3.1 
 
14.3 Safety Data Summary Tables and Figures 
14.3.1 Displays of Adverse Events  
  
Table 
14.3.1.1 
Treatment Emergent Adverse Events by SOC/PT 
Safety Population 
14.3.1.1 
 Yes 
 
Table 
14.3.1.2 
Treatment Emergent Adverse Events by Oral/Non-oral/PT 
Safety Population 
14.3.1.2 
 
 
Table 
14.3.1.3 
Treatment Related Treatment Emergent Adverse Events by 
SOC/PT 
Safety Population 
14.3.1.1 
 
 
Table 
14.3.1.4 
Treatment Related Treatment Emergent Adverse Events by 
Oral/Non-oral/PT 
Safety Population 
14.3.1.2 
 
 
Table 
14.3.1.5 
Adverse Events Related to COVID-19 by System Organ Class 
and Preferred Term 
Safety Population 
14.3.1.5 
 
14.3.2 Listings of Deaths, Other Serious and Significant Adverse Events 
  
Listing 
14.3.2.1 
Death 
All randomized 
subjects 
16.2.7.1 
 
Listing 
14.3.2.2 
Non-fatal Serious Adverse Events 
All randomized 
subjects 
16.2.7.1 
 
 
Listing 
14.3.2.3 
Treatment Emergent Adverse Events Leading to Study or 
Product Discontinuation 
All randomized 
subjects 
16.2.7.1 
 
CCI


Potassium Nitrate Dentifrices 
300024 
 
 
 
 
GlaxoSmithKline Consumer Healthcare Confidential 
 Statistical Analysis Plan Template v6.0 
Page 34 of 37 
CSR 
Section 
TLF 
Number 
Title 
Population 
Template 
Topline 
 
Listing 
14.3.2.4 
Treatment Emergent Adverse Events Classified as Oral 
All randomized 
subjects 
16.2.7.1 
 
14.3.3 Narratives of Deaths, Other Serious and Certain Other Significant Adverse Events 
14.3.4 Other Observations Related to Safety and Abnormal Laboratory Values  
  
Table 
14.3.4.1 
OST examination 
Safety Population 
14.3.4.1 
APPENDIX 
16.1.6 Listing of Subjects Receiving Test Drug(s)/Investigational Product(s) from Specific Batches, where more than one batch was used 
  
NA 
  
  
  
  
  
16.1.7 Randomization Scheme and Codes (Subject identification and treatment assigned) 
  
Listing 
16.1.7.1 
Randomization Information 
All Randomized 
Subjects 
16.1.7.1 
  
16.1.9 Documentation of Statistical Methods 
  
Raw 
output 
16.1.9.1.1 
Statistical Analysis of Change from Baseline in Mean Total 
MLSI (A×I) Score (Reference: Table 14.2.2.2.1) 
mITT Population 
SAS Output 
 
Raw 
output 
16.1.9.1.2 
Statistical Analysis of Change from Baseline in Mean Total 
MLSI (A×I) Score (Reference: Table 14.2.2.2.2) 
PP Population 
SAS Output 
 
 
Raw 
output 
16.1.9.2.1 
Statistical Analysis of Change from Baseline in Mean VITA 
shade (Reference: Table 14.2.3.2.1) 
mITT Population 
SAS Output 
 
 
Raw 
output 
16.1.9.2.2 
Statistical Analysis of Change from Baseline in Mean VITA 
shade (Reference: Table 14.2.3.2.2) 
PP Population 
SAS Output 
 
 
Raw 
output 
16.1.9.3 
Statistical Analysis of Change from Baseline in Mean MLSI 
(A×I) Score by Sites (Interproximal/Gingival/Body) (Reference: 
Table 14.2.4.2) 
mITT Population 
SAS Output 
 
CCI


Potassium Nitrate Dentifrices 
300024 
 
 
 
 
GlaxoSmithKline Consumer Healthcare Confidential 
 Statistical Analysis Plan Template v6.0 
Page 35 of 37 
CSR 
Section 
TLF 
Number 
Title 
Population 
Template 
Topline 
 
Raw 
output 
16.1.9.4 
Statistical Analysis of Change from Baseline in Mean MLSI 
Score by Area and Intensity (Reference: Table 14.2.5.2) 
mITT Population 
SAS Output 
 
 
Raw 
output 
16.1.9.5 
Statistical Analysis of Change from Baseline in Mean VITA 
EasyShade color co-ordinates (L*, a*, b*, WID and Delta E*) 
score (Reference: Table 14.2.6.2) 
mITT Population 
SAS Output 
 
16.2 Subject Data Listings 
16.2.1 Discontinued Subjects 
  
Listing 
16.2.1.1 
Subject Disposition 
All randomized 
subjects 
16.2.1.1 
 
Listing 
16.2.1.2 
Subject Disposition 
Non-randomized 
subjects 
16.2.1.2 
 
16.2.2 Protocol Deviations 
  
Listing 
16.2.2.1 
Important Protocol Deviations 
All randomized 
subjects 
16.2.2.1 
 
Listing 
16.2.2.2 
All Protocol Deviations  
All randomized 
subjects 
16.2.2.2 
 
16.2.3 Patients Excluded from the Efficacy Analysis  
  
Listing 
16.2.3.1 
Exclusions from Analysis Populations 
All randomized 
subjects 
16.2.3.1 
16.2.4 Demographic Data  
  
Listing 
16.2.4.1 
Demographic Characteristics 
All randomized 
subjects 
16.2.4.1 
 
Listing 
16.2.4.2 
Medical History and Current Medical Conditions  
All randomized 
subjects 
16.2.4.2 
 
CCI


Potassium Nitrate Dentifrices 
300024 
 
 
 
 
GlaxoSmithKline Consumer Healthcare Confidential 
 Statistical Analysis Plan Template v6.0 
Page 36 of 37 
CSR 
Section 
TLF 
Number 
Title 
Population 
Template 
Topline 
 
Listing 
16.2.4.3 
Prior medications 
All randomized 
subjects 
16.2.4.3 
 
 
Listing 
16.2.4.4 
Concomitant medications and significant non-drug therapies 
taken during treatment 
All randomized 
subjects 
16.2.4.4 
 
16.2.5 Compliance and/or Drug Concentration Data (if available) 
  
Listing 
16.2.5.1 
Brushing Compliance 
All randomized 
subjects 
16.2.5.1 
 
Listing 
16.2.5.2 
Supervised Brushing 
All randomized 
subjects 
16.2.5.2 
 
16.2.6 Individual Efficacy Response Data 
  
Listing 
16.2.6.1.1 
MLSI (AxI) Score Data 
All randomized 
subjects 
16.2.6.1.1 
 
Listing 
16.2.6.1.2 
Derived MLSI (AxI) Score Data 
All randomized 
subjects 
16.2.6.1.2 
 
 
Listing 
16.2.6.2 
VITA Shade Score Data 
All randomized 
subjects 
16.2.6.2 
 
 
Listing 
16.2.6.3 
VITA EasyShade color co-ordinates (L*, a*, b*, WID and Delta 
E*) score Data 
All randomized 
subjects 
16.2.6.3 
 
16.2.7 Adverse Event Listings  
  
Listing 
16.2.7.1 
Adverse Events 
All randomized 
subjects 
16.2.7.1 
Yes 
 
Listing 
16.2.7.2 
Adverse Events 
Non-randomized 
subjects 
16.2.7.1 
 
CCI


Potassium Nitrate Dentifrices 
300024 
 
 
 
 
GlaxoSmithKline Consumer Healthcare Confidential 
 Statistical Analysis Plan Template v6.0 
Page 37 of 37 
CSR 
Section 
TLF 
Number 
Title 
Population 
Template 
Topline 
 
Listing 
16.2.7.3 
All Adverse Events Related to COVID-19 
All randomized 
subjects 
16.2.7.1 
 
 
Listing 
16.2.7.4 
Incidents 
All Randomized 
Subjects 
16.2.7.4 
Yes 
16.2.8 Other Listings and Listing of Laboratory Measurements, when required by regulatory authorities (if applicable)  
  
Listing 
16.2.8.1 
Oral Soft Tissue examination 
All randomized 
subjects 
16.2.8.1 
 
Listing 
16.2.8.2 
Oral Hard Tissue examination 
All randomized 
subjects 
16.2.8.2 
 
16.4 Individual Subject Data Listings 
  
NA 
  
  
  
  
  
 
CCI